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Chapter 1   
General introduction
Parts adapted from:
Alex C Faesen1, Titia K Sixma1 and Roger D Everett2
“Ubiquitin Specific Protease 7”
Chapter in Handbook of Proteolytic Enzymes
Edited by Neil Rawlings and Guy Salvesen, volume 3 (2011)
1 Division of Biochemistry and Center for Biomedical Genetics, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands. 2 MRC-University of Glasgow Centre for Virus Research, Glasgow, 
Scotland, U.K.
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Ubiquitination
Once DNA is translated and proteins have been 
properly folded, most proteins are subject to a 
diverse range of post-translational processes. 
These processes allow for drastically changing 
both function and fate of the target proteins. It 
is usually a very fast and specific process and it 
effectively expands the functional outcomes of 
a single gene. The modification arsenal is large 
and proteins are differentially hydroxylated, 
methylated, acetylated, phosphorylated or 
conjugated to ubiquitin and ubiquitin-like 
polypeptides. 
Ubiquitin (originally called “ubiquitous 
immunopoietic polypeptide”) was first 
identified in 1975 as an 8.5-kDa protein of 
unknown function that exists in all eukaryotic 
cells. The importance of ubiquitin is nicely 
illustrated by the evolutionary conservation of 
its 76 amino acids, which between mammals, 
yeast, and plants only differs at three positions. 
It is an abundant modification and up to 20% 
of yeast proteins are conjugated to ubiquitin 
under standard culture conditions1. The basic 
functions of ubiquitin and the components of 
the ubiquitination pathway were elucidated in 
the early 1980s. These fundamental discoveries 
describing how cells regulate the breakdown 
of intracellular proteins using protein 
ubiquitination were awarded the Nobel Prize in 
Chemistry in 20042.
Ubiquitination is more versatile and flexible 
than small molecule modifications such as 
phosphorylation and acetylation. Traditionally, 
ubiquitin conjugation has been believed to 
invariably serve as the final station in the destiny 
of a protein, serving to target its substrates for 
degradation by the proteasome3. Nowadays it 
has been recognized that ubiquitination is not 
only a signal for destruction, but represents 
a more general modification influencing a 
broad repertoire of cellular processes4,5. Protein 
ubiquitination is a critical post-translational 
modification that can have profound effects 
on protein stability, localization or interactions. 
Importantly, in order to enable a dynamic 
regulation of signalling events, ubiquitination 
is a reversible process that is specifically 
counteracted by the deubiquitinating (DUB) 
family of proteases.
Degradation by the proteasome
The most studied and best understood role of 
ubiquitin involves the targeted destruction of 
proteins by the proteasome. The proteasome 
can be viewed as the cellular garbage disposal 
machine that literally grinds up proteins into 
small peptides, whilst recycling intact ubiquitin 
molecules6.
In contrast to protein synthesis, ubiquitination 
and degradation are fast processes that take 
place within minutes. Therefore, if steady-
state levels of proteins must undergo fast and 
dramatic changes, they are often regulated by 
active protein degradation. One example is the 
regulation of p53 levels. This tumour suppressor 
is continuously expressed and degraded, 
resulting in low protein levels. However, upon 
stress, the ubiquitination and the corresponding 
degradation of p53 are suddenly stopped, 
resulting in a fast increase of p53 protein levels. 
This allows a cell to respond quickly to changes 
in the environment and adjust to meet the new 
requirements.
The signal for destruction by the proteasome 
Cell biological processes require intense and continuous regulation. This often involves complex 
systems that, when disturbed, fail to generate the desired outcome and finally result in diseases. 
Defects in these systems can have different origins. For example, the translation of the genes can 
be misregulated, leading to altered protein expression levels. Alternatively, genes can encode for 
mutated, truncated or chimeric fusion proteins, altering the function and activity of that protein. 
On the other hand, the defects can also originate from the regulation of the activity of otherwise 
correctly functional proteins. These regulation systems often rely on chemical modifications of the 
proteins, and these are also frequently perturbed in diseases. The focus of this thesis will be on one 
such important modification: ubiquitination. 
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however is not a single ubiquitin molecule. 
As discussed later in more detail, mono-
ubiquitination is only one of the many possible 
ubiquitination states of proteins. Rather, the 
covalent attachment of at least four ubiquitin 
moieties in a poly-ubiquitin chain serves as 
the tag to send the protein for destruction by 
the proteasome. These ubiquitin chains are 
linked through the lysine at position 48 (K48) 
on ubiquitin itself. This was the first ubiquitin 
signal to be identified, however since then also 
K11- and K29-linked poly ubiquitin have been 
identified as degradation markers7-9.
The importance of this system is underlined 
by the critical role of the proteasome that 
has been described in cancer. Changes in 
the profiles of protein degradation are linked 
to defects in apoptosis, the cell division 
cycle, DNA damage signalling and to gene 
transcription10-12. Furthermore, many cancer 
cells are more susceptible to proteasome 
inhibition than normal cells. These discoveries 
lead to intensive research into the application 
of proteasome inhibitors as a cancer drugs. 
Bortezomib (Velcade®) is a first-in-class 
proteasome inhibitor and binds the catalytic 
site of the proteasome with high affinity and 
specificity13 and is approved for treatment of 
multiple myeloma and mantle cell lymphoma, 
while many clinical trials in other malignancies 
are ongoing14. Unfortunately, the mechanism(s) 
responsible for the increased sensitivity of 
cancer cells to proteasome inhibitors remain 
poorly understood.
The mechanism of ubiquitin conjugation
The biochemical processes underlying 
ubiquitination of proteins have been studied in 
great detail. It requires an enzymatic cascade to 
activate and conjugate the ubiquitin molecule 
to a target protein or ubiquitin itself15. This 
results in a covalent isopeptide bond between 
ubiquitin and the target lysine (Figure 1A). 
In this ubiquitin conjugation process, the 
first step is the activation of ubiquitin by 
the E1 ubiquitin-activating enzyme in an 
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Figure 1. Schematic view of the (de-)ubiquitination system. A. Ubiquitination is a multi-step process, where the conjugation 
of ubiquitin is mediated by the E1 activating enzyme, the E2 conjugating enzyme and an E3 ubiquitin ligase, either a HECT or 
RING type. This process can yield a multitude of ubiquitin signals on the target protein and a variety of cellular outcomes. B. In 
contrast to the ubiquitination, the removal of ubiquitin from the target is not mediated by an enzyme cascade but rather by a 
single deubiquitinating enzyme.
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However, a problem with targeting E2’s, is that 
one might affect a wide range of downstream 
targets. To gain more target specificity, E3’s can 
be inhibited instead. For example, the Nutlin 
compounds (cis-imidazoline analogs) inhibit the 
interaction between the E3 ligase HDM2 and its 
substrate, tumour suppressor p5319. Inhibiting 
this interaction stabilizes p53 and is thought 
to selectively induce a growth-inhibiting state 
called senescence in cancer cells20.
Ubiquitination in many flavours
As mentioned before, ubiquitination comes 
in many more flavours than the K48 poly-
ubiquitination. These additional ubiquitin 
signals can equally serve more functions than 
the signal for protein degradation. Mono-
ubiquitination can alter the activity and 
localization of a protein, and is found to regulate 
endocytosis, lysosomal targeting, meiosis and 
chromatin remodelling21-23. 
Ubiquitin itself can be ubiquitinated forming 
poly-ubiquitin chains. There are seven available 
lysines in ubiquitin (K6, K11, K27, K29, K33, K48 
and K63; Figure 2). Besides that, they can also be 
linked through their N- and C-termini resulting 
in linear ubiquitin chains. The precursor of 
ubiquitin is expressed in these head-to-
tail ubiquitin-chains, which is subsequently 
processed by DUBs into mono-ubiquitin and 
then used for conjugation24. However, linear 
poly-ubiquitin chains can also be assembled 
from mono-ubiquitin by a dedicated E3 ligase 
complex, the Linear Ubiquitin Chain Assembly 
Complex (LUBAC)25. Overall, since poly-ubiquitin 
chains can contain mixtures of linkages, there is 
a seemingly endless variability in composition 
and thus downstream signalling. At present, it 
is not clear just how complex the ubiquitination 
system is.
All the different linkages between ubiquitin 
moieties (ubiquitin topoisomers) have been 
found in cells26, and mass spectrometry analysis 
revealed relative abundances of most ubiquitin 
topoisomers27. K48 linked ubiquitin is the most 
abundant ubiquitin chain type (~30%), and the 
K63 linkages accounted for another ~20% of all 
linkages. K11-linked ubiquitin was found to be 
almost as abundant as K48 linkages.
ATP dependent manner. After production 
of a ubiquitin-adenylate intermediate, the 
ubiquitin is transferred to the E1 active site 
cysteine residue, with the release of AMP. This 
step results in a thioester linkage between the 
C-terminal carboxyl group of G76 of ubiquitin 
and the E1 cysteine. In the second step, the 
ubiquitin is transferred from the E1 to the active 
site cysteine of a ubiquitin-conjugating enzyme 
E2. In the third and final step, the isopeptide 
bond is created between the lysine of the target 
protein and ubiquitin. This transfer can occur in 
two ways, either directly from the E2, catalyzed 
by RING/UBox domain containing E3’s that act 
as chaperones by bringing the E2 and target in 
close proximity, or via a covalent E3-ubiquitin 
intermediate, catalyzed by the HECT domain-
type E3’s. 
An interesting feature is the hierarchy within 
this cascade. Until now, only two E1’s have 
been indentified. However, these can bind with 
dozens of E2s, which in their turn cooperate with 
hundreds of E3s, allowing for ubiquitination of 
specific proteins. This hierarchical organization 
is conserved, as ubiquitin-like proteins are also 
conjugated via a dedicated but similar E1–E2–
E3 cascade. 
This enzyme cascade has successfully been 
targeted by drugs in the treatment of cancer. 
One of the most recent successes is the 
MLN4924 compound, which is an specific 
inhibitor of the E1 in the ubiquitin-like Nedd8 
pathway16,17. Inhibiting E2 and E3 enzymes with 
drugs is considered difficult, due to the absence 
of a classic active site. However, a recent study 
reports the first inhibitor of the human E2 
CDC3418. It describes an allosteric inhibitor 
(CC0651) that does not directly contact the 
active cysteine of the enzyme. Instead, it 
binds the helix bearing the catalytic cysteine 
yielding a displacement by 2.0 Å. By doing so, 
it specifically disturbed the ability of CDC34 to 
promote ubiquitin transfer and chain formation 
on substrates, turning its conjugating activity 
on itself and free ubiquitin. This compound 
is remarkably selective for CDC34, and these 
results imply that it might be possible to 
selectively target other E2s in the future.
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In contrast to K48-linked poly-ubiquitin, K63-
linked ubiquitination has non-degradative 
roles, and is involved in endocytosis, in DNA-
damage responses and in cell signalling21. 
K11-linked chains still represent a relatively 
unstudied linkage but seem to also serve as 
a potent proteasomal degradation signal8,9. 
It is involved in many different pathways, 
including the cell cycle9,28.  However, due to 
the lack of tools to study and to make most 
ubiquitin chains29,30, both the functions and the 
conjugation mechanisms of most linkages are 
less well understood.
Ubiquitin binding domains
In comparison to the small molecule modifiers, 
the conjugation of a ubiquitin moiety provides a 
larger and chemically more diverse surface. This 
resulted in the co-evolution of a multitude of 
specialized Ubiquitin Binding Domains (UBDs) 
to translate the many ubiquitination states into 
specific signals. The UBDs bind non-covalently 
to ubiquitin or specific ubiquitin chains and 
mediate different outputs depending on the 
protein they are part of. The various classes 
of UBDs and their biological properties are 
relatively well studied and characterized, and 
several crystal structures provide structural 
insights31-35.
UBDs can bind, and often distinguish, different 
types of ubiquitin modifications. The number 
of identified UBDs is increasing, with more 
than twenty different families36.  They diverge 
both in structure and in the type of ubiquitin 
recognition that they use, but most of them 
use an α-helical structure to bind the β-sheet 
of ubiquitin. Especially the residues L8, I44 and 
V70 in this region on ubiquitin often play an 
important role in the binding.
Usually the affinity for ubiquitin is weak and 
dynamic and the dissociation constants (Kd’s) 
are typically in the (high) micro molar range. 
The majority of UBDs do not have an intrinsic 
specificity towards any type of poly-ubiquitin 
linkage37. Instead, the specificity is induced 
by surrounding domains within the protein of 
complex. Therefore, combinations of UBDs are 
needed to bind poly-ubiquitin or discriminate 
different linkages. 
Interpretation of the ubiquitin chains is 
achieved in several ways and sometimes this 
Figure 2. Ubiquitin itself contains 7 lysines that can be used to produce poly-ubiquitin chains. Ubiquitin can also be linked 
through their N- and C-termini, resulting in linear ubiquitin chains. 
N
C
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protein p5356,57. Besides the degradative role of 
ubiquitination, is the non-degradative type also 
important in tumour suppressor biology. For 
example, the mono-ubiquitination of tumour 
suppressors p53 and PTEN (Phosphatase 
and Tensin Homologue) is involved in cancer 
development, as discussed later in more 
detail58-60. 
Also many DUBs are involved in tumour 
progression, and several deubiquitinating 
enzymes are found overexpressed in tumours 
and stabilize oncogenes. Recent examples are 
USP9X61 and DUB362. USP9X is overexpressed 
in haematological malignancies, where it 
deubiquitinates and stabilizes the pro-survival 
BCL-2 family member MCL1. DUB3 stabilizes cell 
cycle-regulating phosphatase CDC25A, which 
has been linked to breast cancer initiation and 
progression.
Neurodegenerative disease
Neurodegenerative diseases such as Parkinson’s, 
Alzheimer’s and Huntington’s, originate from 
protein aggregates that contain ubiquitin63. For 
example, expansion of the polyglutamine repeat 
in the mutant Huntington protein promotes 
the formation of protein aggregates that are 
resistant to degradation by the proteasome, 
but also impair proteasome function64. Similarly 
in Alzheimer’s disease, proteasome function 
is impaired by the formation of plaques 
associated with amyloid-β protein aggregation 
and ubiquitinated TAU65. In Parkinson’s disease, 
mutations in the E3 ligase PARKIN impair its 
activity in vitro, suggesting that accumulation 
of its substrates could contribute to disease 
development66. Additionally, down-regulation, 
extensive modifications and truncations of 
the DUB UCH-L1 have been observed in both 
Alzheimer’s as well as in Parkinson’s disease 
patients67. UCH-L1 is a multifunctional protein, 
since it displays both deubiquitinating68 and 
ubiquitin conjugation activity69. It is exclusively 
localized in the brain70, and its precise role in 
neurodegeneration is still unresolved.
is accompanied by a preference for ubiquitin 
chains of a specific linkage, like in RAP80 for 
K63-linked ubiquitin38 and NEMO for linear 
ubiquitin39. For example, the C-terminal 
Ubiquitin-Associated (UBA) domain of Rad23A 
binds K48-linked chains 70-fold tighter 
compared to mono-ubiquitin, but additionally 
displays a 4-fold preference over K63-linked 
ones37. The crystal structure nicely explains how 
this is achieved38. It shows that the UBA domain 
is sandwiched between the two ubiquitin 
moieties of the K48-linked di-ubiquitin. There 
it binds to both ubiquitin moieties, using a 
significantly larger binding surface than it could 
form with a single ubiquitin. Since it also binds 
the di-ubiquitin linker region, this binding 
mode induces a linkage preference.
Ubiquitin and disease
Since the ubiquitin pathway is involved in 
many key cellular processes, it is no surprise 
that aberrant ubiquitination or ubiquitin 
signalling has been implicated in various 
diseases, ranging from cancer, viral infection, 
neurodegenerative disorders, muscle wasting, 
diabetes to inflammation. Several published 
reviews adress the role of ubiquitin in specific 
diseases; here we will briefly discuss two40-44.
Cancer
The development of cancer is a multistep 
process, and originates from the accumulation 
of mutations in the cellular pathways regulating 
proliferation and survival under adverse 
conditions45. Deregulation of components 
of the ubiquitination system is common in 
the development of cancers46-49. Many direct 
substrates of E3 ligases and DUBs play key 
roles in the cell cycle45, DNA repair50, NF-κB 
signaling51, RTK signaling52 and angiogenesis53 
and their levels or activity are precisely 
regulated by ubiquitination. Furthermore, 
as discussed before, the clinical success of 
Bortezomib illustrates the importance of the 
ubiquitin-mediated signalling in cancer.
Mutations or overexpression of numerous E3 
ligases render them potent oncogenes54,55, 
examples are the SCF ligases that regulate 
cell-cycle progression, and  HDM2, which is a 
negative regulator of the tumour-suppressor 
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De-Ubiquitination
Like other post-translational modifications, 
ubiquitination is a dynamic and therefore 
reversible process. The removal of ubiquitin 
is carried out by more than 90 DUBs24,71. In 
contrast to ubiquitination, de-ubiquitination 
is performed by single enzymes rather 
than an enzyme cascade. The importance 
of the deubiquitination is illustrated by 
the involvement of several DUBs in various 
diseases72-75. Also, DUBs are overexpressed or 
activated in tumour cells and contribute to the 
transformed phenotype76,77. As a consequence, 
they are acknowledged as promising 
therapeutic targets78,24, and therefore actively 
pursued as potential drug targets, both by 
academia and industry. This led for example 
to a remarkably selective small-molecule 
inhibitor for USP14. This inhibitor enhanced the 
degradation of several proteasome substrates 
that have been implicated in neurodegenerative 
disease79. Also, the partly selective inhibitor 
WP1130 (USP9x, USP5, USP14, and UCH37) 
was found. Applying this inhibitor results in 
the downregulation of anti-apoptotic and 
upregulation of pro-apoptotic proteins, such as 
MCL-1 and p5380. 
Figure 3. A cartoon representation of the structures of representative members of each DUB family. Ubiquitin is coloured 
grey. PDB codes USP7:1NBF, OTUB1:3BY4, AMSH-LP:2ZNV, UCH-L3:1XD3 and Ataxin-3:1JRI (NMR).
USP7 OTUB1
UCH-L3 Ataxin-3
AMSH-LP
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(UBL) folds24. 
Several structures of OTU catalytic domains 
have been solved. The catalytic core domain 
comprises 150 to 200 residues, and the A20-like 
OTU subtype (A20, Cezanne1/2, TRABID and 
VCIP135) contain an N-terminal extension. In 
OTUB1, the ubiquitin binding site is remodelled 
upon ubiquitin binding, and the active site is 
in an unproductive configuration, requiring 
conformational changes to become an active 
enzyme88. This requirement for remodelling is 
shared with members of the UCH, MJD and USP 
families81,89-92.
The OTU family displays remarkable ubiquitin-
linkage specificity. Most OTUs do not cleave 
linear chains efficiently, and therefore are 
strict isopeptidases93. TRABID93 and DUBA86 
cleave K63 ubiquitin chains, while OTUB188 is 
K48-specific. Interestingly, A20 hydrolyzes K48-
linked ubiquitin in vitro, yet its substrates are 
modified with K63-linked chains94,95. There is 
also cross reactivity with other ubiquitin-like 
modifiers; OTUB1 was suggested to cleave both 
ubiquitin and Nedd8 conjugates88. In order to 
evade the host immune response, viral OTUs 
have evolved cross-reactivity and are active 
against both ubiquitin and the ubiquitin-like 
ISG15. Due to recent structures of the viral OTUs 
in complex with ubiquitin and ISG15, this cross 
reactivity is now understood at the molecular 
level96,97.
Remarkably, OTUB1 inhibits the DNA double 
strand break (DSB) response independently of 
its catalytic activity87. It does so by suppressing 
the poly-ubiquitination by the E3 ligase 
RNF168, by binding to and inhibiting the E2 
enzyme UBC13. Non-catalytic roles for DUBs 
are not unique. For example, Ubp6 regulates 
proteasome-dependent degradation in a non-
catalytic manner98. Also DUBs such as USP39 
and USP52 to USP54 lack the necessary active 
residues for peptidase activity71,99, suggesting 
non-canonical functions. 
Ubiquitin C-terminal Hydrolases (UCHs)
The UCH family contains only four members, two 
of which consist of only the minimal catalytic 
domain (UCH-L1 and UCH-L3)24,71. These 
The DUBs are categorized in five structurally 
unrelated families: Ovarian Tumour proteases 
(OTUs), the Ubiquitin C-terminal hydrolyses 
(UCH), the Machado-Josephin disease protease 
(MJD), JAMM (JAB1/MPN/MOV34) proteases 
and the Ubiquitin-Specific proteases (USPs), 
(Figure 3)71. 
Proteolysis by DUBs
Cysteine-protease DUBs
The DUBs from the USP, OTU, UCH and MJD 
families are cysteine dependent proteases. 
They use a papain-like mechanism to hydrolyze 
the isopeptide bond between the carboxyl 
terminus of ubiquitin and the ε-amine of the 
target lysine. The mechanism to break the 
isopeptide bond involves the lowering of the 
pKa of the catalytic cysteine by a histidine, 
resulting in the deprotonation of the cysteine. 
This is facilitated by an aspartate or asparagine, 
by orienting the imidazole ring of histidine to 
allow the deprotonation to take place81. The 
cysteine then performs a nucleophilic attack 
on the carbonyl carbon of the isopeptide bond. 
This frees the ε-amine of the target lysine, and 
forms a covalent acyl-enzyme intermediate 
with ubiquitin. The enzyme is then deacylated 
by a water molecule, thereby releasing free 
ubiquitin.
Metallo-protease DUBs
The JAMM metallo-protease DUBs contain zinc 
ions in their active site, coordinated by histidine, 
aspartate and serine residues82. The zinc ion 
activates a water molecule, and the resulting 
hydroxide performs a nucleophilic attack on 
the carboxyl carbon of the isopeptide bond, 
releasing the ε-amine of the target lysine.
Ovarian Tumour Proteases (OTUs)
There are fifteen family members, that can 
be phylogenetically subdivided in three 
subclasses, the Otubains, the OTUs and the A20-
like OTUs24. So far, the family members mainly 
function in cell signalling processes, where they 
regulate NF-κB signalling83,84, Wnt signalling85, 
IRF3 signalling86 and DNA damage responses87. 
They vary in size (230 - 1200 residues) and 
often contain additional domains with links to 
the ubiquitin system, like Ubiquitin Interacting 
Motifs (UIMs), UBA domains and Ubiquitin-Like 
 1 
 General Introduction               15
both have functions in the brain67,100,101 and 
UCH-L1, has been associated with Parkinson’s 
disease66. A third member, UCH-L5, binds to the 
proteasome, where it is responsible for recycling 
ubiquitin from proteasome substrates102. The 
fourth human UCH enzyme, BRCA1 associated 
protein-1 (BAP1) is a tumour suppressor and 
interacts with the BRCA1 E3 ubiquitin ligase 
which is involved in DNA repair103. Additionally, 
it is involved in chromatin repression by 
deubiquitinating histone 2A (H2A) as part of the 
Polycomb repressive DUB (PR-DUB) complex104. 
Structural and biochemical studies have 
indicated that UCHs preferentially cleave small 
protein substrates (up to 20-30 amino acids) 
from ubiquitin105. 
The crystal structure of UCH-L1 shows that 
both the catalytic residues and several loops 
need remodelling upon ubiquitin binding89. 
Interestingly, in UCH-L3 the ubiquitin C-terminus 
is covered by an active site cross-over loop, 
which forms upon ubiquitin binding106,107. This 
does not allow binding of folded ubiquitinated 
proteins or ubiquitin chains, which would 
be too big to enter through the cross-over 
loop. This feature nicely explains the lack of 
activity against larger substrates108. Possibly, 
UCHs are mainly targeting ubiquitination sites 
in unfolded regions of proteins or residual 
ubiquitin-peptide conjugates after proteasomal 
degradation. Possibly, this cross-over loop can 
be remodelled, like in the case of UCH-L5, where 
binding to the proteasome allows cleavage of 
poly-ubiquitin109.
Machado-Josephin Disease proteases (MJDs)
The MJD family also contains only four 
members110,111. Like the UCH family, two 
members consist of only the minimal catalytic 
domain (Josephin-1 and Josephin-2), while the 
two others (Axatin-3 and Ataxin-3-like) have 
additional UIMs. The most prominent member 
of the family is Ataxin-3, which is mutated in 
Machado-Joseph disease, the most common 
form of spinocerebellar ataxia112. NMR studies 
on Ataxin-3 showed a misaligned catalytic 
triad, but upon ubiquitin binding the active 
conformation is stabilized90-92,113. The key feature 
of MJD domains is a large helical lever that 
restricts access to the active site in absence of 
ubiquitin90,92. Ataxin-3 itself is ubiquitinated by 
which it is activated, possibly by stabilization 
of the helical lever in an open conformation114. 
The substrates of Ataxin-3 and the roles of the 
remaining MJDs are currently unclear.
JAMM motif proteases (JAMMs)
There are eight JAMM containing ubiquitin 
proteases24, of which PRPF8 is predicted to be 
inactive based on structural analysis115. The 
JAMM domain is a general protease domain, 
and is also found in prokaryotes (that do not 
have a ubiquitin conjugation system). The 
JAMMs are metallo-proteases and are active 
as part of multi-subunit protein complexes. 
For example, POH1 binds the proteasome and 
contributes to recycling ubiquitin chains102, 
while AMSH and AMSH-LP regulate membrane 
trafficking within to the ESCRT machinery116. 
The JAMM/MPN+ DUBs seem to prefer K63 
ubiquitin chains, and some show remarkable 
specifity117,118. The specificity of AMSH-LP is 
explained by the crystal structure with K63-
linked di-ubqiuitin119. This shows that it binds 
to both the linker region as well as the of K63 
sequence context. 
Ubiquitin Specific proteases (USPs)
This thesis is focussed on the USP family. 
It is the largest and most diverse family of 
DUBs with more than 60 members24,71. As 
the number of ubiquitin E3 ligases increased 
during evolution, so did the number of 
USPs, suggesting an intimate antagonistic 
relationship120. Knowledge about the USPs is 
increasing, however for a large number both the 
physiological function and specific substrates 
still remain elusive. 
USPs are regulated by interacting proteins 
and about 800 DUB interacting proteins have 
been identified to date121. These interactions 
can be categorised into distinct classes that 
have particular functional consequences. 
The first functional interaction is between 
DUBs and E3 ubiquitin ligases, which protects 
E3s from auto-ubiquitination and thereby 
increases their stability122-127. Examples of 
this regulatory feedback include USP9 that 
prevents auto-ubiquitination of E3 Itch126, 
MARCH7 auto-ubiquitination is prevented by 
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of their USPs, like the transmembrane regions 
in USP19 (endoplasmatic reticulum), USP30 
(mitochondria) and USP48. 
Structures of the USP catalytic domains show a 
conserved fold. It consists of three sub domains, 
Palm, Thumb and Fingers, resembling a right 
hand (Figure 3 and 8B)81. The catalytic centre lies 
at the interface between Palm and Thumb, while 
the Fingers domain grasps the distal ubiquitin. 
Some USPs display dramatic conformational 
changes upon ubiquitin binding For instance, 
in USP7 the active site is remodelled to an 
active conformation upon ubiquitin binding81. 
In contrast, the catalytic residues of USP14 
and USP8 are properly aligned for catalysis 
in absence of ubiquitin, but in these USPs the 
ubiquitin binding site is blocked by surface 
loops131,133. Furthermore, in USP8, which has 
only been crystallized without ubiquitin, the 
Fingers domain is tightened inward, additionally 
blocking the ubiquitin binding site.
About half the USPs have insertions in their 
catalytic domain, and some of these insertions 
are larger than the catalytic domain itself. 
Detailed analysis revealed that the USP 
catalytic core domain can be subdivided into 
six conserved sequence boxes134. The five 
boundaries between the subdomains are 
integration sites of the insertions. Some inserted 
sequences contain additional independently 
folded domains, including protein interaction 
domains (e.g. a B box in CYLD132, the MYND 
domain in USP19135, UBA domains in USP5136, 
and a UIM in USP37134). 
UBL domains in USPs and their functions
USPs have large regions that have been 
annotated for neither fold nor function. Fold 
recognition methods revealed an unexpectedly 
high number of (multiple) UBLs in at least 17 
USPs (Figure 4)137,138. This makes the UBL domain 
the most abundant accessory domain in the 
USP family. The intruiging presence of these 
domains might suggest an auto-regulatory 
function. Though to date, most UBL domains 
remain unstudied.
The UBL domains are located in different 
USP7 and USP9X125, and USP15 prevents auto-
ubiquitination of RBX1124. A second class of 
interaction is a simpler version of the above, in 
which the USP interacts with a target of an E3, 
thereby stabilising the target protein directly. A 
third type of interaction includes proteins whose 
mono-ubiquitination status is regulated by USPs 
without affecting their stability, but instead 
influencing their biological functions. A fourth 
category of interaction partner modulates the 
activity of the USP. For example, USP1, USP12 
and USP46 interact with the WD40 protein UAF1 
(USP1 associated factor, also known as WDR48), 
which subsequently results in an enhanced 
activity of the USP1128,129. And finally, the fifth 
commonly observed interaction exists between 
DUBs, as for example the interaction between 
USP7 and USP11 which plays a role in stabilizing 
the Polycomb Repressive Complex 1 (PRC1)130. 
Most interactions have not been characterized 
and therefore their biological function is still 
unknown.
Concerning the biochemistry of the USPs there 
are still questions to be addressed. For example, 
studies for chain preference of the USPs have so 
far mainly focussed on the canonical K48- and 
K63-linked ubiquitin. Most of the analyzed USPs 
are nonspecific and will cleave any chain type, 
however they do show distinct preferences93. 
Examples are USP14, that preferentially cleaves 
K48 linked ubiquitin chains131, and CYLD, that 
specifically hydrolyzes K63 linked and linear 
chains93,132. In chapter 2 we now for the first 
time include the remaining ubiquitin linkages 
and characterization the differential activity of 
twelve USPs towards all seven lysine-linked di-
ubiquitin.
USP structure
Usually USPs are large proteins with a minimal 
core catalytic domain of about 350 amino 
acids71. Outside of their catalytic domain, USPs 
contain large unrelated sequences that harbour 
additional domains used for protein-protein 
interaction. Some are dedicated for substrate 
binding, while others are more general 
interaction domains. These include UBDs, such 
as the zinc finger ubiquitin specific protease 
domains (ZnF-UBP), UIMs and UBAs. Some 
domains facilitate the subcellular localization 
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positions in the enzymes, and they can be found 
both N- and C-terminally of the catalytic domain. 
Interestingly, eight USPs have a UBL domain 
inserted in a conserved position between two 
subdomains in the catalytic domain (USP4, 
6, 11, 15, 19, 31, 32, and 43). The remainder of 
the inserted sequences mostly lack predicted 
secondary structure elements and therefore are 
most likely unstructured regions. USP19 is the 
only exception, where the UBL is immediately 
followed by an MYND Zn-finger domain, while 
the rest of the insert has no obvious fold. 
UBL domains have a ubiquitin-like fold, which 
is characterized by a five stranded β-sheet 
with a single α-helix on top, but they lack the 
C-terminal residues required for conjugation 
to a target. This β-grasp fold is often found as 
Figure 4. UBL domains in USPs A. Domain architecture of the USPs with predicted UBL domains. The UBL domains can be 
inserted in a conserved site between two subdomains of the catalytic domains, but they are also found in the flanking regions. 
B. Structures of individual UBL domains from USPs show the conserved β-grasp ubiquitin-like fold. 
100 2000 300 400 500 600 700 800 900 1000 1100
C H D
Catalytic
 residues
Cysteine
residues
DUSP
DUSP 
domain
Ubiquitin-
like domain
TRAF/MATH
domain
TRAF CS
CS-domainEF-hand
EF
Uba-
like
TBC
TBC 
domain
Coiled- 
Coil
Domain 
Name
Function hydrolysis unknown variable substratebinding
coordinate
zinc ion
Ca2+
binding
Ub 
binding
DUSP C HDUbl Ubl
TRAF C HD Ubl Ubl Ubl Ubl Ubl
DUSP C HDUblUbl
Ubl
C-C C-C
C-CC-C
C-C
USP4
USP7
USP6
USP9
USP11
USP14
USP15
USP19
USP24
USP31
USP32
USP34
USP40
USP43
USP47
USP48
1200 1300 1400
+600 +400
1500 1600
+1000 +1000
Ubl
Ubl Ubl
Ubl
Ubl
Ubl
UblUbl
Ubl
Ubl Ubl
Ubl
UblUbl Ubl Ubl
Ubl
C HDTBC Ubl
+700 +300
Ubl
HD
C HD
C HD
C
C HD
DUSP
CS CS
C HD
C HD
EF EFEF EF DUSP C HD
C HD
C HD
C HD
C HD
C HD DUSP DUSPDUSP
Zn-Finger
MYND
Protein
binding
Ubiquitin (1UBQ)
N-term UBL 
USP4 (3JYU)
first C-terminal 
UBL USP7 (2KVR)
N-term UBL 
USP14 (1WGG)
B
A
C
N
C
N
C
N
C
N
    1 
18               Chapter 1
development158. Later USP4 was identified as 
a proto-oncogene and shows a consistently 
elevated gene expression level in small cell 
tumours and lung adenocarcinomas159. Several 
functions and targets of USP4 have since been 
identified. First, genetic screens identified 
an interaction between USP4 and two WNT 
signalling components. It binds to the NEMO like 
kinase (NLK), which subsequently leads to the 
recruitment of USP4 to its target, transcription 
factor T-cell factor 4 (TCF4)160. Secondly, USP4 
is involved in the endoplasmic reticulum (ER) 
quality control by binding to the A2A receptor, 
a prototypical G-coupled receptor161. Its de-
ubiquitination by USP4 enhances the cell 
surface expression of the A2A receptor. In the 
third case, USP4 is linked to cell cycle control. It 
interacts with SART3, which is a component of 
the spliceosome complex162. This is a dynamic 
complex of proteins and RNAs that catalyzes 
the excision of intron sequences from nascent 
mRNAs. SART3 recruits the U4 component PRP3, 
which is subsequently deubiquitinated by USP4. 
This deubiquitination probably facilitates the 
ejection of Prp3 from the spliceosome162. The 
loss of USP4 interferes with the accumulation of 
correctly spliced mRNAs and impairs cell cycle 
progression. Finally, a recent study revealed 
a fourth function, where USP4 regulates p53 
protein levels by antagonizing the p53 E3 ligase 
ARF-BP1163,164. 
Interestingly, USP4 has two paralogs: USP11 
and USP15 and they share 60-80% sequence 
similarity (Figure 5A). Despite the striking 
resemblance, the USP4 paralogs seem to have 
different functions. USP11 has been shown 
to interact with a diverse array of cellular 
proteins. For example, it negatively regulates 
TNFα-induced NF-κB activation by targeting 
on IκBα165,166. It is also involved in the double 
strand DNA repair by interacting with BRCA2167, 
and regulating RAD51 and 53BP1 localization 
after the initial γH2AX signal168. As discussed 
later in more detail, together with USP7 it is also 
responsible for stabilizing the PRC1 complex130. 
On the other hand, USP15 seems to be involved 
in the COP9-signalosome, a conserved multi-
protein complex that regulates the Cullin-
RING ligase (CRL) superfamily of ubiquitin E3 
ligases124,169. It is proposed that in this complex, 
part of larger multi-domain protein. Among the 
studied UBL domains, distinct subclasses can be 
identified with different functions139. In the USPs 
the sequence homology of the UBL domains is 
low (below 20%), but in many other proteins 
they strongly resemble ubiquitin in primary 
sequence as well as in fold. These homologies 
are for example found in proteasomal shuttle 
factors RAD23 and Ubiquilin140-143, where the 
UBL is responsible for the association to the 
proteasome. UBL domains are also involved in 
signal transduction and enzymatic activity. For 
example, the UBL domains in IKKβ144,145 and 
IKKε146 are essential for their kinase activity. 
Some have multiple functions, like in the E3 
ligase PARKIN where the UBL domain regulates 
the proteasomal localization, the cellular 
levels of PARKIN, and also inhibits its auto-
ubiquitination147-149. 
Another example of an integrated UBL domain 
is the Ubiquitin-regulatory X (UBX) domain. Like 
the UBL domains in the USPs they have only a 
limited sequence similarity with ubiquitin, but 
still have the β-grasp fold150. UBX domains are 
found in FAF1, p47, Y33K, and Rep8 proteins150, 
and are needed for targeting ubiquitinated 
proteins to the proteasome or ERAD pathway 
(recruitment to p97)150-152. UBL domains are 
often important integrated elements of 
proteins, and are present in a large variety of 
proteins families; however only a few of these 
have been studied functionally153,154. 
Within the USP family, the function of the UBL 
domain in USP14 was the first to be elucidated. 
It is needed for the association of USP14 to the 
proteasome155 and this binding activates USP14 
activity156. Specifically, USP14 resides on the 19S 
regulatory particle of the proteasome where it 
removes ubiquitin from the substrate before 
degradation. In this thesis we present the 
function and mechanism of the UBL domains in 
USP4 (chapter three) and USP7 (chapter four). 
USP4
USP4 was previously known as a ubiquitous 
nuclear protein (UNP)157 that is able to bind 
to the tumour suppressor retinoblastoma 
(RB) protein, suggesting a role in cancer 
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USP15 protects against auto-ubiquitination 
and degradation of CRL components, in 
particular the substrate-specific adaptors170, 
or directly oppose CRL E3 ligase activity by 
deubiquitinating specific substrates171-173. 
USP4 itself is a 963 amino acid (109 kDa) large 
protein (Figure 5A). It has at the N-terminus a 
single DUSP (domain in USPs) domain, which 
is characterized by a tripod-like fold with a 
conserved hydrophobic surface patch that 
is predicted to participate in protein-protein 
interaction (Figure 5B)174,175. This domain is 
followed by a UBL of unknown function. After 
the DUSP-UBL domain comes a split catalytic 
domain, with a second UBL as part of a larger 
insert. In chapters two and three we show 
that this UBL insertion influences the activity 
through a competitive inhibition mechanism.
USP7 / HAUSP
USP7 also contains UBL domains, and in chapter 
two we describe that these that are involved in 
the activity176,177. In USP7 it is not a single UBL 
as in USP4, but in chapter four we show that 
there are five consecutive UBL domains at the 
C-terminal of the protein (Figure 4A). Also in 
contrast to USP4, the UBL domains in USP7 are 
responsible for an intriguing increase of the 
activity, rather than an inhibition178.
USP7 represents one of the most studied DUBs. 
It was originally named HAUSP (herpes virus 
associated ubiquitin specific protease), and 
in practice both names are in use in current 
literature. USP7 is widely expressed in many 
different tissues and it is predominantly a 
nuclear protein. In the nucleus it has a diffuse 
localization, but with discrete accumulations 
associated with nuclear substructures 
Figure 5. Overview of structural information USP4. A. Schematic domain architecture showing the DUSP (blue), two UBL 
(green) and a split catalytic domain (D1 and D2; orange). This architecture is shared with the paralogs USP11 and USP15. B. The 
crystal structure of the DUSP-UBL domain of USP4 (3JYU) shows a possible dimerization. The second molecule is coloured in a 
lighter shade. C.  The crystal structure of the DUSP-UBL domain of USP15 (3PPA) shows a flexible relative orientation of the DUSP 
and UBL domain. No dimerization was observed in the crystal. 
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Functional interactions
Since USP7 was first identified179, the number 
of reported interaction partners and substrate 
proteins has increased significantly. USP7 is 
a direct regulator of activities of numerous 
proteins broadly characterized as tumour 
suppressors, DNA repair proteins, immune 
responders, viral proteins and epigenetic 
modulators. Given the complexity and number 
of all these interactions, it is not surprising that 
USP7 plays a very important role in the cell such 
that in its absence cells exhibit many defects. 
Given the important and the multifaceted role 
of USP7, and also the fact that at least one of 
the interactors (GMPS) can influence the activity 
of USP7, we will now briefly describe the most 
prominent interaction partners of USP7 (Figure 
6).
known as ND10 or promyelocytic leukaemia 
nuclear bodies (PML-NBs)179. Difficulties in the 
maintenance of cell lines lacking USP7 indicates 
that it is required for long term cell survival127, a 
conclusion supported by the observation that 
knock out of the gene in mice causes death in 
early embryo development180. This lethality 
could be related to widespread proteome 
changes in cells depleted of USP7, which link 
the enzyme to the regulation of transcription, 
DNA replication and apoptosis181. USP7 is 
upregulated in prostate cancer and has been 
linked to an important role in non small cell 
lung carcinogenesis, and an aberrant USP7 
function is involved in oncogenesis and viral 
infection182,183.
Figure 6. The most prominent interaction partners and targets of USP7. Ubiquitin is colored purple.
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ICP0
USP7 was first identified as a strong interaction 
partner of herpes simplex virus type 1 (HSV-1) 
immediate-early regulatory protein Infected 
Cell Protein 0 (ICP0; previously also known as 
Vmw110)179. It is a component of the inner viral 
matrix that it is released into the cytoplasm 
shortly after infection. To date, the precise 
function of ICP0 is unknown. However ICP0-
deficient viruses are avirulent due to their 
sensitivity to interferon α/β and have an aberrant 
viral gene expression at a pre-immediate-
early step in infection184,185. ICP0 is required 
for productive low-multiplicity infection, and 
therefore controls the balance between the 
viral latency and lytic states186,187. As HSV-1 
infection prevents induction of apoptosis in an 
ICP0-dependent manner, it is possible that ICP0 
inhibits the initiation of apoptotic responses by 
p53188.
ICP0 contains an N-terminal RING domain, 
needed for its ubiquitin ligase activity, a nuclear 
localization signal, and an oligomerization 
domain in the C-terminus189. It mediates the 
degradation of several cellular proteins by 
inducing ubiquitin conjugation179,190,191 and 
sequesters proteasomes in the nucleus192. The 
C-terminal region is critical for both the HSV-1 
virulence and the interaction with USP7193. An 
intriguing consequence of this interaction with 
USP7 is the occurrence of reciprocal activities 
such that USP7 stabilises ICP0, while ICP0 
ubiquitinates and destabilises USP7122. Possibly, 
the virus recruits USP7 to facilitate its survival in 
the host. 
Interestingly, a recent study showed that ICP0 
expression resulted in export of USP7 from 
nucleus to cytoplasm where USP7 binds and 
deubiquitinates TRAF6 and IKKγ, thereby 
inhibiting the NF-κB mediated innate immune 
response194. This suggests that USP7 regulates 
Toll-like Receptor (TLR) signalling and that ICP0 
exploits this physiologic process to hamper 
innate response to HSV-1. 
HDM2/HDMx, DAXX and p53
The p53 tumour suppressor is essential for the 
cell-cycle arrest and apoptosis after genotoxic 
stress195,196. It is also required for the induction 
of senescence after oncogene activation, 
which is considered to be a mechanism to 
prevent tumourigenesis196. One of the major 
roles of p53 is to activate transcription of a 
wide range of target genes to exert its role the 
stress response197. Its importance as a tumour 
suppressor is nicely demonstrated by the fact 
that it is mutated, inactivated or misregulated 
in almost all human cancers195.
p53 is tightly regulated, mainly at the level 
of protein stability, to allow rapid protein 
accumulation and activation after DNA damage. 
Hence under normal condition, the p53 protein 
levels are kept low, due to continuous  ubiquitin-
dependent degradation by the proteasome198. 
This ubiquitination is carried out by the E3 ligase 
Human Double Minute 2 (HDM2). It is essential 
in regulating p53 levels, since the embryonic 
lethality observed in HDM2 knockout mice is 
rescued in a p53-/- background199,200. 
Interestingly, USP7 interacts and stabilises 
p53 by removing the ubiquitin201. However, 
the regulation of p53 protein levels less 
straightforward. For example, when USP7 
expression is lost, it results in a counterintuitive 
upregulation of p53 with associated cell 
cycle arrest127,202-204. This shows that the p53 
regulation is dynamic and much more complex, 
and that many factors contribute to the control 
and activation of p53195,196. 
Structural studies revealed that both HDM2 
and p53 are able to bind to USP7, and therefore 
are both valid targets of USP7205-208. However, 
since USP7 has a higher affinity for HDM2, it is 
now believed that under normal conditions 
USP7 deubiquitinates and therefore stabilizes 
auto-ubiquitinated HDM2 (Figure 7; left panel). 
Death domain-associated protein (DAXX) 
simultaneously binds to HDM2 and USP7, 
and it mediates the stabilizing effect of USP7 
on HDM2209. In addition, DAXX enhances the 
intrinsic E3 activity of HDM2 towards p53. 
DAXX itself is also a target of both HDM2 and 
USP7210. The net effect of this complex is the 
ubiquitination and subsequently destabilization 
of p53, which explains the upregulation of p53 
after the loss of USP7.
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levels and its target genes212.
The second protein involved in USP7 mediated 
p53 homeostasis is Epstein-Barr Nuclear 
Antigen-1 (EBNA-1), which is essential in 
replicating and maintaining Epstein-Barr virus 
genomes. After infection it alters the host 
cellular processes, including the disruption 
of PML-NBs through the degradation of PML 
proteins213. This degradation affects apoptosis, 
DNA repair and antiviral responses. Finally, it 
can counteract the stabilization of host p53 
by inhibiting host USP7, thereby decreasing 
apoptosis and increasing host cell survival which 
may contribute to malignant transformation214.
Both TSPYL5212 and EBNA-1215 bind to the TRAF 
domain of USP7 (Figure 8). This interaction does 
not influence the stability of either protein, 
but rather this competitive binding negatively 
regulates USP7 activity towards p53. This 
explains the oncogenic-like activity of both 
TSPYL5 and EBNA-1.
However, following stress like DNA 
damage, HDM2 is phosphorylated by 
Ataxia Telangiectasia Mutated (ATM)/Ataxia 
Telangiectasia and Rad3-related protein (ATR). 
This results in first the dissociation of the USP7/
HDM2/DAXX complex, and subsequently the 
proteasomal degradation of HDM2 and DAXX 
(Figure 7; right panel). Now USP7 can target and 
ultimately upregulate p53203. 
Taken together, if USP7 would be targeted by 
drugs as part of cancer therapy, this would 
inactivate HDM2 and activate p53. This would 
result in tumour cell arrest and apoptosis in cells 
retaining a functional p53 pathway. 
TSPYL5 and EBNA-1
The regulation of USP7 mediated p53 
homeostasis has two more players. The first is 
TSPYL5, which is among the genes in a prognostic 
expression signature (MammaPrint®) that 
predicts clinical outcome of breast cancer211. It 
has a causal role in breast oncogenesis, but the 
function of this protein is still unknown. TSPYL5 
overexpression results in the decrease of p53 
Figure 7. USP7 regulates both HDM2 and p53 protein levels. In normal homeostasis, USP7 interacts with DAXX and HDM2, 
antagonizing their (auto-) ubiquitination. This results in ubiquitinated p53, which is subsequently targeted for degradation by 
the proteasome. However, upon stress, HDM2 is phosphorylated by the ATM/ATR pathway. As a result USP7 now switches targets 
and interacts with p53. This prevents its ubiquitination and both HDM2 and DAXX are degraded by the proteasome, since their 
(auto-) ubiquitination is no longer antagonized by USP7127,202,203. Ubiquitin is colored purple.
Normal
Homeostasis
DNA damage
Oxidative stress
Proteasome
USP7
p53
DAXX
HDM2
Ubiquitin
USP7
DAXX
HDM2
p53
 1 
 General Introduction               23
PTEN
Phosphatese and Tensin Homolog (PTEN) is 
among the most frequently lost or mutated 
tumour suppressors, with a 30 to 80% 
mutation frequency in endometrial carcinoma, 
glioblastoma, and prostate cancer and breast, 
colon, and lung tumours216-221. Complete loss 
of PTEN is observed at highest frequencies 
in endometrial cancer and glioblastoma 
and is generally associated with metastatic 
cancers222,223.
PTEN protein acts as a phosphatase to 
dephosphorylate phosphoinositide-3,4,5-
triphosphate (PIP3), which is a potent 
activator of AKT224. Therefore, loss of PTEN 
function stimulates cell growth, survival and 
proliferation225. However, since phosphatase-
inactive PTEN still retains tumour suppressive 
activity, it is believed PTEN also has AKT-
independent functions226. This is carried out 
by the nuclear fraction of PTEN58. This nuclear 
compartmentalization is regulated by the 
ubiquitination state of PTEN59. Specifically, PTEN 
is mono-ubiquitinated by NEDD4-158, which is 
the signal for translocation to the nucleus from 
the cytoplasm. In the nucleus, PTEN interacts 
with the E3 ligase Anaphase Promoting 
Complex (APC)227. The APC is a large E3 ligase 
complex that marks target cell cycle proteins 
for degradation and is therefore one of the 
main players in regulating mitotic events. CDH1 
is one of the co-activator proteins of APC by 
providing substrate specificity to the E3-ligase 
in a cell-cycle regulated manner228. Binding of 
PTEN allosterically promotes the interaction 
between the APC and CDH1, and thereby 
enhancing the tumour-suppressive activity of 
the APC-CDH1 complex. 
The mono-ubiquitination of PTEN is antagonized 
by USP7. Therefore USP7 promotes the nuclear 
exclusion of PTEN. Since this relocalization 
results in a lowered apoptotic potential in 
prostate cancer cells, inhibiting USP7 would be 
beneficial for targeting the PTEN pathway in 
cancer cells182.
FOXO4
The Forkhead box O (FOXO) family of proteins 
are transcription factors that are involved in 
several cellular responses regulating longevity 
and tumour suppression, including cell cycle 
inhibition, oxidative-stress resistance, apoptosis 
and metabolism229. Analogous to PTEN, the 
localization and activity of FOXO4 is regulated 
through mono-ubiquitination, which in turn is 
antagonized by direct binding230 and hydrolysis 
by USP7231.
In normal homeostasis, FOXO4 is 
phosphorylated by the protein kinase AKT 
in response to cellular stimulation by insulin 
and growth factors232. This relocalizes FOXO4 
from the nucleus to the cytoplasm, where it is 
subjected to ubiquitin-mediated proteasomal 
degradation. This ensures low FOXO4 protein 
levels and therefore low transcription of its 
target genes. 
However upon metabolic stress, like a lack 
of insulin, low glucose or increased cellular 
oxidative stress, FOXO4 is mono-ubiquitinated 
by HDM2233 and possibly other E3’s234. This 
mono-ubiquitination is possibly preceded by 
deacetylation by SIRT1231. After this mono-
ubiquitination, nuclear FOXO4 protein levels 
increase and subsequently cause the increase 
of translation of FOXO4 target genes. This 
translates metabolic stress in a FOXO4-mediated 
arrest in G1–G0, increased gluconeogenesis 
and protection against cellular oxidative stress. 
Overall, this mechanism allows mammalian 
cells to quickly respond and survive periods of 
nutrient shortage. 
In addition, the prolyl isomerase PIN1, frequently 
found to be overexpressed in cancer, is a critical 
regulator of the Cyclin dependent kinase 
inhibitor p27 through FOXO4 inhibition235. 
After specific phosphorylation events on 
FOXO4, PIN1 is able to negatively regulate 
FOXO transcriptional activity. Interestingly, 
PIN1 enhances the activity of USP7, thereby 
preventing nuclear accumulation of FOXO4. 
However, the mechanism is still unclear. 
REST
Repressor Elelement 1-Silencing Transcription 
Factor (REST) is a transcriptional repressor 
of the Kruppel-type zinc finger transcription 
factor family. It binds to neuron-restrictive 
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are few overlaps among the interacting 
proteins121. The function and mechanisms of 
these interactions remain unclear.
H2B and GMPS
In contrast to ubiquitinated H2A, which 
functions as a repressive chromatin mark, 
ubiquitinated Histone 2B (H2B) is associated 
with active translation. Interestingly, genetic 
and biochemical experiments revealed that 
USP7 interacts with Guanosine Monophosphate 
Synthetase (GMPS). This interaction enhances 
USP7 activity towards ubiquitinated p53 and 
is essential for H2B deubiquitination, but not 
H2A245-247. This mechanism is independent of the 
enzymatic activity of GMPS. This complex acts 
as a gene-selective transcriptional corepressor 
that associates with Polycomb response 
elements (PREs), ecdysteroid regulated genes 
and the Epstein–Barr virus latent origin of 
replication245-247. Furthermore, this complex 
might be involved in tumorigenesis, since 
GMPS was found upregulated in tumorigenic 
cells248,249, and knockdown of USP7 in carcinoma 
cells increased the levels of ubiquitinated 
H2B247.
In chapter four we study this unexpected 
complex, and explain the general allosteric 
mechanism of USP7 hyper-activation by GMPS. 
However, the GMPS activation most likely 
also involves target specific effects, since it is 
required for the activity on H2B.
CLASPIN
CLASPIN is an adaptor protein that is required 
for checkpoint mediated cell cycle arrest after 
DNA damage. It binds to BRCA1 and CHK1, 
thereby facilitating their ATM/ATR-mediated 
phosphorylation. To terminate the signalling 
invoked by BRCA1 and CHK1, CLASPIN is 
ubiquitinated by both the APC complex and 
SCF-βTrCP, leading to its degradation by the 
proteasome. USP7 in vivo interacts with CLASPIN 
and thereby prevents this ubiquitination and 
therefore increases its stability and subsequent 
CHK1 phosphorylation250. Interestingly, USP7 
specifically prevents the SCF-βTrCP- but not 
APC-mediated degradation of CLASPIN. 
silencer element (NRSE) and therefore represses 
neuronal genes in non-neuronal tissues and 
undifferentiated neuronal progenitor cells. 
It associates with two co-repressors, mSin3 
and CoREST, which in turn recruit the BHC 
complex, which deacetylates and demethylates 
specific histones, thereby acting as a chromatin 
modifier236. Overall, REST is believed to be a 
master negative regulator of neurogenesis237. 
To relieve this repression, REST is ubiquitinated 
during neuronal differentiation by the E3 
ubiquitin ligase complex SCF–β-TrCP which 
targets REST for proteasomal degradation238,239. 
Not surprisingly, aberrant REST function is 
associated with neurodegenerative diseases 
like Huntington’s disease240, but also to 
tumourigenesis241,242. A recent study showed 
that USP7 positively regulates REST protein 
levels, by direct interactions and subsequent 
deubiquitination and therefore promotes the 
maintenance of neuronal progenitor cells243. 
PRC1
Two tandem protein complexes modify histones 
to yield transcriptionally silent chromatin. 
First the Polycomb Repression Complex 
2 (PRC2) complex is recruited to the PRC 
Response Elements (PREs) on the chromatin. 
This complex has histone methyltransferase 
activity and primarily trimethylates histone H3 
on K27244. This silencing is further stabilized by 
subsequent mono-ubiquitination of K119 of 
Histone 2A (H2A) by the second complex: PRC1. 
These complexes are required for long term 
epigenetic silencing of chromatin after cellular 
differentiation and have an important role in 
stem cell differentiation and early embryonic 
development. 
Two ubiquitin-specific proteases, USP7 and 
USP11, are associated with the PCR1 complex 
by direct binding to BMI1 and MEL18130. 
This results in the stabilization of the PRC1 
components. Ablation of either USP7 or USP11 
expression results in de-repression of the p16/
INK4a tumour suppressor accompanied by loss 
of PRC1 binding at the locus and a senescence-
like proliferative arrest. USP7 and USP11 show 
no obvious similarities in their primary sequence 
apart from the catalytic domains71, and there 
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CHFR
Checkpoint Protein with FHA and RING Finger 
Domains (CHFR) is an E3 ligase that functions 
in early prophase before chromosome 
condensation, by actively delaying passage into 
metaphase in response to mitotic stress. It plays 
an important role in cell cycle progression and 
tumour suppression as a stress checkpoint, and 
ensures chromosomal stability by controlling 
the expression levels of key mitotic proteins 
such as PLK1 and AURORA A251,252. CHFR binds 
to USP7 and their interaction greatly increase 
the stability of CHFR, by preventing its auto-
ubiquitination both in vivo and in vitro253. 
DNMT1
DNA (cytosine-5)-methyltransferase 1 (DNMT1) 
is the major DNA methyltransferase responsible 
for maintaining genomic methylation patterns 
through DNA replication cycles. It is localised 
at DNA replication foci during the S phase, 
which agrees well with its role as a maintenance 
methyltransferase254. It is responsible for the 
preservation of the methylation patterns during 
cell divisions by methylation of hemimethylated 
CG dinucleotides254. UHFR1 is an E3 ligase and a 
crucial co-factor of DNMT1. Both proteins form 
a ternary complex with USP7, in which UHFR1 
and USP7 balance the stability of DNMT1255. 
And beyond, towards a molecular 
understanding of USP7
Overall, USP7 is able to directly regulate key 
players in many crucial cellular processes. Since 
a large high confidence proteomics effort 
has identified many more (uncharacterized) 
interactors, more studies are required to fully 
grasp the biological role of USP7 and the 
effect of these interactions on USP7 activity121. 
However, the potential of USP7 as a drug target 
is clear, which is also appreciated by several 
major pharmaceutical companies. This has 
resulted in some initial successes. For example, 
a cyano-indenopyrazine derivative (HBX 41,108; 
Hybrigenics) reversibly inhibits USP7 in the sub-
micromolar range, resulting in stabilization and 
activation of p53256. However, to aid future drug 
design it is crucial that we gain more insights in 
the activity mechanisms of USP7. 
USP7 structural information
USP7 is a single chain enzyme of 128 kDa 
(1102 amino acids) and contains broadly three 
domains; an N-terminal TRAF/MATH domain, a 
catalytic USP domain and a 64 kDa C-terminal 
region (Figure 8). The N-terminal TRAF/MATH 
domain comprises an eight-stranded anti-
parallel β-sandwich and is responsible for 
recruitment of substrates such as p53 and 
HDM2, and TSPYL5257,201,212. It also binds to the 
viral protein EBNA-1257. These proteins bind to 
the TRAF domain through direct interactions 
with its binding groove (Figure 8D)205-207. There 
are virtually no structural changes in the TRAF 
domain upon binding to peptides from these 
interaction partners, with only a slight shift of 
the side chain of W165. The peptide ligands 
bind the same shallow groove on the surface of 
the TRAF domain. The main difference between 
the HDM2 and p53 peptide interactions with 
that of the EBNA-1 peptide is with respect to 
the total buried surface areas (500 and 700 
Å2 compared to 1000 Å2). All three peptides 
bind to the same surface of USP7, explaining 
the competitive nature of the interactions. The 
structures and mutagenesis studies showed a 
preference for a P/AxxS-motif in the peptide. 
Contacts by the serine are identical and crucial 
for all peptides, and W165 in the peptide 
binding pocket of USP7 is also crucial. The 
affinities for the peptides range from 10 μM and 
8 μM for p53 and HDM2, respectively, to 1 μM 
for EBNA-1. However, since the catalytic domain 
provides additional interactions with ubiquitin 
on the target, and at least p53 and HDM2 also 
bind to the C-terminal region177, the affinity for 
the ubiquitinated substrate will be higher. 
Structural studies revealed that the catalytic 
domain of USP7 has the conserved fold of 
the USP family (Figure 8B)81,132,205. They show 
a papain-like architecture plus an extended, 
fingers-like domain that forms the ubiquitin 
binding pocket258. In contrast to many USPs, 
the finger region in USP7 does not contain zinc. 
Several crystal structures show that the catalytic 
domain is maintained in a non-functional state, 
in which the active site residues are in a non-
reactive conformation (Figure 8C). The active 
conformation involves rearrangements of the 
catalytic domain that allow ubiquitin binding 
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to promote sequence specific DNA binding 
of p53177,259. As described in chapter four, this 
C-terminal domain contains five consecutive 
UBL domains. 
Despite our extensive understanding of USP7, 
there are still many questions to be addressed. 
The first question concerns the role of the UBL 
domains in the activity of USP7. They seem 
to activate the catalytic domain, where an 
(competitive) inhibition is expected. Morever, 
do we need all UBL domains or would a smaller 
and organization of the catalytic triad, as was 
shown in the structure of a complex with the 
suicide substrate ubiquitin aldehyde81. Kinetic 
data suggest that the affinity for ubiquitin is in 
the low micro-molar range.
The C-terminal region of USP7 is essential for 
effective catalytic activity against a minimal 
synthetic substrate, ubiquitin with a C-terminal 
fluorescent group, 7-amido-4-methylcoumarin 
(Ub-AMC)176,177. Also, it harbors additional 
HDM2 and p53 binding sites, and is essential 
Figure 8. Overview of structural information USP7. A. Schematic domain architecture showing the TRAF substrate binding 
domain (brown), the catalytic domain (orange) and the predicted UBL domains (rainbow coloured). B. The crystal structures of 
the catalytic domain without ubiquitin co-crystallized (orange; 1NBF) and with ubiquitin (pink; 1NB8). Ubiquitin is purple and the 
β-hairpin remodelled upon ubiquitin binding is green. C. The active is remodelled upon ubiquitin binding. D. Crystal structure 
of the TRAF substrate binding domain (brown) with an EBNA peptide (green) (1YY6).
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part already suffice for this activation. Another 
issue arises with GMPS, of which we know it 
binds and activates USP7, but we do not where 
it binds USP7 and how this (hyper-)activates 
USP7. These and other questions, will be 
discussed and adressed in chapter 4. 
Outline of this thesis
A thourough understanding of the activity and 
biological role of the DUBs is important for drug 
development. To that end, this thesis focuses 
on gaining mechanistic insight in USPs though 
structural and biochemical characterization. In 
chapter two, we characterized the biochemical 
properties of twelve members of the USP family. 
This revealed that despite their homologous 
catalytic domain, they have very different 
kinetic properties. Subsequent analysis of 
their di-ubiquitin topoisomer preference, 
revealed modest but surprising differences. 
The characterization also describes activity 
modulation by both inter- and intra-molecular 
domains and proteins. In the next two chapters, 
we will focus on two distinct cases of intra-
molecular activity modulation and present 
their mechanisms; USP4 in chapter three and 
USP7 in chapter four. The activities of both 
USPs are modulated by internal UBL domains. 
However, the UBL domains have different 
functions. In USP4 the UBL domain is inserted 
in the catalytic domain, where it inhibits USP4 
activity by competing for ubiquitin binding. 
Others USPs can also bind to the UBL insert, 
which in turn relieves USP4 from its inhibition. 
However in USP7, the multiple UBL domains 
just outside the catalytic domain are essential 
for activity and ubiquitin binding, and therefore 
play an activating role. We present the crystal 
structure of this domain and characterized the 
activation, which revealed a mechanism where 
binding of part of this domain remodels the 
catalytic domain, resulting in the activation. 
This activation is dynamic and the metabolic 
enzyme GMP synthetase (GMPS) can 
allosterically hyper-activate USP7 by binding 
to the remainder of the domain, enhancing the 
interaction to the catalytic domain. Finally, in 
chapter five we present a general discussion of 
results described in chapter two to four. 
Table 1. Overview of available structural information of USP7.
Domain     
TRAF     
  
  
  
    
     
TRAF and CD
CD
C-terminal domain
Residues
54 - 205
54 - 206 
53 - 198
54 - 205
54 - 205
43 - 560
208 - 560
208 - 560
537 - 664
PDB code Comments
1YZE206   
1YY6206  with EBNA1-peptide
2FOJ207  with p53 peptide 364-367
2FOO207  with p53 peptide 359-362
2FOP207  with HDM2 peptide 147-150
2F1W, 2F1X205 with p53 peptide
2F1Y205  with HDM2 peptide
3MQR208  with HDMx peptide
3MQS208  with HDM2 peptide
2F1Z205
1NB881
1NBF81  in complex with ubiquitin aldehyde
2KVR  first UBL, NMR
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Abstract
Ubiquitin-specific proteases (USPs) are papain-like isopeptidases with variable inter- and intra-mo-
lecular regulatory domains. To understand the effect of these domains on USP activity, we have 
analyzed enzyme kinetics of a set of twelve USPs in presence and absence of modulators using 
synthetic reagents. We synthesized all seven wild-type lysine-linked di-ubiquitins and provide the 
first comprehensive analysis comparing ubiquitin (Ub) chain preference. Our data reveal large varia-
tions in both the catalytic turnover and Ub binding between USPs and modest preferences for di-Ub 
topoisomers. Interestingly, our data show that the preference of USP7 for di-Ub topoisomers can 
be attributed to the binding affinity (KM) for the substrate, while the intermolecular activators UAF1 
and GMPS mainly increase the catalytic turnover (kcat). Together, this comprehensive kinetic analysis 
highlights the variability within the USP family.
Introduction
Since the 1980s, the post-translational 
modification of proteins by Ub has been the 
focus of many studies due to their important 
roles in many cellular processes1,2. However, 
the processing and removal of Ub and thus 
reversal of the modification of target proteins 
is equally important and is carried out by De-
ubiquitinating enzymes (DUBs).
The human genome encodes nearly 100 putative 
DUBs, belonging to at least five subfamilies of 
isopeptidases3. The Ubiquitin-Specific proteases 
(USP) family is the largest class of DUBs, with 
more than sixty members3,4. USPs are cysteine 
proteases that use a papain-like mechanism to 
hydrolyze the isopeptide bond between the 
carboxy terminus of Ub and the ε-amine of the 
target lysine. 
USPs are variable both in size and their modular 
domain architecture, which can include 
substrate binding domains, ubiquitin-like (UBL) 
domains and other protein-protein interaction 
domains3,5 (Figure 1A). They share a common 
papain-like fold, but the catalytic domains can 
have large insertions6, possibly directly affecting 
activity, Ub binding or localization as seen in 
USP47, USP58, USP149 and CYLD10. Additionally, 
some USPs need structural rearrangements to 
bind their substrate and catalyze hydrolysis11-15.
USPs are often found in large protein complexes 
and many interaction partners of USPs have 
been identified16. Although the function of 
most interaction partners is still unclear, some 
play a role in the modulation of USP activity. For 
example, GMP synthetase (GMPS) interacts and 
activates USP717-19, whereas the WD40-repeat 
containing UAF1 activates USP1, USP12 and 
USP4620,21. 
With its diversity of domain architectures, 
internal insertions within the catalytic 
domain and external modulators, the USP 
family apparently requires different levels of 
regulation. This poses a number of unanswered 
questions. For instance, what is the variability of 
the activity between the catalytic domains and 
the full-length proteins? Are there preferences 
for Ub-chain types and does this change in the 
presence of external modulators?
To address these questions, we have developed 
and produced22 chemical tools, and used these 
to characterize a set of twelve USPs. This revealed 
variations of several orders of magnitude in 
catalytic turnover and Ub binding, and allowed 
characterizing intra- and inter-molecular 
activity modulation. Using synthetic di-Ub, we 
determined the chain preferences of all USPs 
against all seven lysine-linked topoisomers. 
This showed a modest chain specificity that was 
variable between USPs, but did not change in 
the presence of the modulators. Kinetic analysis 
of the hydrolysis by USP7 showed that there is 
no additional Ub binding site, suggesting that 
the chain preferences are achieved by steric 
hindrance.
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Results
Protein cloning, expression and purification
After protein expression trials23, we identified 
constructs suitable for large-scale protein 
expression of twelve different USPs in either 
E.coli or in Sf9 insect cells (Figure 1A). In this 
study we could therefore include sixteen 
constructs containing either the (almost) full-
length constructs (USP1ΔN, USP7FL, USP11FL, 
USP12FL, USP16FL, USP25FL and USP46ΔN, 
with ΔN and ΔC denoting N- and C-terminal 
truncations respectively), or the catalytic 
domain (USP4CD, USP7CD, USP8CD, USP16CD, 
USP21CD, USP30CD and USP39CD) (Figure 1A 
and B). Additionally, we expressed and purified 
two known USP activity modulators: UAF121 and 
GMPS19. Cloning, expression and purification 
Figure 1: Overview of the characterized USPs. A. Domain architecture of the USPs used in this study. The constructs used in 
this manuscript are highlighted with corresponding residue numbers and expression system. B. Final purification product of the 
USP constructs shown on SDS-PAGE gel. An asterisk indicates the expressed USP. USP7FL has an N-terminal GST tag.
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protocols are provided in the materials and 
methods section.
Large variations in both catalytic turnover 
and Ub binding
Although USP family members share a 
homologous catalytic domain, many contain 
insertions within their catalytic domain or 
have additional domains that could influence 
their activity6,7 (Figure 1A). To study these 
effects, we determined the kinetic parameters 
of all the USPs. To this end, we produced a 
minimal synthetic Ub substrate with fused at 
its C-terminus the small molecule 7-amino-
4-methylcoumarin (UbAMC)22,24. The UbAMC 
substrate is a widely used reagent to assay 
DUB activity. Upon hydrolysis by the DUB, 
the free AMC reporter molecule produces a 
fluorescent signal, which allows for a direct 
read-out of activity (Supplemental Figure S1). 
Since this universal DUB substrate contains an 
AMC moiety instead of the endogenous USP 
target, it is suitable for comparing the relative 
activity among the USP family members. With 
this substrate, we observed variations of several 
orders of magnitude in both KM and kcat between 
the USP constructs (Figure 2). Our data are in 
agreement with earlier reports for USP1, USP4, 
Figure 2. Kinetic parameters using UbAMC. A. and B. The Michaelis-Menten curves for the different USPs obtained by 
determining the initial rates (V0) at different UbAMC concentration. (B) Shows the USPs with intra-molecular modulation. C. 
Overview of the kinetic parameters (kcat, KM and Kcat/KM) for the different USPs. D. Activity classification of USPs, based on kinetic 
parameters, where group 1 represents the USPs with the lowest activity; group 2 contains USPs with intermediate activity and 
group 3 contains the USPs with the highest activity. Dashed lines link the catalytic domains with the corresponding full length 
USPs. Solid lines show the effect of intra-molecular activating and inhibiting domains. 
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USP7, USP8 and USP39 (Supplemental Table 
S1)7,11,21,25,26. Based on their KM and kcat values, 
the USPs could be classified in three groups 
(Figure 2D). Group 1 represents the USPs, whose 
activity is very limited due to a low kcat (USP1ΔN, 
USP4CD, USP12, USP30CD, USP39CD and 
USP46ΔN). The “intermediate” group 2 contains 
the USPs that show moderate activity (USP4-
D1D2, USP11FL, USP16CD, USP16FL, USP21CD 
and USP25FL), and group 3 contains very active 
USPs (USP7FL, USP7CD-HUBL and USP8CD). 
As expected, group 1 contains USP39CD. It 
shows no activity, since it lacks the catalytic 
cysteine and histidine residues3. Group 1 also 
contains USP1ΔN, USP12FL and USP46ΔN, 
all three known to have low activity, which is 
enhanced by the external modulator UAF120,21. 
Interestingly, also USP30CD shows very little 
activity. To date there is no known activator for 
USP30CD, although several interaction partners 
have been identified16.
In contrast, group 3 represents the most active 
USPs, and contains both USP8CD and the USP7 
constructs with activating C-terminal Hausp 
UBL (HUBL) domain17. Interestingly, USP8CD has 
an unusual high KM, which is possibly due to an 
inserted α-helix in the catalytic domain, which 
is suggested to stabilize the observed closed 
conformation11. However, this is compensated 
by a very high catalytic turnover, rendering it a 
very active USP overall.
Intra-molecular modulation of USP activity
Not only do we observe differences in enzymatic 
behavior between the USPs, but we also observe 
differential effects of intra-molecular domains 
on the activity of the (minimal) catalytic domains 
in USP4, USP7 and USP16 (Figure 2B). 
We recently showed that USP4 contains a 
UBL domain inserted in its catalytic domain5 
(USP4CD; Figure 1A),  which inhibits the activity 
of USP4CD (group 1; Figure 2B,D). The presence 
of this UBL domain in USP4CD increases the KM 
and is therefore less active than the minimal 
catalytic domain USP4-D1D27 (group 2; Figure 
2D). In contrast, both kcat and KM are affected 
in USP7, where the minimal catalytic domain 
(group 1) shows far less activity than the full-
length enzyme (group 3). Here, the activity of 
USP7 is modulated by its HUBL domain which 
is essential for both activity and Ub binding in 
vitro and  in vivo17,25,27. The activity of USP16CD 
is modulated by the zinc-finger Ub specific 
protease (ZnF-UBP) domain. Surprisingly, the 
activity is enhanced by increasing catalytic 
turnover, rather than the KM (Figure 2B,D). Since 
it is a Ub binding domain, the effect of the zinc-
finger could be more prominent in poly-Ub 
processing28, which might add up to a bigger 
difference than observed here. USP39CD also 
contains a Znf-UBP domain, but it is unlikely 
that this will lead to enzymatic activation since 
USP39CD does not have the catalytic residues.
Overall, this shows that several intramolecular 
domains are able modulate USPs. The 
modulation can affect KM (USP4), kcat (USP16), or 
both (USP7), and both inhibitory and activating 
domains are found in USPs. Together, this 
creates an additional layer of regulation on the 
catalytic activity of USPs.  
Some USPs show small preference for di-Ub 
topoisomers 
Most studies of DUB specificity have focused 
on processing K48- and K63-linked poly-
Ub. However, since the additional linkages 
serve equally important cellular functions, 
we synthesized all seven lysine-linked di-Ub 
topoisomers22 and we used them in a qualitative 
assay to assess all linkage preferences of the 
panel of USPs (Figure 3 and Supplemental Figure 
S2). In agreement with the kinetic parameters 
from the UbAMC assay, the USPs from group 1 
showed very little activity; USP8CD from group 
3 is the most active USP, and most USPs from 
group 2 show an intermediate activity. However, 
there were two clear changes. Where USP7 was 
amongst the most active USPs in the UbAMC 
assay, now it shows an intermediate activity. 
In contrast, USP21CD showed intermediate 
activity in the UbAMC assay, but is very active 
in the di-Ub assay and displays activities almost 
matching the most active USP; USP8CD.
The USP family seems to be rather promiscuous 
compared to other DUB families. For example, 
Cezanne29 (K11), OTUB130 (K48) and TRABID31 
(K29) from the OTU family display strong 
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linkage preferences for di-Ub topoisomers. 
However, figure 3 shows that the differential 
activity of the USPs is smaller. All the active USPs 
from this study hydrolyze all di-Ub topoisomers. 
Nevertheless, there are clear differences 
in efficiency. For instance, most USPs have 
difficulties in hydrolyzing K27- and, to a lesser 
extent, K29-linked di-Ub. For example, USP7 
has limited activity towards hydrolyzing K27- 
and K29-linked di-Ub. In contrast, the K6, K11, 
K48 and K63 Ub topoisomers are hydrolyzed 
relatively efficiently. Another clear example 
is USP4, for which K63-linked di-Ub is a better 
substrate than K48-linked di-Ub. Apparently, 
some USPs seem to prefer specific di-Ub 
isoforms. 
We wondered whether the intramolecular 
modulating domains in USP4, USP7 and USP16 
change the linkage preferences. However, this 
does not seem to be the case. The different USPs 
respond differently to modulation by internal 
Figure 3. Di-Ub topoisomer preference for the different USPs. A. Ubiquitin (1UBQ) showing all lysines. The distal ubiquitin 
binds the catalytic domain. B. Overview of a time-course using all seven different di-Ub topoisomers (5 μM) (K6, K11, K27, 
K29, K33, K48 and K63) for the active USPs (75 nM). Samples from each time-point (0, 5, 10, 30, 60, 180 min) were analyzed on 
coomassie stained SDS-PAGE gels. 
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domains, analogous to what was observed 
with UbAMC (Figure 3 and Supplemental 
Figure S2B,C). However, no change in linkage 
preference was seen between catalytic domain 
and longer constructs, showing that the 
modulation effects are substrate independent 
mechanisms.
 
Overall, this shows that USPs can hydrolyze 
all Ub lysine-linked di-Ub topoisomers, but 
with differences in efficiency. Moreover, these 
differences are preserved in the presence of the 
intra-molecular activity modulators. 
In the case of USPs, isopeptide-linked Ub is 
not representative for di-Ub 
To explain the Ub linkage preference, we might 
not need full-length di-Ub32. To test this in an 
activity assay, we designed and synthesized 
a panel of fluorescence polarization-based 
(FP) di-Ub mimics. In these reagents, TAMRA-
labeled Ub peptides were linked via an 
isopeptide linkage to the carboxy-terminus 
of wild-type full-length mono-Ub33 (Figure 4A 
and Supplemental Figure S3A,B). Therefore, in 
contrast to the peptide linkage in UbAMC, these 
FP-reagents use the natural isopeptide linkage. 
The proximal Ub is represented by 14-mer 
peptides, each representing one of the seven 
lysines of Ub (Figure 3A and 4A). In addition, 
the di-peptide (KG) was prepared to serve as 
a minimal substrate. Mass spectrometry and 
SDS-PAGE analysis of these new Ub substrates 
showed that the synthesis was successful for 
all eight different TAMRA labeled isopeptide-
linked Ub FP-reagents (Supplemental Figure 
S3C,F).
As a proof of principle, we used the minimal 
´KG´ FP-reagent to determine the kinetic 
parameters of USP4-D1D2 (Figure 4B and 
Supplemental Figure S3D,E,F,H). With this 
reagent we determined KM (293 nM) and kcat 
(0.07 s-1) values similar to the kinetic parameters 
obtained using UbAMC. Only the kcat is higher, 
possibly due to the difference in the chemical 
and steric nature of the linkage, since the FP-
reagents contain a natural isopeptide linkage 
in contrast to the UbAMC reagent. However, 
Figure 4. Isopeptide linked-ubiquitin FP reagents. A. Schematic view of N-terminal TAMRA labeled ubiquitin peptide (K6) 
conjugated with ubiquitin. Table shows the peptide sequences used with the corresponding residue numbers for the different 
types of ubiquitin linkages. The conjugated lysine is highlighted. B. Michaelis-Menten curves for USP4-D1D2 (top) and USP7FL 
(bottom) were obtained using the TAMRA labeled ubiquitin peptides in a FP hydrolysis assay. The curves for USP7 could not be 
fitted. 
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Figure 5. Michaelis-Menten kinetics of di-Ub hydrolysis by USP7. A. Representative western-blot Michaelis-Menten analysis 
di-Ub hydrolysis USP7. Assay performed using 2-fold dilutions of the di-Ub starting at 15 μM for 5 minutes at 37 degrees. B. 
Michaelis-Menten analysis for USP7FL for di-ubiquitin hydrolysis. Initial rate (V0) of di-Ub conversion into mono-Ub was 
determined at different substrate concentration from Western Blots shown in A. The conversion to mono-Ub was quantified 
using the di-Ub signal corrected for conversion.
since the KM values are similar, both represent 
comparable Ub reagents.
In the di-Ub time course assay, we observed 
linkage preferences of USP4-D1D2 and USP7; 
e.g. USP7 prefers the hydrolysis of K6- over 
K27-linked di-Ub, and USP4-D1D2 prefers K63- 
over K48-linked di-Ub (Figure 3B). Although 
difficult to fit for USP7, with our FP-reagents 
we observed no difference in activity for either 
USP4-D1D2 or USP7, and therefore could not 
recapitulate the preferences observed in the 
di-Ub assay (Figure 4B and Supplemental Figure 
S3G,H). This shows that these FP reagents do 
not contain the required information to mimic 
di-Ub for USPs.
The proximal Ub does not contribute, but 
rather hinders binding to USP7
Since the FP-reagents were not sufficient to 
reproduce the observed linkage preference, we 
used full-length di-Ubs to determine the kinetic 
parameters directly. We determined KM and kcat 
of the hydrolysis of all seven lysine linked di-
Ubs by USP7, using initial rate experiments that 
monitored the appearance of mono-Ub (Figure 
5). These experiments showed that the linkages 
that are efficiently hydrolyzed by USP7 (K6, K11, 
K33, K48 and K63) have similar kinetic behavior 
(Figure 5B). Interestingly, the KM and kcat values 
are similar to the minimal substrate UbAMC, 
which contains only a single Ub moiety. This 
suggests that there is no induced binding or 
catalysis effect by the proximal Ub moiety. 
In the initial di-Ub assay, two linkages (K27 
and K29) showed a clear delay in hydrolysis 
by USP7 (Figure 3). This was nicely reproduced 
in this kinetic di-Ub assay. Interestingly, there 
was hardly any change in kcat, but rather the KM 
increased far above the concentrations used in 
our assays. This suggests that the preference 
for the di-Ub topoisomers arises from steric 
hindrance, rather than an additional binding 
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site for the proximal Ub moiety. Therefore 
the binding of some linkages to the catalytic 
domain is impaired, resulting in lower activity. 
Intermolecular activation of USPs by UAF1 
and GMPS only affects kcat.
Besides their intrinsic activity, some USPs are 
activated by intermolecular modulation. For 
example, USP1, USP12 and USP46 are activated 
by the WD40-repeat containing UAF1, and 
USP7 is activated by GMPS17,19-21. Here, we used 
the UbAMC assay to quantify this activation 
(Figure 6A,B and Supplemental Figure S4). In 
agreement with previous data, we observe 
mainly a kcat increase (7-fold) of USP1ΔN activity 
in the presence of UAF1. The USP1 used in this 
study has a mutation in the self-cleavage site 
(Gly671,672Ala)21. UAF1 also activates USP12FL 
and USP46ΔN, where the kcat is increased by 
66- and 70-fold, respectively. Also in the case of 
USP7 we observed a kcat increase (5.5-fold) in the 
presence of its modulator GMPS. Interestingly, 
in contrast to variable modulation invoked by 
internal domains (Figure 2D), intermolecular 
modulation is achieved mainly by an increase 
in the catalytic turnover rather than in substrate 
binding (Figure 6B).
To investigate whether this activation also 
induces new linkage preferences of these USPs, 
we repeated the di-Ub assay in the presence of 
UAF1 or GMPS (Figure 6C). As expected from 
the UbAMC kinetics, USP1ΔN shows limited 
activity in the absence of UAF1, while USP12FL 
and USP46CD show no activity. However, in 
the presence of UAF1, the activity of all three 
USPs is increased, albeit not to the same level. 
In complex with their activators, USP1ΔN 
and USP7CD-HUBL show most activity, but 
no change in chain type preference by UAF1 
or GMPS. This agrees well with an activation 
mechanism that only increases kcat, but does 
not induce binding, which should translate in 
changing KM values. 
Figure 6. Intermolecular USP activity modulation is achieved by increasing kcat. A. Kinetic parameters (kcat, Km and kcat/KM) 
using UbAMC as substrate for USP1ΔN, USP12FL and USP46ΔN in presence of UAF1 and USP7CD-HUBL in presence of GMPS. B. 
Alternative representation of the kinetic parameters comparing the USP activity between the USPs and in the presence of their 
modulator. C. Activity modulation by UAF1 and GMPS towards all seven di-Ub topoisomers. Samples from each time-point (0, 5, 
10, 30, 60, 180 min) were analyzed on coomassie stained SDS-PAGE gels.
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Discussion
In this study, we used chemical reagents to 
determine the kinetic parameters of substrate 
independent activity of 12 USPs, their di-Ub 
linkage preference and characteristics of both 
intra- and intermolecular activity modulation. 
We observe large variations in both the catalytic 
turnover (kcat) and Ub binding (KM) between 
USPs, which can be further modulated by 
several intra-molecular domains. Interestingly, 
the interactors UAF1 and GMPS can activate 
USPs by increasing their catalytic turnover (kcat). 
Additionally, the USPs have a small preference 
for individual di-Ub topoisomers. We show that 
in USP7 there is no additional Ub binding site, 
but rather that the differences in hydrolysis of the 
topoisomers are achieved by hindering binding 
(KM) sterically. The combined data provide 
insights in the variation in the biochemical 
behavior of the USP enzyme family.
Based on their specific catalytic efficiency 
(Figure 2), the USPs can be classified into three 
groups: (1) a group of USPs showing very low 
DUB activity, (2) an ´intermediate´ group and (3) 
USPs that exhibit high activity. This variability 
in activity can be explained in several ways. 
First, the activity can be affected by structural 
rearrangements in both Ub binding sites and 
active sites, as shown by structural studies11,12. 
Secondly, intra-molecular domains of USPs 
can modulate the DUB activity, as seen here 
for USP4, USP7 and USP16. External modulator 
proteins can further regulate the activity of the 
USP by enhancing its activity, as seen for USP1, 
USP7, USP12 and USP46 (Figure 6A,B).
Here we report a few cases where intra-
molecular modulators regulate the USP activity: 
either insertions within or additional domains 
outside the catalytic domain. For both USP7 
and USP16 the enzymatic behavior is regulated 
by intra-molecular domains (the HUBL and 
ZnF-UBP domain, respectively) outside the 
catalytic domain, resulting in the increase of the 
activity. Additionally, variations in kinetics can 
be induced by (large) insertions in the catalytic 
domains themselves, as demonstrated for USP4, 
where a UBL containing insert is inhibiting the 
catalytic efficiency7. These variations and intra-
molecular modulations result in the unique 
activity of each USP. 
For the last decade, the focus on DUB specificity 
has been on K48- and K63-linked poly-Ub chains. 
However, different Ub linkage topoisomers can 
result in different cellular fates, some of which 
are very specific34-36 and others requiring a 
minimal chain length to invoke its function37,38. 
Our study presents the first complete and 
comprehensive study on di-Ub preference of all 
seven lysine linked di-ubiquitins for USP family 
members. Although none of the DUBs so far 
has been tested for all Ub linkages, some DUBs 
show remarkable specificity. For example the 
OTU protease DUBA39 is K63-specific, OTUB130 
is K48-specific, while AMSH40 and BRCC341 
both from the JAMM/MPN+ family are K63-
specific. Next to CYLD10, the USPs do not have 
strict chain-type specificity, but rather have 
preferences. Kinetic studies on USP7 showed 
us that there is no proximal S1’ Ub binding 
site to induce Ub topoisomers preference, but 
rather the proximal Ub moiety induces steric 
constraints for binding to the USP in the case 
of K27 or K29 linkages. However, it is possible 
that linkage specificity is increased when using 
longer Ub chains. 
Overall, the hydrolysis efficiency of the USPs 
towards K6-, K11-, K48- and K63-linked Ub was 
higher than for K27- and, to a lesser extent, 
K29- and K33-linked di-Ub. These residues 
localize in distinct regions on Ub (Figure 3A). 
The lysine residues involved in the easiest 
hydrolyzed linkages (K6, K11, K48 and K63) are 
in the β-sheet or loops. In contrast, the lysine 
residues of the more difficult linkages (K27, 
K29 and K33) are positioned on the other side 
of the Ub molecule, and are all in the α1-helix. 
Additionally, K27 is barely accessible, which 
possibly induces a steric constraint, resulting 
in the lower activity. This interesting bi-polar 
behavior needs future investigation. 
Previous studies suggested that Ub-peptide 
reagents were sufficient to mimic di-Ub 
and discriminate between  topoisomers in 
binding32. However, in our activity assays with 
the FP Ub-peptide reagents, we observed no 
difference between Ub linkages. This suggests 
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that the peptides do not contain enough 
information to mimic the proximal Ub for the 
USPs. Nevertheless, they may be sufficient for 
DUBs from families with more pronounced Ub 
specificity and be useful tools in those cases. 
In addition, the ‘KG’ FP-reagent might prove 
a good alternative for UbAMC, as the kinetic 
parameters are similar, while it contains the 
natural isopeptide linkage, which is not present 
in UbAMC. 
This study confirmed that two known 
intermolecular USP activity modulators UAF1 
and GMPS activate USP1, USP12, USP46, and 
USP7 respectively. This activation is mainly 
by increasing the kcat. However, the biological 
roles of the UAF1 and GMPS activation are 
distinct. UAF1 activation is almost essential for 
USP activity of USP1, USP12 and USP46. This 
resembles the Ubp8 activation by Sgf1114,15. 
Surprisingly, USP12 in complex with UAF1 is still 
not very active, possibly requiring additional 
partners, like WDR2042. In a different manner, 
GMPS hyper-activates USP7, by allosterically 
stabilizing the active state of the enzyme 
induced by the HUBL domain17. Besides a general 
activation, the GMPS activity modulation most 
likely has additional substrate specific roles, as 
it induces H2B de-ubiquitination.
Although the function of an increasing number 
of USPs is elucidated, they still represent a 
relatively uncharacterized enzyme family. To 
aid in the biochemical understanding of these 
enzymes, we here report the large variations 
in kinetics and intra-molecular modulation (kcat 
and KM), the modest but surprising differential 
activity towards the seven di-Ub topoisomers 
(KM), and a characterization of the activation by 
intermolecular interactions (kcat). 
Significance
Ubiquitination is a dynamic process, which is 
involved in numerous key cellular processes. 
The removal of the Ub molecules is an integral 
part of this process, and is carried out by 
Deubiquitinating enzymes (DUBs). These are 
increasingly recognized as interesting drug 
targets. However, to date we lack the markers 
to predict the biochemical behavior based on 
sequence alignments and therefore a need 
exists for comprehensive kinetic studies. This 
is where chemical tools that allow fast and 
accurate read-outs will contribute to answer 
these biological questions. In this study, we 
designed and produced several of such chemical 
reagents to determine the kinetics and di-Ub 
linkage preferences of twelve USPs. Despite 
the homologous catalytic domain, the kinetic 
data underline the large variability within the 
USP family, and the intra- and intermolecular 
activity modulators create an additional layer of 
regulation. 
In addition this study for the first time reports 
the linkage preference of twelve USPs against 
all seven-lysine linked di-Ubs. Kinetic analysis of 
the hydrolysis of the di-Ub topoisomers, suggest 
that within the USP family the preferences are 
induced by steric hindrance, rather than the 
induced binding, as seen in other DUB families.
Together, this data provides insight in the 
biochemical behavior in the USP family, and 
validates the chemical tools that now also can 
be applied in characterizing other DUB families. 
Experimental procedures
General
General reagents were obtained from Sigma 
Aldrich, Fluka and Acros and used as received. 
Solvents were purchased from Biosolve or 
Aldrich. Peptide synthesis reagents were 
purchased from Novabiochem. USP25 cDNA 
was provided by Erik Meulmeester and Frauke 
Melchior.
General plasmids and proteins
Di-Ub moieties were produced as previously 
described22. USP4CD (aa 296-954), USP4-D1D2 
(aa 296-490/766-932), USP8CD (aa 776-1110), 
USP11FL (aa 1-920), USP16FL (aa 1-823), 
USP16CD (aa 193-823), USP21CD (aa 211-565), 
USP30CD (aa 65-500), USP39CD (aa 222-565) 
and USP46ΔN (aa 8-366) are cloned into the 
pETNKI-LIC vector for expression in bacteria as 
described23. USP1ΔN (aa 21-785 self-cleavage 
site glycine 671 and 672 are mutated to alanine), 
USP7FL (aa 1-1102), USP12FL (aa1-355) and 
STREP-TEV-UAF1 (6-677) are cloned into the 
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pFastBac-HTb vector for expression in insect 
cells. Both USP7CD-HUBL (aa 208-1102) and 
USP7CD (aa 208-560) are cloned into the pGEX 
vector17 and USP25FL is cloned in the pET11a 
vector43. Codon optimized full length USP7 
and GMPS cDNA was obtained from DomainEx 
(Cambridge, UK). Both were amplified by PCR 
and subcloned (SpeI/NotI) into a pFastBac 
vector (Invitrogen) containing an N-terminal 
GST tag (BamHI/SpeI) and Prescission Protease 
cleavage site. cDNA for USP11 and USP16 were 
obtained from ImaGenes (Berlin, Germany).
Protein expression and purification 
As specified in figure 1, the USPs were 
expressed in both E.coli and insect cells and 
purified as described7,17. GMPS was expressed 
and purified as before17. USP constructs and 
GMPS cloned both in bacterial and baculovirus 
expression vector are expressed and purified as 
described17,23. Depending on the type of vector, 
the tag was removed with either TEV or the HRV 
3C protease. Bacmids were prepared following 
the manufacturer’s guidelines. USP1, USP12 
and UAF1 were produced using Sf9 and Sf21 
insect cell expression. Infection was done using 
a low-MOI infection protocol44. The cells were 
harvested 72 hours after a baculovirus induced 
growth arrest was observed. USP46 was 
produced in E.coli. USP1, 12, 46 and UAF1 were 
purified using Ni2+ sepharose (GE Healthcare) 
in 20 mM Hepes (pH 7.5), 150 mM NaCl, 0.1 mM 
PMSF, and 0.1 mM DTT followed by elution using 
imidazole. His-tag was removed by overnight 
cleavage with TEV protease whilst dialyzing 
to remove imidazole. Uncleaved product was 
removed with Ni2+ sepharose. Size exclusion 
chromatography was performed using a 
Superdex 200 or 75 column (GE Healthcare), 
equilibrated against buffer containing 10 mM 
Hepes [pH 7.5], 100 mM NaCl and 1 mM DTT. All 
proteins were concentrated to ~10 mg/ml and 
stored at -80°C.
UbAMC assay
Kinetics were determined as described 
before7. UAF1 and GMPS were added in a 
1:1 stoichiometry. USP concentration varied 
between 1 and 100 nM, depending on relative 
activity. In order to calculate the kinetic 
parameters for the hydrolysis of UbAMC, curves 
obtained by plotting the measured enzyme 
initial rates (v) versus the corresponding 
substrate concentrations ([S]). These were 
subjected to nonlinear regression fit using the 
Michaelis–Menten equation V = (Vmax • [S]) ⁄ 
([S] + KM) (eqn 1), where Vmax is the maximal 
velocity at saturating substrate concentrations 
and KM the Michaelis constant. The kcat value was 
derived from the equation kcat = Vmax ⁄ [Eo] (eqn 
2) where [Eo] is the total enzyme concentration. 
Experimental data was processed using Prism 
5.01 (GraphPad Software, Inc.).
Di-Ub assay
Di-Ub hydrolysis reactions were performed at 
37°C in 50 mM Hepes buffer at pH 7.5, with 100 
mM NaCl, 1 mM EDTA, 5 mM dithiothreitol and 
0.05% (w⁄v) Tween-20 with constant enzyme 
concentration (75 nM). When indicated UAF1 
was added in a 2-fold excess (150 nM) and GMPS 
in a 1:1 stoichiometry. Reactions were stopped 
by addition of SDS loading buffer and followed 
by SDS-PAGE analysis. For the kinetic analysis, 
the reaction mixture was pre-heated to 37 °C 
degrees before adding USP7. Samples were 
run on a 12% Bis-Tris NuPage gel (duplicates 
on one gel), and western blots were performed 
with anti-Ub antibody (Santa Cruz; P4D1).  The 
ChemiDoc system (Biorad) was used to read 
the chemiluminence  signal and subsequent 
quantification of mono-Ub was done using the 
quantification tools of ImageLab (Biorad) using 
the non-saturated di-Ub signal (corrected for 
conversion to mono-Ub). Experimental data 
was processed using Prism 5.01 (GraphPad 
Software, Inc.).
Solid Phase Peptide Synthesis (SPPS) of the 
TAMRA thiolysine peptides
SPPS was performed on a Syro II MultiSyntech 
Automated Peptide synthesizer using standard 
9-fluorenylmethoxycarbonyl (Fmoc) based solid 
phase peptide chemistry at 25 μmol scale, using 
fourfold excess of amino acids relative to pre-
loaded Fmoc amino acid Wang type resin (0.2 
mmol/g, Applied Biosystems). The following 
protected amino acids were used during Ub 
peptide synthesis: Fmoc-L-Ala-OH, Fmoc-L-Arg- 
(Pbf )-OH, Fmoc-L-Asn (Trt)-OH, Fmoc-L-Asp 
(OtBu)-OH, Fmoc-L-Gln (Trt)-OH, Fmoc-L-Glu 
(OtBu)-OH, Fmoc-Gly-OH, Fmoc-L-His (Trt)-OH, 
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Fmoc-L-Ile-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys 
(Boc)-OH, Fmoc-L-Met-OH; Fmoc-L-Phe-OH; 
Fmoc-L-Pro-OH; Fmoc-L-Ser (tBu)-OH; Fmoc-L-
Thr (tBu)-OH, Fmoc-L-Tyr (tBu)-OH, Fmoc-L-Val-
OH. Fmoc-5S- (methyldisulfanyl)- (L)-Lys (Boc)-
OH was synthesized as described previously22. 
The coupling procedure starts off with single 
couplings in N-methylpyrrolidon (NMP) for 45 
min using PyBOP (4 equiv) and DiPEA (12 equiv) 
in a total volume of 750 μL. Followed by the 
removal of Fmoc with 20% piperidine in NMP 
for 2×2 and 1×5 min. Finally the procedure ends 
with  NMP wash steps after each coupling (3×) 
and deprotection (5×).
The resin was washed with diethylether 
and dried under high vacuum. Next, the 
polypeptide sequence was detached from the 
resin and deprotected by treatment with TFA/
H2O/Phenol/iPr3SiH 90.5/5/2.5/2 v/v/v/v for 2.5 
h. After washing the resin with 3×1 mL TFA, the 
crude protein was precipitated with cold Et2O/
n-pentane 3:1 v/v. The precipitated protein was 
washed 3× with diethylether, the pellet was 
dissolved in a mixture of H2O/CH3CN/HOAc 
(65/25/10 v/v/v) and finally lyophilized. All 
peptides were analyzed by LC-MS and purified 
by RP-HPLC when necessary.
LC-MS
LC-MS measurements were performed on a 
Waters 2795 Seperation Module (Alliance HT), 
equipped with a Waters 2996 Photodiode Array 
Detector (190-750nm), Phenomenex Kinetex 
C18 column (2.1×50, 2.6 μm) and LCTTM 
Orthogonal Acceleration Time of Flight Mass 
Spectrometer. Samples were run using two 
mobile phases: A = 0.1% formic acid in water 
and B = 0.1% formic acid in acetonitrile. Flow 
rate = 0.8 mL/min, runtime = 6 min, column T = 
40 °C. Gradient: 0 − 0.5 min: 5% B; 0.5 − 4 min: 
5% to 95% B; 4 − 5.5 min: 95% B. Data processing 
was performed using Waters MassLynx Mass 
Spectrometry Software 4.1 (deconvulation with 
Maxent1 function).
Ligation of Ub to the peptides followed by 
desulphurization
Schematic overview of reaction scheme and 
final yields can be found in Supplemental 
Figure S3. A mixture of 4-mercaptophenylacetic 
acid (MPAA, 100 mM) and TCEP (50 mM) in 6M 
Guanidinium ∙HCl (1 mL, pH 7) was added to 
Ub-MesNa thioester (5 mg, prepared according 
to the procedure described previously 22). To 
this the TAMRA thiolysine peptide (100 µL of a 
20 mM stock solution in DMSO) was added and 
the whole mixture was incubated at 37 °C. After 
overnight incubation, all low-molecular weight 
material was removed using a 3 kDa cutoff 
spin-column (Amicon Ultra) in four centrifuge 
cycles. The crude material was taken up in 6M 
Guanidinium∙HCl, 0.1M sodium phosphate (4 
mL, pH 6.5) and to this was added TCEP (187 mg) 
and glutathione (30 mg), after which the pH of 
the mixture was adjusted to pH 6.5 by addition 
of 1M NaOH. Next, the mixture was degassed 
with argon, after which radical initiator VA-
044 was added. The mixture was incubated at 
37 °C overnight. All constructs were purified 
by RP-HPLC and analyzed by LC-MS and gel 
electrophoresis and were obtained as purple 
solids.
C18 RP-HPLC
Purification by RP-HPLC was performed on a 
Shimadzu system equipped with a LC-20AT 
liquid chromatography pump, CTO-20A column 
oven (T = 40 °C), SPD-20A UV/VIS detector 
(detection simultaneously at 230 nm and 254 
nm), RF-10AXL fluorescence detector (ex/em 
= 540/600 nm) and an Atlantis Prep T3 column 
(10×150 mm, 5 μm). Samples were run using 
two mobile phases: A = 0.05% trifluoroacetic 
acid in water and B = 0.05% trifluoroacetic acid 
in acetonitrile. Flow rate = 7.5 mL/min, runtime 
= 30 min. Gradient: 0 – 6 min: 5% to 10% B; 6.5 
– 26 min: 25% to 47% B; 26.5 – 29.5 min: 95% B. 
Pure fractions were pooled and lyophilized.
Isopeptide linked Ub FP  hydrolysis assay
FP assays were performed on a PerkinElmer 
Wallac EnVision 2010 Multilabel Reader with 
a 531 nm excitation filter and two 579 nm 
emission filters. The confocal optics were 
adjusted with TAMRA-KG (synthesized by 
SPPS as described above) and the G factor 
was determined using a polarization value for 
TAMRA-KG (25 nM) of 50 mP. The assays were 
performed in “non binding surface flat bottom 
low flange” black 384-well plates (Corning) at 
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room temperature in a buffer containing 20 mM 
Tris•HCl, pH 7.5, 5 mM DTT, 100 mM NaCl, 1 mg/
mL 3-[ (3-cholamidopropyl) dimethylammonio] 
propanesulfonic acid (CHAPS) and 0.5 mg/
mL bovine gamma globulin (BGG). Each well 
had a volume of 20 μL. Buffer and enzyme 
were predispensed and the reaction was 
started by the addition of substrate. Kinetic 
data was collected in intervals of 2.5 or 3 min. 
From the obtained polarization values (P) 
the amount of processed substrate (Pt) was 
calculated with to the following equation45: 
S = S0 – S0 • ( (Pt - Pmin) / (Pmax - Pmin)), 
where Pt is the polarization measured (in mP); 
Pmax is the polarization of 100% unprocessed 
substrate (determined for every reagent at 
all used substrate concentrations); Pmin is 
the polarization of 100% processed substrate 
(determined for every linkage at all used 
substrate concentrations by measuring the mP 
value for the corresponding deubiquitinated 
TAMRA-peptide, which were synthesized by 
SPPS according to the procedure describes 
above); S0 is the amount of substrate added 
to the reaction. From the obtained Pt values 
the values for initial velocities were calculated, 
which were used to determine the Michaelis-
Menten constants. All experimental data 
was processed using Ms Excel and Prism 4.03 
(GraphPad Software, Inc.).
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Supplemental Figure S2. Related to Figure 3. Di-Ub assay for inactive USPs and comparison USP7CD versus USP7CD-
HUBL. A. and B. Di-Ub assay for USP12FL, USP39CD, USP46FL, USP7CD, USP16CD and USP30CD. Time-course using all di-Ub 
topoisomers (5 μM) (Linear, K6, K11, K27, K29, K33, K48 and K63) for USPs (75 nM). Samples from each time-point (0, 5, 10, 30, 
60, 180 min) (A) and (0, 10, 30, 60 min) (B) were analyzed on coomassie stained SDS-PAGE gels. C. Di-Ub assay USP7CD versus 
USP7CD-HUBL. Time-course using all di-Ub topoisomers (5 μM) (Linear, K6, K11, K27, K29, K33, K48 and K63) for USP7 constructs 
(10 μM and 75 nM). Samples from each time-point (0, 10, 30, 60 min) were analyzed on coomassie stained SDS-PAGE gels.
Supplemental Figure S1. Related to Figure 2. Exemplary raw data of UbAMC hydrolysis by USP7CD-HUBL. Measurements 
were done using a five minute interval. The signal was stable for at least one hour.
Supplemental Table S1. Related to Figure 1. Published UbAMC kinetics of USPs.
k cat 
[s -1 ]
K M 
[μM]
k cat /K M 
[x10 3  M -1  s -1 ]
Reference
USP1FL 0.014 1.4 10.2 Cohn et al. (2007)
USP1FL+UAF1 0.26 0.7 371 Cohn et al. (2007)
Ubp8/SAGA 0.17 1.5 110 Samara et al. (2011)
USP2CD 0.62 2.5 250 Zhang et al. (2011)
USP2CD 0.14 0.55 252 Renatus et al. (2006)
USP7FL 3.56 17.5 203 Fernandez-Montalvan et al. (2007)
USP7CD 0.077 44.2 1.7 Fernandez-Montalvan et al. (2007)
USP7CD-HUBL 0.805 22.8 35 Fernandez-Montalvan et al. (2007)
USP8CD 2.4 10.2 235 Avvakumov et al. (2006)
USP21CD 0.041 0.26 158 Ye et al. (2011)
USP25FL 0.12 5 24 Meulmeester et al. (2008)
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Supplemental Figure S3. Related to Figure 4. Synthesis, LC-MS of FP reagents, exemplary raw data and Michaelis-Menten 
curves of USP4 and USP7. A. Ligation of Ub to the peptides. B. Peptide sequence, molecular weight and typical yield of the 
reaction. C. Coomassie staining and fluorescence scan of SDS electrophoresis analysis of the FP-reagent. D. Kinetic parameters of 
USP4-D1D2 using the FP-reagents. E. Exemplary data of hydrolysis of FP reagents (K29 with USP4-D1D2).
Figure and legend continue on next page 
Linkage type Peptide sequence MW (Da) Yield 
K G  TAMRA-K (Ub)G  9162 1.3 m g  (25% ) 
K 6 (U b  1-14) TAMRA-M Q IF V K (Ub)T LTG K T IT  10540 0 .8  m g (16% ) 
K 11 (U b 4-17) TAMRA-FV K T LT G K (Ub)T IT LE V  10509 1 .0  m g (18% ) 
K 27 (U b 20 -33) TAMRA-S D T IE N V K (Ub)A K IQ D K  10548 0 .5  m g (10% ) 
K 29 (U b 22 -35) TAMRA-T IE N V K A K (Ub)IQ D K E G  10532 1 .8  m g (30% ) 
K 33 (U b 26 -39) TAMRA-V K A K IQ D K (Ub)E G IP P D  10497 1 .7  m g (28% ) 
K 48 (U b 41 -54) TAMRA-Q R LIF A G K (Ub)Q LE D G R  10590 0 .6  m g (12% ) 
K 63 (U b 56 -69) TAMRA-LS D Y N IQ K (Ub)E S T LH L 10620 1 .6  m g (32% ) 
 
A
B
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D
M Ub KG K6 K11 K27 K29 K33 K48 K63M Ub KG K6 K11 K27 K29 K33 K48 K63
Fluorescence (ex/em 550/590)CBB staining
3
6
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38
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USP4-D1D2
 k cat [s -1] K m  [nM ] k cat/K m  [M -1 s -1] 
K G  0 .068  ± 0 .006  271 .8  ± 43 .2  2 .51  ×10 5 
K 6  0 .157  ± 0 .015  1532  ± 256  1 .03  ×10 5 
K 11  0 .060  ± 0 .001  229 .2  ± 16 .0  2 .61  ×10 5 
K 27  0 .038  ± 0 .001  150 .1  ± 11 .4  2 .56  ×10 5 
K 29  0 .060  ± 0 .002  299 .7  ± 20 .5  1 .99  ×10 5 
K 33  0 .048  ± 0 .002  330 .5  ± 31 .6  1 .46  ×10 5 
K 48  0 .044  ± 0 .001  165 .5  ± 11 .7  2 .65  ×10 5 
K 63  0 .047  ± 0 .001  220 .7  ± 12 .2  2 .12  ×10 5 
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Figure and legend continued from previous page.
Supplemental Figure S3. Related to Figure 4. Synthesis, LC-MS of FP reagents, exemplary raw data and Michaelis-Menten 
curves of USP4 and USP7. F. LC-MS spectra of the FP-reagents. G. Michaelis-Menten analysis of USP7 hydrolysis of the FP 
reagents. Data could not be fitted with an exponential Michealis-Menten curve. 
Figure and legend continue on next page
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Supplemental Figure S4. Related to Figure 6. Curves of the Michaelis-Menten analysis of the UAF1 and GMPS modulation. 
The Michaelis-Menten curves for the different USPs obtained by determining the initial rates (V0) at 2-fold serial dilutions of 
UbAMC.
Figure and legend continued from previous page.
Supplemental Figure S3. Related to Figure 4. Synthesis, LC-MS of FP reagents, exemplary raw data and Michaelis-Menten 
curves of USP4 and USP7. H. Michaelis-Menten analysis of USP4 hydrolysis of the FP reagents. Kinetic pararameters are in (D).
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Abstract
USP4 is a member of the ubiquitin-specific protease (USP) family of deubiquitinating enzymes 
that has a role in spliceosome regulation. Here, we show that the crystal structure of the minimal 
catalytic domain of USP4 has the conserved USP-like fold with its typical ubiquitin-binding site. A 
ubiquitin-like (Ubl) domain inserted into the catalytic domain has autoregulatory function. This Ubl 
domain can bind to the catalytic domain and compete with the ubiquitin substrate, partially inhibit-
ing USP4 activity against different substrates. Interestingly, other USPs, such as USP39, could relieve 
this inhibition.
Introduction
Post-translational modification by the small, 
highly conserved ubiquitin (Ub) protein has an 
essential role in the regulation of many cellular 
processes in eukaryotes1,2. In this process, the 
carboxy-terminus of Ub forms an isopeptide 
with lysines on the target proteins, or on Ub 
itself, to form poly-Ub chains. The activity of 
the conjugating enzymes E1–E2–E3 is actively 
balanced through hydrolysis by deubiquitinating 
enzymes (DUBs)1,3,4,5,6. Deregulation of the 
ubiquitination pathway can lead to cancer and 
neurodegenerative diseases7,8.
More than 100 putative DUBs are known so far, 
belonging to five subfamilies of isopeptidases. 
The Ub-specific protease (USP) family is the 
largest, with more than 60 members in the human 
genome4,6,9. USPs share a papain-like catalytic 
domain and crystal structures show a conserved 
catalytic core that undergoes conformational 
changes after Ub binding10,11,12,13,14.
USPs are variable in size with modular domain 
architecture including, for example, TRAF-like, 
DUSP or Znf domains4,6. Sequence analysis 
predicted the presence of Ub-like (Ubl) domains 
in 17 different USPs15. Integrated Ubl domains 
are stretches of 45–80 amino acids that share 
the β-grasp fold of Ub, but often have poor 
sequence conservation among subfamilies16,17. 
The Ubl domains in the USP family are located 
amino-terminally, within or C-terminally to the 
catalytic domain. Structural studies of the N-
terminal Ubl domain of USP14 confirmed the 
Ubl-fold (Protein Data Bank (PDB): 1WGG) and 
showed involvement in proteasome binding 
that promotes the DUB activity of USP1418. 
Similar to USP14, USP4 has a Ubl domain N-
terminal of its catalytic domain, but it has 
an additional Ubl domain embedded in the 
catalytic domain.
USP4 was previously known as ubiquitous 
nuclear protein (UNP)19. Identified as a proto-
oncogene related to Tre 2/Tre 17 (USP6), 
USP4 shows a consistently elevated gene 
expression level in small cell tumours and lung 
adenocarcinomas, suggesting that it may have 
a possible causative role in neoplasia20. Besides 
possible roles in Wnt signalling21 and recruitment 
to the A2A receptor22, USP4 is recruited to the 
spliceosome by complex formation with Sart323. 
Here, it preferentially deubiquitinates K63-linked 
chains on the U4 component Prp3. Another 
component of the spliceosome complex is the 
catalytically inactive USP3923,24, which controls 
the messenger RNA levels of Aurora B25.
Here, we report on the crystal structure of the 
catalytic domain of USP4 without the internal 
Ubl domain, and show how this Ubl domain 
acts as an autoregulatory domain that partially 
inhibits catalytic activity by competitive 
inhibition.
Results
Identification of USP4–D1D2
To gain insight into the structure and function 
of USP4, we expressed and purified the USP4 
catalytic domain (amino acids 296–954, 
Figure 1A) in Escherichia coli. To improve the 
chances for crystallization, we used limited 
proteolysis. After treatment with thermolysin, 
two fragments (domain 1 (D1) and 2 (D2)) were 
obtained, which copurified on size exclusion 
chromatography and together retained DUB 
activity (supplementary Figure S1A,B). We 
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identified the composition of D1 and D2 using 
mass spectrometry and N-terminal sequencing 
(supplementary Figure S1C) and compared 
them against a multi-sequence alignment of 
USP family members. This showed that the 
protease treatment removed an insertion 
between Leu 481 and Leu 766 (supplementary 
Figure S2), yielding an enzymatically active 
complex of two fragments: USP4–D1D2
Structure of the USP4–D1D2 catalytic 
domain
We crystallized and determined the USP4–
D1D2 structure by molecular replacement 
using the USP8 catalytic domain (PDB: 2GFO) 
as the search molecule, and refined it to 2.4 Å 
resolution with an R/Rfree of 0.178/0.21 and 
good geometry (Figure 1B; supplementary 
Table S1). There are six molecules of USP4–
D1D2 per asymmetric unit, with a pairwise root-
mean-square deviation of approximately 0.7 Å 
over 344 residues using the PISA program26.
Figure 1: The catalytic domain of USP4–D1D2. A. Domain architecture of USP4 and fragments expressed. B. Crystal structure 
of USP4–D1D2 catalytic domain in cartoon representation, with secondary structure elements labelled. D1 and D2 are coloured 
as in (A). Catalytic triad and the cysteines (yellow) coordinating zinc (grey sphere) are shown in stick representation. C,D. 
Superposition of six non-crystallographic symmetry-related copies in the asymmetric unit showing flexibility in (C) the zinc-
finger ribbon and (D) blocking loops, BL1–3.
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Similar to crystal structures of other USPs, the 
catalytic domain of USP4–D1D2 resembles 
an extended right hand comprising three 
domains: Fingers, Thumb and Palm (Figure 1B; 
supplementary Figure S3). The D1 fragment 
contains the Thumb domain and part of the 
Fingers domain with the Cys box (amino acids 
303–320) and QQD box (amino acids 390–403) 
of the active site, whereas the D2 fragment 
completes the active site with the His box 
(amino acids 864–885, 894–903, 915–922) and 
makes the remaining part of the Fingers and 
the Palm9) (supplementary Figure S2). Like 
other USP structures11,12,13,14,18, except USP710, 
the catalytic triad is in a catalytically competent 
configuration, wherein His 711-ND1 is 3.2 Å 
away from Cys 311-SG and His 711-ND2 is 
hydrogen bonding with Asp 898-OD1 (2.7 Å; 
Figure 1B). 
The zinc-finger ribbon observed in USP2 and 
USP8 is present in USP4 (Figure 1B,C). The Zn2+ 
ion brings together the D1 and D2 domains, 
tetrahedrally coordinated by cysteines on anti-
parallel β-strands β1 and β2 in D1, and β4 in D2. 
This zinc-finger ribbon in the Fingers domain 
seems to be in the contracted ‘closed-hand’ 
configuration seen in USP8 that blocks access 
of Ub to its binding site11. A similar role was 
assigned to the two Ub-binding surface loops 
(BL1 and BL2) in USP1418 that block the active 
site, but relocate after Ub binding. In USP4, both 
loops (Figure 1D), as well as a third blocking 
loop (BL3) that hinders access of the C-terminal 
tail of Ub to the binding pocket, are observed.
Superposition of the six non-crystallographic 
symmetry-related molecules of USP4–D1D2 
shows that both the zinc-finger ribbon and the 
three blocking loops show flexibility (maximal 
Cα displacement 4 Å; Figure 1C,D), which is in 
agreement with their role in activation10,11. 
The insert inhibits deubiquitinating activity
We compared the catalytic activity of the USP4 
catalytic domain with and without the large 
insert, by using in vitro deubiquitinating assays. 
In these assays we followed the hydrolysis 
of K63- and K48-linked di-Ub into mono-Ub 
(Figure 2A,B; supplementary Figure S4A,B). We 
observed that K63 di-Ub is more efficiently 
degraded than K48, in agreement with the 
role of USP4 in splicing23. Interestingly, 
quantification (Figure 2D; supplementary Figure 
S4D) shows that USP4–D1D2 without insert is 
more efficient at degrading both di-Ubs than 
the complete catalytic domain. When D1 and 
D2 are fused through a short linker, as found in 
USP7 (supplementary Figure S2), their activity is 
similar to that of USP4–D1D2, showing that the 
cause of the activation is the lack of insert and 
not the chain break (Figure 2C; supplementary 
Figure S4C).
In Ub-7-amido-4-methylcoumarin (Ub-AMC) 
assays the intact USP4 catalytic domain is 
also less active than USP4–D1D2 or the fusion 
protein. As only AMC is cleaved off, the inhibition 
is not dependent on the protein target. When 
analysed by Michaelis–Menten kinetic analysis 
(Figure 2E) the Vmax values were similar, but 
the KM for the intact catalytic domain (13.5 μM) 
was weaker than that for USP4–D1D2 (0.20 μM), 
leading to approximately 90-fold lower catalytic 
efficiency overall (kcat/KM) for USP4CD than for 
USP4–D1D2.
As the insert seems to inhibit the DUB activity of 
USP4, we tested whether it could do so in trans. 
We expressed and purified the insert (amino 
acids 483–765) and added it in increasing 
amounts to USP4–D1D2 in the Ub-AMC assay 
(supplementary Figure S5A). We observed that 
the insert slows deubiquitination by USP4–
D1D2. To investigate whether this reduction 
in DUB activity is due to molecular crowding, 
we repeated the in trans inhibition assay with 
USP4–D1D2 in the presence of either SUMO 
or BSA (supplementary Figure S6). Neither of 
these reduced DUB activity, confirming that the 
insert is intrinsically able to inhibit the catalytic 
activity of USP4.
Competitive inhibition of the USP4 insert
We tested whether USP4–D1D2 would directly 
interact with the insert. In a surface plasmon 
resonance (SPR; Figure 3B) experiment, we 
observed binding of USP4–D1D2 to the insert, 
with a Kd of 1.32 μM after equilibrium fitting. 
This affinity closely resembled the affinity of 
USP4–D1D2 for Ub itself (Kd of 1.39 μM; Figure 
3A).
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Therefore, we tested whether the insert could 
compete with Ub for binding to USP4–D1D2, 
experiment we flowed USP4–D1D2 over a 
glutathione S-transferase (GST)-tagged insert 
in the presence of increasing amounts of Ub 
(Figure 3D). We observed decreasing binding 
of USP4–D1D2 to the GST-insert as the Ub 
concentration increased. The data could be 
fitted with a one-site competition binding 
model with a Ki of 1.4 μM, showing that the 
USP4 insert competes with Ub for binding to 
USP4–D1D2.
Interestingly, the Kd of intact USP4CD for Ub 
is only fourfold less, compared to USP4–D1D2 
in an isothermal titration calorimetry (ITC) 
experiment (Figure 3E). Although the exact 
Kds are slightly tighter in the ITC experiment, 
qualitative analysis of SPR experiments agrees 
with this assessment. Non-specific binding at 
high concentrations precluded detailed fitting 
of these data (supplementary Figure S7), but 
the curves show that binding of Ub to USP4CD 
has a slower off-rate than that of Ub to USP4–
D1D2, and together with the Kd value also 
suggest that it has a slower on-rate. As the KM is 
dependent on Kd as well as the binding rate, the 
combination of slow kinetics and slightly lower 
affinity explains the differences in KM values. 
Apparently, the insert prevents rapid binding 
as well as rapid release of the Ub substrate, 
allowing competitive binding. 
Figure 2: Insert inhibits the DUB activity of USP4CD. A–C. The full-length USP4 catalytic domain (A) is much less active than 
(B) USP4–D1D2 or (C) USP4 fusion in deubiquitinating K63 di-Ub (Coomassie-stained SDS–PAGE gels). D. Quantification of mono-
Ub in K63 di-Ub cleavage assays. The intensity of the mono-Ub band is plotted against time. E. The inhibitory effect of the insert is 
observed in a Ub-AMC assay. On comparing Kcat/Km between USP4CD and D1D2, we observed a 90 times lower enzyme efficiency 
for the insert containing USP4CD. F. Inhibition of USP4–D1D2 in trans in Ub-AMC assays at different Ubl-insert concentrations (5, 
15, 45 and 90 μM) can be jointly fit as a competitive inhibitor. 
A UblD1 D2USP4CD
Ub
 M    -    0   
Ub2-K63
 min
D1 D2B USP4CD-D1D2
 M    -    0 
Ub2-K63
Ub
 min
C D1 D2SIKGKKNUSP4CD-Fusion
Ub2-K63
Ub
 M    -    0  min
D
Km:   0.46(±0.02)µM
Vmax: 7.8(±0.68)µM
Ki:     47(±5.4)µM
R2:   0.99
F
E
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Finally we analysed whether the enzymatic 
activity is competitively inhibited by the 
addition of the insert in trans. We tested the 
enzymatic activity with varying inhibitor 
concentrations against a range of substrate 
concentrations (Figure 2F), and fitted the 
data against different inhibition models27. We 
found that the data were best explained by 
competitive inhibition with Ki=47 μM.
Although this value is lower than expected on 
the basis of the binding data alone, it explains 
why the USP4CD is not completely inhibited in 
the continuous presence of the insert. It seems 
that additional conformational changes take 
place. One possibility is that the enzyme reaches 
a state after turnover that has lower affinity for 
the insert, and is therefore not as effectively 
inhibited. 
The Ubl domain is sufficient for inhibition.
The presence of a Ubl domain within the insert 
was predicted (supplementary Figure S2)15. 
To test whether the Ubl domain is sufficient 
for binding to the USP4 catalytic domain, we 
performed the SPR experiment with the purified 
Ubl domain (amino acids 483–571, Figure 1A) 
and found a Kd of 1.36 μM towards USP4–D1D2, 
Figure 3: Ubiquitin competes with the insert or Ubl-domain for binding to USP4–D1D2. A–C. Interaction of Ub and the 
insert fragments with USP4–D1D2 was studied by SPR experiments. Top: (A) GST-tagged Ub, (B) GST-insert and (C) GST-Ubl 
domain were immobilized on anti-GST antibodies coupled to a CM5 Biacore chip and USP4–D1D2 was flowed over the chip 
at different concentrations. Bottom: Langmuir binding curves. D. Competition experiment with immobilized GST insert on 
USP4–D1D2 with varying concentrations of Ub. A one-site competition binding model was fitted (Ki=1.4 μM). E. The interaction 
of Ub with USP4–D1D2 (left) and with full-length USP4CD (right) were studied by ITC. Thermodynamic values for USP4–D1D2 
(ΔH=−14.3 kcal/mol and ΔS=−16.9 cal/mol/deg), for USP4CD (ΔH=−11.4 kcal/mol and ΔS=−10.0 cal/mol/deg). 
A
D
CB
E
USP4CD
KD: 0.641µM
USP4-D1D2
KD: 0.154µM
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which is similar to that for the complete insert 
(Figure 3C). This suggests that the Ubl domain is 
the functional part of the insert.
To test whether the Ubl domain can inhibit 
the DUB activity of USP4, we repeated the in 
trans inhibition assay with USP4–D1D2 in the 
presence of increasing amounts of the Ubl 
domain (supplementary Figure S6) and found 
that it provides inhibition equal to the insert. 
We therefore conclude that the Ubl domain is 
sufficient to inhibit the DUB activity of USP4, 
through competitive inhibition of Ub binding.
Regulation by other USP enzymes.
As the Ubl domain seems to bind in the substrate 
Ub-binding site of USP4, we wondered whether 
other USP enzymes could also bind to the Ubl 
domain. We tested whether our Ubl domain 
containing insert could bind to the catalytic 
domain of USP39 and USP8, and found similarly 
high affinities as for USP4CD (Figure 4B,C).
Then, we analysed whether these DUBs could 
modulate USP4CD activity. We repeated the 
in trans Ub-AMC assay with USP4CD in the 
presence of the intrinsically inactive USP39CD 
or an inactive variant of the USP8 catalytic 
domain, USP8CD-mut (Figure 4A). For both USPs 
we observe a modest activation of USP4CD that 
was dependent on the presence of the Ubl-
containing insert, as it does not increase the 
DUB activity of USP4–D1D2 in this manner.
Apparently, other USP enzymes can regulate 
USP4 activity by competing for binding to the 
Ubl domain. This effect could be larger when 
the USPs have further interactions. As USP39 
forms a stable complex with USP4 in cells23,24, 
it is a prime candidate for an activating role in 
vivo.
Discussion
We show that the predicted Ubl domain within 
a large insert embedded in the USP4 catalytic 
domain partially inhibits DUB activity by 
competing with Ub for binding. Superposition 
of the crystal structure of USP4–D1D2 and 
any Ubl domain on USP7 in complex with Ub-
aldehyde (PDB: 1NBF), respectively, shows that 
the Ubl domain would fit like a Ub molecule 
into the hand of USP4–D1D2 (Figure 5A), only 
requiring movements in the blocking loops and 
the zinc-finger ribbon. Hence, we propose a 
model in which the Ubl domain partially inhibits 
DUB activity through competitive inhibition 
by binding into the hand of USP4 and thus 
preventing Ub substrate binding (Figure 5B)
This function of an integrated Ubl domain is 
relatively new. The Ubl domains in proteasomal 
shuttle factors Rad23 and Dsk2, as well as in 
Figure 4: USP39CD binds to the Ubl domain and increases the deubiquitinating-enzyme activity of USP4CD. A. Other 
USPs activate the DUB activity of USP4CD in trans in a Ub-AMC assay (USP39CD: 10, 20, 50, 100, 500 and 1,000 nM; USP8CD-mut: 
1,000 nM). B. USP39 and C. USP8-mut bind to Ubl insert, in an SPR assay analogous to Figure 2B.
A B C
USP4CD
D1D2
USP39CD
USP8CD-mut
+
+ + +
+ +
+ + + + + + +
+ + +
USP39CD USP8CD-mut
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Parkin and USP14, function in recruitment of 
ubiquitinated proteins to the proteasome18,28. 
Other Ubl domains regulate the enzymatic 
activities of immune-response inducible 
kinases such as IKKβ (a subunit of IκB kinase 
complex)29, or as PB1 (Phox and Bem1) 
domains, have a role in the regulation of signal 
transduction in proteins such as P62, MEK5 and 
protein kinaseC30,31. However, all these Ubl-
domain families have low sequence similarities, 
indicating that their functions are probably 
distinct between subfamilies.
The activity of USPs is regulated through an 
inactive conformation of the catalytic triad, as 
in USP7, or through a series of blocking loops 
or a blocking zinc-finger ribbon. USP4 seems 
to combine the blocking loops and zinc-finger 
ribbon with a further regulation through the 
Ubl domain.
Whether Ubl domains provide a common 
regulation mechanism for the DUB activity 
of USPs is an interesting question for future 
research. A second Ubl domain is found within 
USP4, at its N-terminus. A recent crystal structure 
(PDB: 3JYU, amino acids 139–226) shows that 
this Ubl domain interacts extensively with the 
adjacent DUSP (domain in USP) domain (amino 
acids 27–125). This region of the protein is 
primarily important for interaction with Sart323 
and hence might not have this function.
However, USP4 is not the only DUB with a Ubl 
fold within its catalytic domain. Sequence 
analysis identified an integrated Ubl fold within 
the catalytic domain of USPs 6, 11, 15, 19, 31, 
32 and 43, embedded in a larger insert, like 
in USP415. In particular, USP11 and USP15 are 
closely related to USP4. This subgroup of USPs 
probably also regulates DUB activity through its 
Ubl domain.
The way in which Ubl-domain inhibition 
itself is regulated is an exciting question. One 
could imagine that further post-translational 
modification by, for example, phosphorylation 
or acetylation would enable the release of the 
A B
C
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et
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et
Figure 5: Model for Ubl domain inhibition on USP4. A. Structural model in which interaction of the Ubl domain with USP4CD 
inhibits the binding of Ub. B. Schematic model of the auto-inhibitory role of the Ubl domain in USP4. C. Other USP enzymes, such 
as USP39, may relieve the inhibition by binding to the Ubl domain. 
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full activity of the DUB enzyme. In addition, 
we have shown that binding partners such as 
USP39, can activate USP4 function by binding 
to the Ubl domain (Figure 5C). Although the 
activation is modest (Figure 4A), this could be 
increased by further interactions, as observed in 
the spliceosome complex.
Regardless of the mechanisms that regulate 
USP4 activation, it is clear that this type of 
internal regulation by a Ubl domain allows the 
creation of an extremely fast response element 
to external signals.
Experimental procedures
Plasmids and cloning
cDNA for human USP4 and USP8 was a gift 
from Hidde Ploegh and cDNA for USP39 was a 
gift from R. Medema. USP4CD (aa 296-954) and 
the D1 fragment (aa 296-490) of human USP4, 
USP39CD (aa 219-565) and USP8CD (aa 771-
1118) were cloned using ligation independent 
cloning into pET-46 Ek/LIC vector (Novagen). 
The D2 fragment (aa 766-932) of USP4 was 
cloned into the pET-NKI b/3C32. The fused 
USP4-D1D2 was created by inserting aa 353-359 
of USP7 (SIKGKNN) between residues Leu479 
and Leu777. The USP4 insert (aa 483-765), Ubl 
domain (aa 483-571) and Ub were cloned into 
pGEX-6P-1 (GE Healthcare). The USP8CD mutant 
was generated by site-directed mutagenesis of 
the catalytic cysteine (C786A). 
Protein preparation
Purification of E2-25K33, Ubc13/Mms234 was 
as described. GST-tagged proteins were 
overexpressed in Escherichia coli strain 
Rosetta2(DE3)-T1R using IPTG (200μM) 
induction overnight at 15°C. Cells were lysed 
by microfluidizer into buffer A (50mM Hepes 
pH7.5, 150mM NaCl, 5mM β-mercaptoethanol, 
1mM PMSF). The fusion protein was purified 
using glutathione sepharose resin, eluted, 
followed by removal of the GST-tag with 3C 
protease and size-exclusion using HiLoad 
16/60 Superdex 200 (GE Healthcare). Peak 
fractions were concentrated to 10mg/ml in 
25mM Hepes (pH7.5), 200mM NaCl and 5mM 
β- mercaptoethanol. D1 and D2 co-expression, 
other USP4 variants, USP39CD and USP8CD-
mut were overexpressed as above, with 200μM 
ZnCl2 during induction and lysed in buffer A 
supplemented with 1mM ZnCl2 and 10mM 
Imidazole. These His-tagged proteins were 
purified by a Co2+-affinity (Talon resin) step. 
Upon Imidazole elution the Histag was removed 
by TEV cleavage at 4°C overnight during dialysis 
in buffer B (25mM Hepes pH7.5, 150mM NaCl, 
5mM β-mercaptoethanol). This was followed 
by POROS Q affinity chromatography and 
size-exclusion using HiLoad 16/60 Superdex 
200 (GE Healthcare), where the protein eluted 
as a monomer. The peak fractions were 
concentrated to 5mg/ml in buffer B.
Limited Proteolysis and protein 
identification
Purified USP4CD (9mg/ml) was incubated 
with Thermolysin (0.8units) for 1,5hr at 
room temperature and subjected to size 
exclusion chromatography using Superdex75 
16/60. Fractions containing USP4-D1 and 
–D2 were subjected to LC-MS analysis. LC-MS 
measurements were performed on a system 
equipped with a Waters 2795 Seperation 
Module (Alliance HT), Waters 2996 Photodiode 
Array Detector (190-750nm), Waters Alltime C18 
(2.1x100mm, 3μm), Waters Symmetry300TM C4 
(2.1x100mm, 3.5μm) and LCTTM Orthogonal 
Acceleration Time of Flight Mass Spectrometer. 
Data processing was performed using Waters 
MassLynx Mass Spectrometry Software 4.1 
(deconvolution with Maxent 1 function). N-
terminal sequencing of USP4-D1 and –D2 were 
performed by AltaBioscience in Birmingham, 
England.
Crystallization and structure determination 
of the USP4-D1D2
Crystals were grown overnight in sitting-drops 
mixing 200nl USP4-D1D2 (~3.5mg/ml) with 
200 nl 100mM Bis-Tris propane [pH8.5], 25mM 
Na2SO4 and 18% PEG3350 (w/v) at 19°C. Crystals 
were cryoprotected in mother liquor with 25% 
ethyleneglycol. The crystals belong to the space 
group P212121 with six molecules per asymmetric 
unit (supplementary Table S1). Diffraction data 
were collected at the ESRF (Grenoble, France) 
beamline ID14-2 and processed with MOSFLM35 
and SCALA36. The structure was solved by 
molecular replacement with PHASER37 using 
72               Chapter 3
    3 
USP8CD (PDB: 2GFO) as search model. Iterative 
rebuilding and refinement were done with 
Coot38 and PHENIX39 and BUSTER40. The structure 
was validated with MOLPROBITY41 and WHAT-
CHECK42 and structure figures were generated 
using PYMOL (Delano, 2002). Cysteine residue 
311 in all chains have been chemically modified 
by β-mercaptoethanol.
Ub-AMC assays. 
UbAMC assays were done in 50mM Hepes 
[pH7.5], 100mM NaCl, 5mM DTT, 0.05% Tween-20 
and 1mM EDTA and reaction progress was 
monitored with a Fluostar Optima plate-reader 
(BMG Tech) by the increase in fluorescence 
emission at 460nm (λex = 355nm) generated 
by Ub-AMC cleavage. Quantitative activity 
(triplicate) and in trans inhibition (duplicate) 
assays or USP modulation assays (triplicate) 
were performed using Ub-AMC with 10 nM 
enzyme in 30 μl reaction volume in 384-well 
plates and preincubated for 15 min at 21° C, for 
inhibition assays with Ubl insert and with other 
DUBs for modulation assays. Initial velocities 
against Ub-AMC concentration were computed 
to derive steady-state kinetic parameters using 
GraphPad Prism5 (GraphPad Software Inc.). 
Non-linear fitting of four inhibition models was 
compared in GraphPad.
Di-Ub assays. 
Di-Ub assays were performed in similar buffer 
as in UbAMC assays at 37°C in 75μl reaction 
volume. Aliquots (5μl) were stopped by addition 
of 4x SDS-sample loading buffer and subjected 
to SDS-PAGE analysis on a 4- 12% coomassie 
stained gel (Invitrogen).  K48 and K63 di-Ub 
substrates were produced and purified as 
described43. 75 nM enzyme was incubated with 
3 μM di-Ub, subjected to SDS–polyacrylamide 
gel electrophoresis and image analysis, and 
quantitation was performed in duplicate with 
TINA 2.09 (Raytest Co.).
SPR and ITC. 
SPR was performed on a Biacore T-100, with 
GST-Ub, GST-insert and GST-Ubl domain 
immobilized on anti-GST antibodies coupled to 
a CM5 chip. Quantitative binding analysis was 
done in duplicate at 25°C on a Biacore T-100 
instrument (GE Healthcare). GST fused Ub, insert 
and Ubl domain were immobilized on α-GST 
antibodies lysine-coupled to a CM5 chip. USPs 
were injected in varying concentrations over the 
sensor chip at 30μl/min with a 120s association 
phase followed by a 10min dissociation phase. 
For the binding inhibition assay Ub was added 
in varying concentrations to USP4-D1D2. 
Standard double referencing data subtraction 
methods were used before and equilibrium 
curve fitting with BiaEvaluation (GE Healthcare) 
and GraphPad software (GraphPad Software 
Inc). Data (duplicate) were processed using 
BiaEvaluation (GE Healthcare) and GraphPad 
Prism5.
Isothermal titration calorimetry (ITC) 
experiments were performed with the VP-ITC 
Micro Calorimeter (MicroCal, Inc.) at 25°C. Stock 
solutions of USP4CD, USP4-D1D2 and Ub were 
prepared by dialysis of the purified proteins 
against a buffer containing 25mM Hepes pH8.0, 
150mM NaCl and 5mM β-mercaptoethanol at 
4°C and were degassed before use. The sample 
cell (1.8ml) contained USP4-D1D2 (10μM) 
or USP4CD (20μM) which was titrated with 
100μM Ub or 200μM Ub respectively using 16 
injections. The injections after saturation were 
used to determine the background signal. 
Corrected data were analyzed using software 
supplied by the ITC manufacturer to calculate 
the dissociation constant Kd and fitted with a 
one to one binding model.
Accession numbers
Coordinates and structure factors were 
deposited in the Protein Data Bank under 
identification code 2Y6E.
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Supplemental Table S1. Data collection and refinement statistics.
 Table SI Data collection and refinement statistics.
Data collection statistics Native
Wavelength (Å) 0.993
Space group P212121
Unit cell (Å) 110.5, 151.0, 178.7
Molecules per asymmetric unit 6
Resolution (Å)a 47.0 - 2.4 (2.53 - 2.4)
Rmerge (%) 8.8 (66.1)
<I/σ(I)> 11.0 (1.1)
Completeness (%) 94.9 (74.0)
Redundancy 3.4 (2.4)
Refinement
Rwork/Rfree (%) 17.5/21.3
Number of reflections 111078
Number of protein atoms 15775
Number of zinc ions 6
Number of waters 867
RMSD from ideal geometry
Bond lengths (Å) 0.009
d l ( )Bon  ang es ° 1.01
Ramachandran statisticb
(prefered/allowed/outliers)
1849 / 66 / 2
a Numbers in parentheses are for the highest-resolution shell
b Calculated using Molprobity
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 3 Supplemental Figure S1. Identification of USP4-D1D2. A Limited proteolysis analysis of thermolysin cleavage on USP4CD at 37°C. Samples at different time-points were taken and analyzed on a SDS-PAGE gel. B Proteolytic sample of USP4CD was 
subjected to a size exclusion chromatography and fraction samples were analyzed on a SDSPAGE gel. C Mass Spectrometry 
analysis and N-terminal sequencing determined the identity of the two fragments, D1 and D2.
Supplemental Figure S2. Structure based multiple sequence alignment. Secondary structure elements are colored and 
labeled according to structure of USP4-D1D2 in Figure 1. The internal Ubl is depicted as a yellow bar and the two black arrows 
indicate where the protease thermolysin cleaved in the catalytic domain of USP4. The catalytic triad residues are indicated with 
an asterisk. The four black triangles indicate the positions of the Cys residues coordinating the zinc ion.
A B
Calc. mass: 
D1) 19687.46 Da
D2) 22230.30 Da
Theor. mass:
D1) 19685.54 Da
D2) 22227.46 Da
N-terminal sequencing:
D1) Gly -Met - His -Ile - Gln
D2) Leu - Gln - Pro - Gln - Lys
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Supplemental Figure S3. Overview and superposition of USP catalytic domain structures with USP4-D1D2. Comparison 
between catalytic domains depicted in cartoon representation of USP4-D1D2 (red-cyan), Ubp8 (brown, PDB: 3MM9), CYLD 
(orange, PDB: 2VHF), USP21 (marine blue, PDB: 3I3T), USP2 (yellow, PDB: 2HD5), USP8 (purple, PDB:2GFO), USP14 (green, PDB: 
2AYO) and USP7 (light pink, PDB:1NB8). The structures depicted in ribbon representation were superposed in Coot (RMSD of 
2.1Å over 323 residues).
USP4-D1D2 [2Y6E] Ubp8 [3MM9] CYLD [2VHF]
USP7 [1NB8]USP14 [2AYO]
USP2 [2HD5] USP8 [2GFO]USP21 [3I3T]
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Supplemental Figure S4. Deubiquitinating 
assay with K48 di-Ub as substrate A-C The full-
length USP4 catalytic domain (A) is much less 
active than USP4-D1D2 (B) or USP4-fusion (C) 
in a deubiquitinating assay using K48 di-Ub as 
substrate on coomassie-stained SDS-PAGE gels. (D) 
Quantification of mono-Ub in K48 di-Ub cleavage 
assays. The intensity of the mono Ub band is plotted 
against time.
Supplemental Figure S5. In trans inhibition of USP4-D1D2 DUB activity A The inhibitory effect of the insert is observed in a 
Ub-AMC assay with increasing amounts of insert (5, 10, 25, 50 and 75μM). B The Ubl domain (5, 10, 25, 50 and 100μM) is sufficient 
to show this in trans inhibition.
Ubl UblInsert Ubl
A B
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Supplemental Figure S6. The molecular crowding of high 
concentrations of SUMO or BSA (100μM) does not have an 
effect on USP4-D1D2 DUB activity.
Supplemental Figure S7. Kinetic comparison of USP4-
D1D2 and USP4CD binding to Ub, Ubl and insert on SPR. 
Binding curve of 0.8 μM of USP4-D1D2 and of 1 μM of USP4CD 
were normalized for maximum binding in order to compare 
offrates.
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Abstract
The ubiquitin specific protease USP7/HAUSP regulates p53 and MDM2 levels, and cellular localiza-
tion of FOXO4 and PTEN, and hence is critically important for their role in cellular processes. Here we 
show how the 64kDa C-terminal region of USP7 can positively regulate deubiquitinating activity. We 
present the crystal structure of this USP7/HAUSP Ubiquitin-Like domain (HUBL), comprised of five 
ubiquitin-like domains (Ubl) organized in 2-1-2 Ubl units. The last di-Ubl unit, HUBL-45, is sufficient 
to activate USP7, through binding to a ‘switching’ loop in the catalytic domain, which promotes 
ubiquitin binding and increases activity 100-fold. This activation can be enhanced allosterically by 
the metabolic enzyme GMPS. It binds to the first three Ubl domains (HUBL-123), and hyper-activates 
USP7 by stabilization of the HUBL-45 dependent active state. 
Introduction
The deubiquitinating enzyme (DUB) Ubiquitin 
Specific Protease 7 (USP7), also known as Herpes-
virus Associated Ubiquitin-Specific Protease 
(HAUSP), regulates the function of the tumor 
suppressor p53 that is mutated or inactivated 
in approximately 50% of human cancers1. 
USP7 removes ubiquitin from p53 itself, but 
also from the p53 E3 ubiquitin-ligase MDM22-5. 
These combined effects determine functional 
p53 levels, creating an important role for USP7 
in p53-dependent stress responses6-8. Precise 
regulation of USP7 expression and activity is 
therefore necessary for maintaining proper cell 
proliferation, and both up and down regulation 
of USP7 inhibit colon cancer cell proliferation9. 
USP7 also counteracts mono-ubiquitination 
of the transcription factor FOXO4 oncogene, 
and the phosphatase PTEN tumor suppressor, 
regulating their nuclear localization10-12. 
Consequently, USP7 over-expression in 
prostate cancer was directly associated with 
tumor aggressiveness, most likely through 
PTEN mislocalization. Altogether, USP7 activity 
regulates important pathways for cell survival, 
proliferation and apoptosis, misregulation 
of which often lead to tumorigenesis. Better 
understanding of USP7 activity may therefore 
contribute to insights in the role of these 
pathways in cancer.
USP7 is a cysteine isopeptidase of the ubiquitin 
specific proteases (USP) family13. It contains an N-
terminal TRAF/Math domain, a catalytic domain 
and a 64 kDa C-terminal region (Figure 1A). 
The N-terminal TRAF domain directly interacts 
with the substrates of USP7 such as p53, MDM2 
and TSPYL514-17. The catalytic domain of USP7 
has the conserved fold of the USP family16,18,19. 
It shows a papain-like architecture plus an 
extended, fingers-like domain that forms the 
ubiquitin binding pocket. Interestingly, the 
USP7 crystal structures show that the catalytic 
domain is maintained in a non-functional state, 
with the active site residues in a non-reactive 
conformation. The active conformation involves 
rearrangements of the catalytic domain that 
allow ubiquitin binding and organization of the 
catalytic triad, as shown in the structure of USP7 
in complex with the suicide substrate ubiquitin 
aldehyde18. 
The C-terminal region of USP7 is essential for 
effective catalytic activity against a minimal 
synthetic substrate20,21. It harbors additional 
MDM2 and p53 binding sites and promotes 
sequence specific DNA binding of p5321,22. It was 
predicted to contain at least 4 domains with a 
Ubiquitin-Like (Ubl) β-grasp fold23, and a NMR 
structure of one of these is reported (2KVR). Ubl 
domains are also predicted at various positions 
in sixteen additional USP enzymes. Two more 
Ubl domain structures are available: the N-
terminal domains in USP14 (1WGG) and in USP4 
(3JYU, residues 134-222). Among the USP family 
enzymes, USP7 is unique in containing a large 
number of consecutive Ubls. 
Ubl domains share the ubiquitin fold, but lack 
the C-terminal Gly-Gly residues required for 
conjugation to a target. Although many Ubl 
domains are found in the human genome, 
mostly as part of multi-domain proteins, only 
few of these have been studied functionally24,25. 
Among these, distinct subclasses have different 
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functions26. Most classes of Ubl domains 
however, have not yet been characterized. 
Moreover, since different classes have only 
limited sequence similarity they may have very 
different functions.
A number of interaction partners of USP7 have 
been identified27, but for most neither function 
nor interaction site are known. So far, the TRAF 
domain seems dedicated to binding substrate 
proteins MDM2, p53 and TSPYL5. The C-
terminal domain is also used for interactions, as 
was shown for Ataxin-128 and the viral E3-ligase 
ICP029. The metabolic enzyme GMP-synthetase 
(GMPS) interacts with USP7 in Drosophila30 and 
human cells31. GMPS was found upregulated in 
tumorigenic cells32,33, and together with USP7 is 
involved in cell survival, chromatin maintenance 
and transcriptional regulation of ecdysteroid 
target genes34. This interaction promotes USP7 
activity towards H2B as well as enhancing 
activity against p53 in Drosophila. The activation 
mechanism is unclear, but possibly involves 
both general and target specific aspects. 
Here we investigate how Ubl domains in the C-
terminal region of USP7 promote activity. We 
show that USP7 exists in two states, an active 
and an inactive state. In the active state the C-
terminal Ubl domains HUBL-45 interact with 
a ‘switching loop’ in the catalytic domain. We 
identified point mutations that interfere with 
the activation to validate its relevance in cells. 
Finally we show that GMPS can allosterically 
stabilize the interaction between HUBL-45 and 
the catalytic domain and thus promote the 
active state.
Results
The HUBL domain is essential for USP7 
activity in vitro and in vivo
To study the function of the 64 kDa C-terminal 
HUBL domain of USP7 we purified a series of 
different USP7 constructs (Figure 1A,B), and 
compared their activity against ubiquitinated 
p53. In this assay, purified p53 was ubiquitinated 
in vitro with human MDM2/MDMX and then 
incubated with the USP7 constructs. p53 
could only be efficiently deubiquitinated 
by USP7 constructs that contain the HUBL 
domain (Figure 1C, top panel). Removal of the 
N-terminal p53-binding domain (TRAF) does 
not affect the role of the HUBL domain, and has 
a relatively limited influence on the activity in 
these experiments (Figure 1C, bottom panel). 
We then analyzed the importance of the HUBL 
domain for activity against ubiquitin chains, 
by monitoring hydrolysis of K48-linked di-
ubiquitin into mono-ubiquitin. Consistently, 
we saw robust activity in the presence of 
the HUBL domain, whereas in its absence no 
activity was observed (Figure 1D). Only when 
the concentration of the catalytic domain was 
1000-fold increased, activity could be observed 
(Figure S1B). Thus the HUBL domain is essential 
for full enzymatic activity of the USP7 catalytic 
domain. 
To study the in vivo significance of the HUBL 
domain, we transfected U2OS cells with 
GFP-fused full-length USP7 and USP7N-CD 
and investigated protein levels of two USP7 
substrates, p53 and MDM2. Our experiments 
showed an accumulation of p53 and MDM2 in 
the presence of full length USP7 compared to 
USP7N-CD (Figure 1E). This suggests that the 
HUBL domain is required to de-ubiquitinate p53 
and MDM2, and thereby prevents degradation, 
resulting in a net stabilization. This shows that 
the HUBL domain is important for the activity 
of USP7 in vivo, and therefore essential for its 
biological function.
To quantify the HUBL-mediated activation we 
used a minimal synthetic substrate, ubiquitin 
fused to a C-terminal fluorescent group, 
7-amido-4-methylcoumarin (Ub-AMC). Full-
length USP7 and a construct that lacks the 
TRAF domain (USP7CD-HUBL) showed very 
similar activity, with similar Michaelis-Menten 
kinetic parameters (Vmax 1.4 nmole s-1 and KM 
3 μM) (Figure 1F and Table S2). In contrast, the 
catalytic domain alone (USP7CD) was much less 
active, with a decrease in Vmax to 0.06 nmole/s 
(22-fold) and an increase in KM to 15 μM (5.5-
fold). Altogether, the enzyme efficiency (kcat/
KM) decreases 120-fold, suggesting that the 
C-terminal HUBL domain is essential to achieve 
full enzymatic efficiency and therefore activates 
the catalytic domain. 
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Since all USP7 constructs eluted as monomers 
from gel filtration, it is likely that this activation 
occurs within the same molecule. However, we 
wondered whether the HUBL domain could 
activate the catalytic domain when it is not part 
of the same chain, in trans. First we showed 
that the HUBL domain itself has no DUB activity 
on Ub-AMC, and then we mixed the catalytic 
domain with the HUBL domain. Adding 10 μM 
HUBL domain to the catalytic domain resulted 
in a 2-fold increase of catalytic turnover (Figure 
S1A). However, when adding a higher excess 
of the HUBL domain (50 μM), a clear activation 
can be observed (Figure 1F). This result shows 
that the catalytically inactive HUBL domain can 
indirectly activate the USP7 catalytic domain 
also in trans, at least at high concentrations.
To exclude the possibility that the observed in 
vitro activation was due to assay conditions, we 
tested the effect of pH and salt concentration. 
The USP7 activity is strongly dependent on 
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Figure 1. The HUBL domain is essential for USP7 activity. A. USP7 contains a TRAF substrate binding domain (brown) a 
catalytic domain (orange) and five Ubl domains (rainbow). B. USP7 constructs used in this study. C. Only in the presence of the 
HUBL domain can p53 be deubiquitinated. The presence of the N-terminal TRAF domain has a minor additional effect. D. Using 
10 μM di-ubiquitin and 1 nM USP7, only USP7CD-HUBL is able to hydrolyse the substrate to mono-ubiquitin. E. In U2OS cells, 
p53 and MDM2 protein levels increase compared to control levels by over-expression of full-length USP7. However, with over-
expression of USP7N-CD, this stabilization is not observed. HSP90 was used as a loading control. F. Kinetic analysis of Ub-AMC 
hydrolysis shows similar activity for USP7FL and USP7CD-HUBL, while USP7CD is 90-fold decrease in KM/kcat. Kinetic parameters 
can be found in Table S2.
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pH (Figure S1C), with an optimum between 
pH 8 and 9, and also shows considerable 
dependence on ionic strength (Figure S1D). 
Since p53 is responsible for stress responses, 
these pH and ionic strength dependencies may 
well be relevant in cells. However, the presence 
of the HUBL domain has no effect on the pH 
response and only a mildly positive effect 
on the response to salt (Figure S1C, D, right 
panels). Thus, although activation may have an 
electrostatic component, we concluded that 
neither ionic strength nor pH effects explain 
how the activation is achieved.
Altogether these data confirm and extend 
the observation that the C-terminal domain 
is essential for full activity against Ub-AMC. 
As expected, the N-terminal TRAF domain 
Figure 2. Crystal structure of the HUBL domain shows five Ubl domains. A. Secondary structure assignment of the 
HUBL domain. The residues are coloured to the corresponding Ubl. Disordered residues (1084-1102) are boxed. B. Cartoon 
representation of the HUBL domain with surface representation of the Ubls. See Table S1 for crystallographic information. C. 
Structure superposition shows that the Ubls share the β -grasp fold with ubiquitin, with variations in the length of the loop 
regions. (red: α-helix; blue: β-strand; green: ubiquitin). D. Di-Ubl units HUBL-12 and HUBL-45 are somewhat similar in Ubl 
orientation, showing a relative 30 degree rotation of HUBL-5 compared to HUBL-2. The ubiquitin Ile44 equivalents in the HUBL 
domains are labelled and depicted in sticks.
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increases the activity against p53, but not 
against the minimal target Ub-AMC and has 
therefore no effect on the HUBL activation itself. 
We thus show that the catalytically inactive 
HUBL domain indirectly activates USP7 catalytic 
domain in a target-independent manner. 
The USP7 HUBL structure shows five Ubl 
domains in three units
To investigate the mechanism underlying 
USP7 activation by its HUBL domain, we 
determined the crystal structure of the HUBL 
domain (residues 560 to 1102) using single 
anomalous dispersion (SAD) phasing from 
seleno-methionines (Figure 2A,B). The final 
model was refined to 2.7Å with Rfree of 0.216 
(Supplementary Table S1), and includes residues 
560 to 1083 with no Ramachandran outliers. 
The HUBL domain comprises five modules 
with the ubiquitin-like ββαβαβ-fold, one more 
than previously predicted based on consensus 
fold recognition23. The Ubl domains adopt 
an extended conformation, linked through 
regions of varying size that contain either one 
or two α-helices. The helices connecting HUBL-2 
and -3 interact with HUBL-2 (Figure S2A), but 
otherwise these linkers have little contact with 
the individual domains. 
The Ubl domains closely resemble ubiquitin 
(rmsd 1.9-2.5 Å, Figure 2C and S2B,C) and 
SUMO-2 (rmsd 2.2-2.9 Å), according to SSM35 
and DALI36 structural similarity searches 
against all structures in the PDB. Despite the 
structural similarities, the sequence identities 
with ubiquitin are very limited, varying from 6-
19% (Figure S2B). There are no obvious specific 
resemblances to other ubiquitin-like domains 
beyond the conserved fold, and hence it is not 
obvious that there is a shared function with 
other classes of Ubl domains. 
Although the five Ubl domains share the 
ubiquitin fold they are no more similar to each 
other than to other ubiquitin-like structures 
(rmsd 2.1-2.9 Å), and they are widely divergent 
in sequence (3-15% sequence identity) (Figure 
S2B). This leads to large variations in charge 
distribution, such that under physiological 
conditions HUBL-1 and -2 are negatively charged 
(calculated pI 4.4 and 4.5 respectively), HUBL-3 
is positively charged (pI 9.8) and HUBL-4 and -5 
are neutral (pI 5.6 and 6.0 respectively) (Figure 
S5D). Mutations in these charged patches do 
not affect the enzymatic activity of USP7 (Figure 
S5C), although they may play a role in other 
functions of the protein, such as protein-protein 
interactions with its binding partners.
The HUBL domain is organized in an elongated 
arrangement, where HUBL-3 has limited 
contacts with the other domains (Figure 2B) and 
HUBL-1 and -2, as well as HUBL-4 and -5 form 
di-Ubl units. Analysis with PISA35, shows that 
the di-Ubl interfaces bury a large surface area 
(total ~1200 and ~740 Å2, respectively) with 
negative solvation energies ΔiG (Figure S2D), 
suggesting that they are stable in solution. This 
was supported by the degradation pattern of 
semi-purified USP7CD-HUBL, which degrades 
to three stable fragments that correspond to 
the masses of USP7CD-123, USP7CD-12 and 
USP7CD (Figure S2E). From this we concluded 
that the HUBL domain is organised in a 2-1-
2 fashion that contains three units: HUBL-12, 
HUBL-3 and HUBL-45. 
Structural comparison of these di-Ubl units 
reveals that HUBL-12 and HUBL-45 are similarly 
arranged (Figure 2D). Superposing the N-
terminal domains HUBL-1 and HUBL-4 shows 
that equivalent interfaces are buried on the first 
Ubl in each pair, including the residue that is 
equivalent to the canonical Ile-44 of ubiquitin 
(Trp-623 and Leu-942, respectively). The second 
Ubl domains do not bury their Ile-44 equivalent 
residues (Tyr 735 and Ala 1041) and they are 
arranged slightly differently with a relative 
rotation of ~30 degrees resulting in small 
differences in detailed contacts. In both di-Ubl 
units the interfaces are mediated by extensive 
hydrophobic contacts as well as hydrogen 
bonds and electrostatic interactions (Figure 
S2D). This suggests that these di-Ubl units are 
functionally relevant.
SAXS analysis suggests flexibility and 
interaction between USP7CD and HUBL 
We were intrigued by the extended structure of 
the HUBL domain and wondered whether it was 
relevant in solution. To address this question we 
used Small Angle X-ray Scattering (SAXS). 
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When we compared SAXS curves recorded for 
the USP7CD, HUBL-123 and HUBL-45 domains 
to scattering curves calculated from their 
corresponding crystal structures, we obtained 
a good fit between the experimental and 
calculated curves (Figure 3A). The calculated 
molecular weights (Mw), radii of gyration (Rg) 
and maximum interatomic distance (Dmax), 
also correspond well with the expected values 
(Figure 3B), with only the Rg of HUBL-45 
approximately 30% larger than expected from 
the structure. These data show that USP7CD, 
HUBL-123 and HUBL-45 are structurally stable 
sub-domains of USP7 also in solution. 
In contrast, the scattering curve for the complete 
HUBL domain does not fit the calculated 
scattering curve (Figure 3A). The interatomic 
distance probability distribution P(r) shows a 
non-symmetrical shape, including a significant 
proportion of long distances (Figure 3C). This 
suggests that the extended conformation is 
retained in solution. Since rigid body modelling 
did not yield a single model, we conclude that 
the structure of the HUBL domain in solution is 
not static, most likely exhibiting considerable 
flexibility between the two stable domains, 
HUBL-123 and HUBL-45.
The HUBL domain and USP7CD-HUBL have a 
similar radius, with the HUBL domain being 
marginally smaller as expected (Figure 3B,C). 
However, in the USP7CD-HUBL domain P(r) 
plot (Figure 3C) the asymmetry due to long 
interatomic distances mostly disappears, 
indicating a more compact molecule, despite 
the addition of the catalytic domain. This 
suggests that the HUBL domain folds back to the 
catalytic domain, resulting in a more compact 
shape. Since rigid body modelling did not yield 
a single solution, the interaction between the 
catalytic domain and the HUBL domain could 
be dynamic. 
Figure 3. SAXS analysis of the HUBL domain. A. Scattering curves of the USP7 fragments (red symbols) with corresponding 
scattering curves calculated from the crystal structures (black lines). B. Overview of the SAXS analysis results. C. The symmetrical 
interatomic distance probability distribution (P(r)) of USP7CD-HUBL shows that it has less extended shape than the HUBL 
domain,indicating that the HUBL domain folds back onto the CD.
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HUBL-45 is sufficient for USP7 activation 
To identify the minimal region in the HUBL 
domain that is required for activation of 
the USP7 enzymatic activity, we produced 
C-terminal deletion constructs (Figure 1B). Upon 
deletion of the last one or two Ubl domains, 
the resulting USP7CD-1234 and USP7CD-123 
has a severely compromised catalytic turnover, 
similar to the catalytic domain alone (Figure 4A). 
As HUBL-45 is an independent folding unit that 
seemed essential for in vitro activity, we tested 
if deleting it would affect USP7 function in vivo.
After transfecting U2OS cells with full-length 
USP7, USP7N-CD or USP7N-CD-123, we 
monitored p53 and MDM2 protein levels. Our 
experiments showed an accumulation of p53 
and MDM2 in the presence of the full length 
USP7, which is not observed in absence of HUBL-
45 (USP7N-CD-123) (Figure 4B), suggesting that 
it is required to de-ubiquitinate p53 and MDM2. 
This shows that HUBL-45 is essential for USP7 
function in vivo. 
Then we analyzed whether HUBL-45 alone is 
enough to reconstitute full activity. We deleted 
HUBL-123, coupling the HUBL-45 unit directly 
to the catalytic domain via a 2-amino acid 
linker (USP7CD-45). This variant had Vmax and 
KM values almost identical to the complete 
USP7CD-HUBL (Figure 4D) in the Ub-AMC assay. 
In addition, USP7CD-HUBL and USP7CD-45 
Figure 4. HUBL-45 is sufficient for activation. A. Any C-terminal deletion reduces activity to similar levels as USP7CD in Ub-
AMC assays. However, the USP7CD-45 construct showed similar activity as USP7CD-HUBL. Removing the C-terminal peptide 
(USP7CD-45 ΔC) resulted in greatly reduced activity. B. Loss of HUBL-45 reduces USP7 activity in U2OS cells: protein levels of p53 
and MDM2 did not increase as seen with the wild type full length USP7. HSP90 was used as a loading control. C. USP7CD-HUBL 
and USP7CD-45 have similar activity towards 10 μM di-ubiquitin (K48), while USP7CD did not show any activity. D. USP7CD-45 
still showed full activity in Ub-AMC assays. E. SPR binding experiments, show an interaction with a Kd of 50 (± 11) μM between 
GST-USP7CD and HUBL-45.
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have similar efficiency against a di-ubiquitin 
substrate (Figure 4C). These results show that 
HUBL-45 is sufficient to reconstitute the USP7 
activation. 
HUBL-45 consists of the di-Ubl unit and a flexible 
C-terminal 19 residue peptide that is disordered 
in the crystal structure. When we deleted this 
C-terminal tail of HUBL-45 (USP7CD-45ΔC) we 
observed a greatly reduced activity, similar 
to USP7CD (Figure 4A), showing that the C-
terminal peptide is critical for the activation. To 
see whether this peptide alone was sufficient 
to promote activation, we performed in trans 
activation experiments with Ub-AMC using 
the peptide alone versus complete HUBL-45, 
including the peptide. In these assays (Figure 
S3A), the peptide marginally activates USP7CD 
in trans, whereas the full HUBL-45 domain 
provides robust levels of activation (Figure S3A). 
Therefore, we conclude that the C-terminal 
activation peptide is essential to increase the 
activity of USP7CD, but only in the context of 
HUBL-45.
Collectively, the activation of the catalytic 
domain and the SAXS data imply that the 
activation mechanism is through a direct 
interaction between the catalytic domain 
and HUBL-45. Indeed, when using a Surface 
Plasmon-Resonance (SPR) binding assay with 
immobilized GST-USP7CD, we observed a 50 μM 
dissociation constant (Kd) for HUBL-45 (Figure 4E), 
in agreement with the concentrations required 
for trans activation by the HUBL domain (Figure 
1F and S3A). When the flexible C-terminal 
peptide was removed (HUBL-45ΔC), the affinity 
for the catalytic domain did not change (Figure 
4E). Since no binding was detected between 
the catalytic domain and the peptide (Figure 
S3B), we concluded that although the peptide 
is essential for activity, the HUBL-45 di-Ubl unit 
is required for binding to the catalytic domain. 
This brings the flexible C-terminal activation 
peptide close to the catalytic domain, resulting 
in its activation.
The HUBL domain promotes ubiquitin 
binding
When considering the mechanism of USP7 
activation, we realized that the lower KM value in 
the catalytically efficient constructs suggested 
an increase in substrate affinity. Therefore we 
tested whether the HUBL domain affected the 
ubiquitin affinity of USP7CD. We incubated with 
the suicide substrate ubiquitin-VME (20 μM)37. 
While USP7CD alone was loaded only partially, 
USP7CD-45 loading was essentially complete 
(Figure S4A). 
Since this could indicate an increase of ubiquitin 
affinity, we decided to validate this by SPR 
experiments. Neither USP7CD nor USP7CD-
12 show appreciable ubiquitin binding, with 
almost no responses measured up to 17 μM, 
suggesting very little affinity for ubiquitin 
(Figure 5A and S4B). Also, no ubiquitin binding 
was observed for the HUBL domain itself (Figure 
5A). However, the catalytically efficient USP7CD-
HUBL construct showed a clear association and 
dissociation from ubiquitin. Both the kinetic 
and equilibrium data could be fitted with a 
Kd of 1.5 μM (Figure 5B,E). This indicates that 
the catalytic and HUBL domains cooperate to 
achieve ubiquitin binding. USP7CD-45 also 
binds ubiquitin with a Kd of 4 μM, similar to 
USP7CD-HUBL (Figure 5C,E), confirming that 
HUBL-45 is sufficient for the activation of USP7. 
Interestingly, although these Ubl domains 
may resemble ubiquitin, they do not compete 
for ubiquitin binding to USP7. Instead, they 
promote this interaction.
In the kinetic analyses, we observed that the 
catalytic domain and the HUBL domain cooperate 
in trans (Figure 1F). To test if that also translates 
to ubiquitin binding, different concentrations 
of USP7CD were flowed over the GST-ubiquitin 
chip in the presence of 50 μM HUBL. A partial 
reconstitution of the ubiquitin binding to a Kd 
of 13 μM was achieved, confirming that trans 
activation of the catalytic domain translates 
in an increased ubiquitin affinity (Figure 5D,E). 
The observed ubiquitin affinities correlate with 
the KM values for Ub-AMC derived in the kinetic 
analysis, and therefore show that the increase of 
KM can be explained by the increase of Kd (Table 
S2).
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Point mutants prevent HUBL auto-activation 
To understand how HUBL-45 conveys the 
activation to the catalytic domain, we used 
site-directed mutagenesis and tested a number 
of different options (Figure S5). In USP7 the 
residues forming the catalytic triad adopt an 
inactive conformation18 (Figure S5A). However 
upon ubiquitin binding, the active site is 
remodelled to the active conformation. With 
this conformational change a small loop close 
to the active site (residues 285 to 291), that we 
name ‘switching loop’, shows dramatic changes 
(Figure 6A).
We mutated several residues in this ‘switching 
loop’, both in the context of USP7CD and 
USP7CD-45, and tested their activity using Ub-
AMC (Figure 6B and Table S2). These mutations 
show a limited activating effect when tested 
in the catalytic domain alone. However, in the 
context of USP7CD-45, two switching loop 
mutants, W285D and E286A, greatly reduce 
Figure 5. Ubiquitin affinity is increased by the HUBL domain. A. SPR binding studies using GST-tagged ubiquitin, showed 
weak ubiquitin binding for USP7CD, and no responses with the HUBL domain. B. USP7CD-HUBL binds to ubiquitin, which could 
be fitted using the binding kinetics (black line) to a Kd 1.5 (± 0.5) μM. The inset shows the residuals. C. USP7CD-45 binds ubiquitin 
with a dissociation constant of 4.15 (± 0.6) μM. The inset shows the residuals. D. The dissociation constant for ubiquitin of the 
USP7CD is increased to 12.90 (± 1.4) μM in the presence of 50 μM of the HUBL domain. E. Overlay of the normalized equilibrium 
responses.
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Figure 6. Mutants in the catalytic domain and HUBL-45 prevent activation. A. Crystal structures of the USP7 catalytic domain 
(1NB8 and 1NBF) show a remodelling of the “switching–loop” (residues W285 - F291) and active site upon binding of ubiquitin 
aldehyde. Schematic diagram of USP7CD-45 shows catalytic residues, the switching loop and activation peptide. B. Mutating 
‘switching loop’ residues W285 and E286 in the catalytic domain dramatically reduced the activity of USP7CD-45. In USP7CD a 
limited activating effect is seen, due to destabilization of the inactive form. Mutating F291 resulted in extra HUBL activation. 
The activity is normalized to full length USP7. C. Mutating conserved residues in the C-terminal activation peptide of HUBL-45 
resulted in decreased activity on Ub-AMC, with a complete loss of activation for mutant Ile1100Ser. D. SPR shows dramatic 
decrease in ubiquitin binding for USP7CD-45 W285D E286A (Kd = 67.9 ± 5.3 μM). E. USP7FL activity in U2OS cells is reduced for 
mutants in the switching loop (1. W285D E286A), or in the activation peptide (2. ∆C; 3. I1100S) since protein levels of p53 and 
MDM2 only increase with wild-type USP7. HSP90 was used as a loading control.
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the activation effect conferred by HUBL-45. 
Moreover, the W285D E286A double mutant 
has a greatly reduced ubiquitin affinity (Figure 
6D and S4C,D). 
The 19 residues in the flexible C-terminal 
peptide of HUBL-45 are essential for the 
activation (Figure S3A and 6C). Several single 
point mutants of conserved residues displayed 
a reduction in activating capacity (Figure 6C). 
Strikingly, the single point mutant I1100S 
completely abolished the HUBL activation and 
greatly reduced ubiquitin binding (Figure 6C, 
S4D and Table S2). Consistently, over-expressing 
these USP7 mutants in U2OS cells completely 
abolished the stabilisation of p53 and MDM2 
observed for the wild-type enzyme (Figure 6E). 
This shows that, although they are not in direct 
contact with ubiquitin, both the switching loop 
and the C-terminal peptide of the HUBL domain 
are required for the HUBL mediated increase of 
activity and ubiquitin affinity.
GMPS binds to HUBL-123 and allosterically 
promotes activation
Due to the intrinsic flexibility and weak 
interactions with the catalytic domain, the HUBL 
domain may not always be in the activated state. 
Therefore, the HUBL activation mechanism may 
be susceptible to regulation. A prime candidate 
for this regulation is GMPS, a metabolic enzyme 
that binds and activates USP7 in Drosophila30 
and humans31. To analyze whether the HUBL 
domain intrinsically and constitutively activates 
USP7, or whether it can be further regulated, 
we studied the modulation of USP7 activity by 
GMPS. 
First, we wondered which USP7 domains are 
involved in GMPS binding. Using pull-down 
experiments with various GST-tagged USP7 
constructs we show that GMPS binds to USP7 
only when HUBL-123 is present (Figure S7A). 
USP7CD-HUBL, USP7CD-123 and HUBL-123 
have a very tight interaction with GMPS (Kd 
of 30-40 nM), as shown by SPR (Figure 7A and 
S7B,C). Neither USP7CD or USP7CD-45 showed 
any appreciable binding to GMPS (Figure 7A 
and S7C), confirming that HUBL-123 is sufficient 
for the USP7-GMPS interaction.
Next, we wanted to see if GMPS binding affects 
USP7 activity. Indeed, the activity of USP7CD-
HUBL in Ub-AMC assays is increased 5.5-fold in 
the presence of GMPS (Figure 7B and Table S2). 
Kinetic analysis reveals an increased kcat, with 
only a slightly increased KM, consistent with the 
observation that the ubiquitin affinity of the 
complex does not change (Kd 2.5 ± 0.17 μM) 
(Figure S7D). The presence of GMPS does not 
activate USP7CD-123 even if they interact tightly 
(Figure S7E). Importantly when we introduced 
the W285D E286A and I1100S mutations to 
USP7CD-HUBL, the mutant proteins bound 
GMPS equally well as the wild type (Figure 
S7A,B,C), but could no longer be activated 
by GMPS (Figure 7C). This shows that GMPS 
hyper-activation of USP7 requires a functional 
switching loop in the catalytic domain and works 
through the HUBL-45 dependent activation.
To confirm whether the GMPS-dependent 
activation indeed acts through HUBL-45 we 
analyzed whether GMPS changed the affinity 
of the HUBL-45 region for the catalytic domain. 
Strikingly, whereas the HUBL-123 has no affinity 
for the catalytic domain in the presence of 
GMPS, the dissociation constant between the 
full HUBL domain and the catalytic domain 
increases from 48 (± 9.7) μM to 1.8 (± 0.42) μM 
in the presence of GMPS (Figure 7D). This shows 
that GMPS can allosterically activate USP7 by 
binding to HUBL-123, stabilizing the contact 
between HUBL-45 and USP7CD, thus promoting 
the activated state.
Discussion
We show here that the C-terminal HUBL-45 
domain is required, and sufficient for full activity 
of the USP7/HAUSP deubiquitinating enzyme. 
This mechanism depends on contacts between 
the C-terminal tail of HUBL-45 and a ‘switching 
loop’ in the catalytic domain, which leads to 
organization of the active site and an increased 
affinity for ubiquitin. Single point mutants in 
the switching loop or C-terminal tail interfere 
with USP7 activity in vivo and in vitro. 
Apparently USP7 has the unusual ability to 
switch the active site between an active and an 
inactive state, resulting in the change in both 
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to the active conformation. This increases both catalytic turnover and ubiquitin affinity (top panel). Subsequent binding of 
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an increased affinity between the catalytic domain and the HUBL-45 unit of the HUBL domain (bottom panel).
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kcat and KM. This was observed in the crystal 
structures of the catalytic domain, with and 
without ubiquitin. Most USP catalytic domains, 
USP8 (2GFO), USP14 (2AYN), USP4 (2Y6E) and 
CYLD (2VHF), do not have this non-organized 
state of the catalytic triad. USP14 is activated by 
binding to the proteasome38, which is mediated 
by a single Ubl domain37. However only for USP7 
and Ubp8, a member of the SAGA complex, the 
two states are suggested based on biochemical 
and structural data39,40. Here we show USP7 
is able to switch, since in trans activation is 
possible. Apparently, the pre-folded catalytic 
domain can still be activated by the HUBL 
domain.
At first glance, full-length USP7 is continuously 
in the active state. However, we show that 
binding of GMPS can further activate USP7. 
The HUBL-123 domain, which is dispensable 
for USP7 intrinsic activity, serves as a binding 
platform for GMPS. This binding results in hyper-
activation of USP7 through a mechanism that is 
completely dependent on a functional HUBL 
activation, since point-mutants in this interface 
can not be activated by GMPS. Rather, GMPS 
binding results in an increased affinity between 
the catalytic domain and the HUBL-45 unit of 
the HUBL domain, stabilizing the interaction. 
Therefore we propose a model where USP7 
exists in equilibrium between an active and an 
inactive state (Figure 7E, top panel). The switch 
between states involves an increase of ubiquitin 
binding and remodelling of the active site and 
switching loop, due to interactions with the 
HUBL-45 domain. Allosteric interaction with 
GMPS stabilizes the active state, promoting the 
interaction between HUBL-45 and switching 
loop (Figure 7E, bottom panel). It does not affect 
ubiquitin binding or KM but activates through 
kcat, resulting in substantially more molecules in 
the active state.
Since the interaction between USP7CD and the 
HUBL domain is weak, and single point mutants 
can completely prevent HUBL activation, USP7 
is not always in the “on” state, but rather displays 
flexibility, as seen in the SAXS experiments. That 
would explain how GMPS could hyper-activate 
USP7 through an increase of HUBL affinity 
for USP7CD, by serving as a molecular lock to 
reduce HUBL flexibility. 
GMPS most likely has additional target specific 
regulatory functions in cells30,31. Since not all 
USP7 is found in complex with GMPS or vice 
versa34, it is clear that USP7 is not always in this 
activated state in cells.
This opens the interesting possibility that 
other regulators could further modulate the 
interaction between the catalytic domain and 
the HUBL domain, either promoting the ‘on-
state’, like GMPS, or by sequestering HUBL-45 
from the catalytic domain and promoting the 
‘off-state’. Since USP7 is an important player in 
key cellular processes, such ability to hundred-
fold modulate - increase or decrease - catalytic 
efficiency, provides a very fast response to 
external stimuli. The subsequent regulation could 
be achieved by post-translational modification, 
by interaction with other partners27 or even by 
substrate interactions, since e.g. MDM2 and p53 
were shown to interact with the HUBL domain. 
Regulation of USP catalytic activity through 
allosteric interaction has been observed before, 
e.g. for the SAGA complex, where binding of 
Sgf11 is necessary to maintain the catalytic 
residues of Ubp8 in the proteolytically active 
conformation39,40. Interestingly, this allosteric 
activation depends on the topologically 
equivalent ‘switching loop’ as in USP7. Moreover, 
USP7 and Upb8 share the conserved W285 that 
is involved in the switching of USP7, confirming 
its importance. However, the mechanism in 
Ubp8 is distinct, since it relies on inter-molecular 
interactions, rather than an intra-molecular 
interaction as in USP7.
Surprisingly, both the activation of USP7 and the 
GMPS binding are conveyed by Ubl domains. 
None of these Ubl domains seem to resemble 
ubiquitin enough to compete for ubiquitin 
binding in the substrate binding site. This is in 
contrast to the internal Ubl domain in USP4, 
which competitively inhibits catalytic activity 41. 
In USP7 the Ubl domains behave as larger units, 
with different functions. Although Ubl domains 
were predicted in other USPs, the large number 
of Ubl domain in the HUBL domain itself seems 
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to be unique for USP7. 
The importance of USP7 for localisation and 
stability of critical cancer targets such as FOXO4, 
PTEN and p53/MDM2 make it into an interesting 
drug target. The unique features of its regulation 
may well offer specific opportunities for drug 
development. 
Experimental procedures 
General plasmids, proteins, antibodies
Plasmids for human MDM2, MDMX were a 
gift from Martin Scheffner, plasmids encoding 
ubiquitin variants for chain formation were 
a gift from Shaari Rahzi. Purified hyperstable 
p5342 was a gift from Caroline Blair and Alan 
Fersht, UBA1, UBCH5c, ubiquitin were purified 
as described43,44; human MDM2/MDMX was 
purified using Martin Scheffner’s protocol45, di-
ubiquitin with a K48 linkage was produced as 
previously described44. 
Generation of plasmids, bacmids and 
baculoviruses
Codon optimized full length USP7 and GMPS 
cDNA was obtained from DomainEx (Cambridge, 
UK). Both were amplified by PCR and subcloned 
(SpeI/NotI) into a pFastBac vector (Invitrogen) 
containing an N-terminal GST tag (BamHI/SpeI) 
and Prescission Protease cleavage site. Bacmids 
were prepared following the manufacturer’s 
guidelines. Virus was produced using the low-
MOI infection protocol46. DNAs coding for the 
truncation and deletion constructs of USP7 were 
amplified with 5’-BamHI and 3’-NotI overhangs 
and subcloned into the pGEX-6P-1 vector (GE 
Healthcare) or by introducing stop codons 
using the QuickChange mutagenesis kit from 
Stratagene (La Jolla, CA, USA). All constructs 
were checked by sequencing. USP7CD-45 was 
produced by amplifying the catalytic domain 
(residues 208 to 564) with 5’-BamHI and 3’-
XhoI overhangs and HUBL-45 (residues 890 to 
1102) 5’-XhoI and 3’-NotI overhangs and both 
fragment subsequently subcloned into the 
pGEX-6P-1 vector (GE Healthcare). This resulted 
in the addition of two extra residues (Leu-Glu) 
between the catalytic domain and HUBL-45. 
Mutants were created with the QuickChange 
mutagenesis kit (Stratagene).
Protein expression and purification 
Full length USP7 and GMPS were produced 
using Sf9 and Sf21 insect cell expression. 
Infection was done using a low-MOI infection 
protocol46. The cells were harvested 72 hours 
after a baculovirus induced growth arrest was 
observed. All USP7 truncation constructs, USP7 
mutants and GST-ubiquitin were expressed in 
E.coli BL21(DE3) T1-R cells using auto-induction 
medium47 overnight at 15°C. Selenomethionine 
HUBL was produced for crystallization and was 
expressed in E.coli B834(DE3) T1-R cells using 
SelenoMet Medium Base (Athena Enzyme 
Systems). All proteins were purified using GST 
sepharose (GE Healthcare) in 50 mM Hepes (pH 
7.5), 250 mM NaCl, 0.1 mM PMSF, 1 mM EDTA 
and 1 mM DTT followed by elution in 50 mM 
reduced glutathione and overnight cleavage 
by Prescission Protease (GE Healthcare). Size 
exclusion chromatography was performed 
using a Superdex 200 or 75 column (GE 
Healthcare), equilibrated against buffer 
containing 10 mM Hepes [pH 7.5], 100 mM NaCl 
and 1 mM DTT. All proteins eluted as monomers 
from the gel filtration. When necessary the 
cleaved GST-tag was removed by attaching a 
GST FF column (GE Healthcare) to the end of the 
gel filtration column. USP7/GMPS complexes 
were purified using co-lysis, or mixing of the 
individual proteins before the last gel-filtration. 
Protein was concentrated to ~10 mg/ml and 
stored at -80°C. 
In vitro p53 de-ubiquitination assay
Purified hyperstable p5342 was ubiquitinated 
using 0.5 μM Uba1, 3 μM UbcH5c, human MDM2/
MDMX, 250nM p53, 2 μM ubiquitin and 10mM 
ATP in 25 mM Tris (pH 8.0), 150 mM NaCl, 10 mM 
MgCl2, 2 μM ZnCl2, 5 μM β-mercapto-ethanol 
and 1 mM DTT for 1 hour at 37 degrees. The 
reaction was stopped by adding 11 mM EDTA 
and incubated with varying concentrations of 
USP7 for 1 hour at 37 degrees. Western blot was 
performed using mouse 1:1000 p53 antibody 
(PAB240 Santa Cruz) and the Pierce Fast Western 
Blot Kit.
Cell cultures, transient transfections
U2OS cells were cultured in Dulbecco’s modified 
eagle medium (DMEM), supplemented with 
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10% foetal calf serum. Transfections were done 
with the calcium phosphate method. Cells were 
transfected with 10 μg GFP-USP7 construct 
and 0.5 μg pBabePuro per 10 cm dish. 48 hours 
after transfection, cells were selected with 
puromycin. Puromycin selected cells were lysed 
in RIPA buffer supplemented with “complete” 
protease inhibitors (Roche). Western blots were 
performed using whole cell extracts, separated 
on 8% SDS-PAGE gels and transferred to 
polyvinylidine difluoride membranes (Millipore). 
Western blots were probed with the indicated 
antibodies. Antibodies used were anti-GFP (FL), 
p53 (DO-1), and MDM2 (SMP-14), Hsp90 α/β (H-
114), all from Santa Cruz.
Di-ubiquitin assay
Di-ubiquitin hydrolysis reactions were 
performed at 37°C in 50 mM Hepes buffer (pH 
7.5), 100mM NaCl, 1 mM EDTA, 5 mM DTT and 
0.05% (w⁄v) Tween-20 with either constant 
enzyme concentration (50nM) or constant 
substrate concentration (10 μM) with two-fold 
serial dilutions of the USP7 construct (starting 
from 20 μM). Reactions were stopped by 
addition of SDS loading buffer.
Ubiquitin-AMC assay
Activity towards Ub-AMC (Sigma) was assayed 
at 25°C in 50 mM Hepes buffer (pH 7.5), 100mM 
NaCl, 1 mM EDTA, 5 mM DTT and 0.05% (w⁄v) 
Tween-20. Assays were performed in “Non 
binding surface flat bottom low flange” black 
384-well plates (Corning) in a 30 μl reaction 
volume. Fluorescence was measured in 
intervals of 5 min using a Fluostar Optima plate 
reader (BMG Labtechnologies) at excitation 
and emission wavelengths of 355 nm and 460 
nm, respectively. All assays were performed in 
triplicate.
Kinetic analysis with Ubiquitin-AMC assay
To determine the assay linearity range, serial 
dilutions (from 200 nM) of each USP7 construct 
were used to completely hydrolyze 1 μM of Ub-
AMC. For Michaelis-Menten analysis, constant 
enzyme concentrations (1nM for full length 
USP7, USP7CD-HUBL and USP7CD45; 10 nM 
for USP7CD) were used to hydrolyze varying 
substrate concentrations (from 15 μM in two-
fold dilutions). In order to calculate the kinetic 
parameters for the hydrolysis of Ub-AMC, curves 
obtained by plotting the measured enzyme 
initial rates (v) versus the corresponding 
substrate concentrations ([S]). These were 
subjected to nonlinear regression fit using the 
Michaelis–Menten equation V = (Vmax • [S]) ⁄ 
([S] + KM) (eqn 1), where Vmax is the maximal 
velocity at saturating substrate concentrations 
and KM the Michaelis constant. The kcat value was 
derived from the equation kcat = Vmax ⁄ [Eo] (eqn 
2) where [Eo] is the total enzyme concentration. 
Experimental data was processed using Prism 
4.03 (GraphPad Software, Inc.).
Crystal structure determination
For data collection statistics, see Supplementary 
Table S1. HUBL (residues 560 to 1102) was 
crystallized at 4°C in sitting drops against 10% 
(w/v) PEG4000, 200 mM sodium chloride, and 
100 mM MES at pH 6.0 and cryoprotected in 
mother liquor supplemented with 20% (w/v) 
glycerol. A single-wavelength anomalous 
diffraction (SAD) experiment at the selenium 
anomalous peak wavelength, was performed 
at the PX beamline at the Swiss Light Source 
(SLS), while a native data set was collected at 
the ESRF microfocus beamline ID23-2. Both 
data sets were collected from a single crystal at 
100K. Diffraction images were integrated with 
iMOSFLM48 and scaled with SCALA49, to 3Å for 
the selenomethionine crystal and 2.7Å for the 
native crystal. Structure solution was carried 
out using SHARP/autoSHARP50, and resulted to 
a phase probability distribution with an overall 
figure of merit of 0.47 before solvent flattening. 
ARP/wARP51 was used to built an initial 
incomplete model (375 out of 547 residues) 
which was used as a template to build a model 
manually in Coot52. This refined in iterative cycles 
with PHENIX53 and Buster54. For crystallographic 
parameters, see Supplementary Table S1. 
For residues 1084-1102, no electron density 
has been observed. Structure figures were 
generated using PyMOL (http://www.pymol.
org). Pictures of the electrostatic potential 
mapped on the protein surface were generated 
using CCP4MG55. Further structural analysis was 
performed with Espript56, PISA57, DSSP58 and 
SSM35.
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SAXS analysis
Samples for the SAXS experiments were 
prepared immediately after gel filtration in 
buffer containing 10 mM Hepes [pH 7.5], 100 
mM NaCl and 1 mM DTT with an additional 5% 
(v/v) glycerol as a radiation scavenger. Samples 
were taken during concentration and the flow-
through was collected and used for the blank 
measurements. Typically five concentrations 
were measured, ranging from 0.5 to 10 mg/ml. 
Data were collected at the ESRF beamline ID14-
3. Data were processed, analysed and modelled 
using programs from the ATSAS software 
package59. For the HUBL domain aggregation 
was observed and only the lowest concentration 
was used. The interatomic distance distribution 
probability function P(r) was calculated using 
Gnom. Rigid body modeling was performed 
using SASREF, using individual Ubl domains 
and/or the di-Ubl units. Distance constraints 
to define covalent links, or linkers when the 
connecting loops were removed, yielded similar 
results as using no distance restraints. Where 
possible, multiple merged scattering curves 
were used when the constructs overlapped. The 
ab initio models were calculated by DAMMIF 
and averaged over ten models using DAMAVER.
Surface Plasmon Resonance (SPR)
SPR was performed at 25°C on a Biacore T100. A 
CM5 sensor chip was prepared with monoclonal 
GST antibody via amino coupling (~20000 
response units). This chip was used to load 
roughly 50 response units of GST-ubiquitin or 
400 response units of GST-USP7CD. Biotinylated 
peptides were coupled to a SA chip (200 RU’s). 
Concentration series of the USP7 constructs in 
running buffer (10 mM HEPES [pH 7.5], 100mM 
NaCl, 5 mM DTT, and 0.05% Tween-20) were 
tested at 30 μl/min. Saturation binding values 
were plotted against concentration (GST as 
reference) and fit to a steady-state affinity 
model for calculation of apparent dissociation 
(Kd) and association (Ka) constants (Prism 4.03, 
GraphPad Software, Inc.). All experiments have 
been repeated at least three times.
Accession numbers
Coordinates and structure factors were 
deposited in the Protein Data Bank under 
identification code 2YLM.
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Faesen et al. Table 1
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Supplementary Table S1. Data collection and refinement statistics
Supplementary Table S2. Summary of the kinetic data determined in Ub-AMC assays and ubiquitin binding, determined 
using SPR
Faesen et al. Supplementary Table S1
kcat/K m [M
-1 s -1]
US P 7F L 1.42  ± 0.02 2.89  ± 0.10 4.92 *105
US P 7C D-HUB L 1.35  ± 0.06 3.62  ± 0.42 3.72 *105 1.5  ± 0.5
US P 7C D 0.06  ± 0.02 15.13  ± 1.09 0.04 *105
US P 7C D-45 1.32  ± 0.03 2.89  ± 0.20 4.57 *105 4.0  ± 0.6
US P 7C D + HUB L 0.29  ± 0.03 14.67  ± 1.98 0.20 *105 12.9  ± 1.4
US P 7C D-HUB L W E 285DA 0.31  ± 0.05 9.80  ± 0.59 0.32 *105 65.0  ± 5.3
US P 7C D-HUB L I1100S 0.07  ± 0.02 10.51  ± 0.58 0.07 *105
US P 7C D-HUB L / G MP S 7.69  ± 0.23 8.95  ± 0.53 8.60 *105 2.5  ± 0.2
US P 7C D-HUB L W E 285DA / G MP S 0.32  ± 0.05 10.78  ± 0.59 0.30 *105
US P 7C D-HUB L I1100S  / G MP S 0.07  ± 0.001 13.05  ± 0.13 0.05 *105 n.d.
n.d.
>>35
n.d.
n.d.
kcat [s
-1] K m [μM] Ub K d [μM]
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Faesen et al. Supplementary Figure S1
Zoom
+
A
C
D
USP7CD
USP7CD-HUBL
Concentration enzyme
2.4 nM 20 µM
di-Ubiquitin (K48)
mono-Ubiquitin
di-Ubiquitin (K48)
mono-Ubiquitin
+
B
Supplementary Figure S1 related to Figure 1. Characterization of HUBL activation. A. USP7CD can be activated both in 
trans and in cis by the HUBL domain. Using 1 μM UbiAMC and 1 nM USP7, the activity decreases strongly in the absence of 
the HUBL domain. This loss can be partially recovered by adding 10 μM HUBL to USP7CD. B. USP7CD concentrations need 
to be 1000-fold increased to achieve the same catalytic turn-over as USP7CD-HUBL. C. The pH profile was determined of the 
USP7 activity was monitored using 1 μM UbiAMC. Both USP7CD and USP7CD-HUBL show a similar pH profile, but it is more 
pronounced with USP7CD-HUBL due to the higher catalytic rate. D. The activity of both USP7CD and USP7CD-HUBL decrease 
upon increasing NaCl concentration, with a limited strengthening effect of the HUBL domain.
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Supplementary Figure S2 related to Figure 2. Structural analysis HUBL crystal structure.  A. The second helix in the linker 
region between HUBL-2 and -3 interacts with HUBL-2. Left: Cartoon representation, colours as in Figure 2, Right: Interface 
parameters, calculated with SSM 1. B. Despite the homologous fold, which is quantified by the low Cα rmsd, the primary 
sequence identity between the Ubl’s and with ubiquitin is low. Numbers based on the alignment in C. C. Structure based 
sequence alignment using SSM shows that the Ubl’s share the β-grasp fold with ubiquitin. D. Interface analysis by PISA 1 
revealed extensive interactions between HUBL-1 and -2 and HUBL-4 and -5. E. The Ubl domains within HUBL group in a 2-1-2 
configuration in solution. USP7CD-HUBL degrades during purification to stable intermediates with masses corresponding to 
USP7CD-123, USP7CD-12 and USP7CD.
Faesen et al. Supplementary Figure S2
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Faesen et al. Supplementary Figure S3
A
B
µM HUBL-45 µM tail peptide
+ +
Binding of C-terminal flexible tail 
to USP7CD
Supplementary Figure S3 related to Figure 4. The C-terminal peptide is essential, but not sufficient, for activation. A. 
Activity on Ub-AMC shows that upon removal of the C-terminal 19 residues in the flexible peptide loop (ΔC), the activation by 
the HUBL domain is greatly reduced. However, this peptide is not sufficient to achieve in trans activation, to similar levels as 
complete HUBL-45. B. Using SPR, no binding between USP7CD and the C-terminal peptide is observed. The responses are due to 
aspecific binding to the SPR chip and show no concentration dependence.
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Faesen et al. Supplementary Figure S4
Ubiquitin-VME
USP7CD USP7CD-45
*
*
- + - +
50 kDa
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A B
USP7CD-12 binding to ubiquitin
C
USP7CD-45 W285D E286A
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* UbVME
USP7CD-HUBL
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USP7CD-HUBL
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Supplementary Figure S4 related to Figure 5. Ubiquitin affinity is increased by the HUBL domain. A. When incubated with 
20 μM suicide substrate ubiquitin-VME2, only USP7CD-45 and not USP7CD was robustly able to form covalent complexes with 
ubiquitin as shown in this Coomassie stained SDS PAGE gel. Asterisk shows the USP7-ubiquitin complex. B. Using SPR binding 
experiments, very weak binding to ubiquitin was observed for USP7CD-12. GST-ubiquitin was immobilized to the CM5 sensor 
chip. C. Mutations in the ‘switching loop’ lower affinity for ubiquitin. SPR Sensorgram of the ubiquitin binding of USP7CD-45 
W285D E286A (Kd = 65 μM). D. When incubated with 5 μM suicide substrate ubiquitin-VME, only WT USP7 and not the mutants 
was robustly able to form covalent complexes with ubiquitin as shown in Coomassie stained SDS PAGE gel. Asterisk shows the 
USP7-ubiquitin complex
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Faesen et al. Supplementary Figure S5A
The catalytic site is remodelled to an active conformationA β-hairpin is more structure upon ubiquitin binding 
and creates an extra binding interface
The switching loop changes conformation in the active state
Ubiquitin
USP7CD 
Inactive
USP7CD + ubiquitin 
Active
A
Supplementary Figure S5 related to Figure 6. Crystal structure of USP7CD shows conformational changes upon 
remodelling of the active site and ubiquitin binding. A. Comparison of the apo structure of USP7CD (1NB8), with the 
ubiquitin complex of USP7CD (1NBF) show movement of a β-hairpin (bottom left), organization of the active site (bottom right) 
and remodelling of a ‘switching loop’ (top right), for which the sequence conservation is indicated.
Figure and legend continue on next page
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    4 Random or conserved solvent exposed residues
domain HUBL-45
Electrostatic 
patches
domain HUBL-13
Ubiquitin binding β-hairpin
in catalytic domain
Backside “fingers“
in catalytic domain
and HUBL-45
Faesen et al. Supplementary Figure S5B
R854D H855D
pI 4.4
pI 4.5
pI 9.8
pI 5.6
pI 6.0
D758R E759K
K869E R871D
E785K D789K
Catalytic domain (PDB: 1NBF)HUBL domain
Electrostatics HUBL domain
B
C
D
Continued from previous page
B-D. Overview mutations. A priori, three possible activation mechanisms could be envisaged, i) the stabilization of a β-hairpin 
in the catalytic domain (residues 410 to 420), which is more structured when co-crystallized with ubiquitin, making an extra 
interface with ubiquitin, ii) restricting the movement of the “finger region”, as is achieved in other DUBs by the insertion of an 
extra helix that stabilizes the fingers domain, or iii) near the active site there is dynamic switching of a loop that dependents on 
ubiquitin binding. However, since mutations within the ubiquitin binding β-hairpin or the backside of the “finger region” did 
not have an effect on activation by the HUBL domain, we excluded the first two possibilities. Domains are depicted in cartoon 
respresentation and the mutants are show in sticks. The activity is normalized to full length USP7. The electrostatic potential is 
calculated using CCP4MG.
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Faesen et al. Supplementary Figure S6
C GMPS binding to 
USP7CD-HUBL WT
GMPS binding to 
USP7CD-HUBL WE285DA
GMPS binding to 
USP7CD-HUBL I1100S
USP7CD-HUBL / GMPS binding to ubiquitin
D E
GMPS activation of USP7CD-123
USP7CD123 / GMPS
USP7CD123
GMPS binding to 
USP7CD-123
GMPS binding to 
USP7CD-45
A
W285D E286A (Kd = 50nM)
I 1100 S (Kd = 36nM)
WT (Kd = 36nM)
B
* * * * *
- - - - - -+ + + + + +
USP7CD
USP7CD-123
USP7CD-45
USP7CD-HUBL
W285D
E286A
I1100SWT
GMPS binding to 
USP7CD
Kd = 31 nMKd = 36 nM
Kd = 36 nMKd = 50 nM
Supplementary Figure S6 related to Figure 7. GMPS activation and binding. A. GMPS can only robustly be pulled down by 
GST-tagged USP7 constructs containing HUBL-123. B and C. Equilibrium responses (B) and sensorgrams (C) of GMPS binding 
to USP7 constructs and mutants.  Using SPR a Kd of 30-40 nM was determined between USP7CD-HUBL and GMPS. The mutants 
WE285DA and I1100S, and USP7CD-13 behaved similar as wild-type in GMPS binding. No binding was observed for USP7CD 
and USP7CD-45. D. SPR sensorgram of USP7CD-HUBL/GMPS binding ubiquitin (Kd = 2.5μM). E. USP7CD-123 can not be hyper-
activated by GMPS in the Ub-AMC assay.
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Enzyme kinetics
To understand the biochemical properties of 
the USP family, we determined the activity 
kinetics of twelve USPs, as described in chapter 
two. This revealed large variations in the two 
kinetic parameters: catalytic turnover (kcat) and 
ubiquitin binding (approximated by KM). This 
shows that the USPs apparently have evolved 
to play specific biological roles. It would be 
interesting to see how these numbers correlate 
with the biological function and context of the 
DUBs. For example, one could envision that the 
very active DUBs have a lot of substrates or are 
needed in very fast processes.
One of the major biochemical questions of the 
DUBs in general, concerns their differential 
activity towards the different ubiquitin 
topoisomers. Until now, most studies have 
focussed on the canonical K48- and K63-linked 
poly-ubiquitin. However, the other linkages 
have also been found in vivo and also have 
important functions1. Therefore, we for the first 
time analysed the activity of all our twelve USPs 
towards all seven lysine-linked di-ubiquitin 
topoisomers. We found that the small, but 
surprising differences are probably due to a 
steric hindrance by the proximal ubiquitin. A 
possible function for these preferences can 
be that DUBs remove the ubiquitination by 
a certain linkage, and therefore specifically 
change the function of that protein. 
Alternatively the DUBs can trim the ubiquitin 
chains of unwanted linkages. Whether these 
preferences are biologically relevant remains 
a question. This will depend on the ubiquitin 
linkages found on the substrates and biological 
complex the USPs are part of. Fact is that DUBs 
are often found in complex with E3 ligases, and 
therefore potentially change or fine-tune their 
biological activity.
We determined the ubiquitin topoisomers 
preference by using di-ubiquitin. However, 
ubiquitin chains can be much longer than 
di-ubiquitin, and these longer ubiquitin 
chains possibly have different properties. For 
example, K48-linked ubiquitin adopts a closed 
conformation when it is composed of at least 
four ubiquitin moieties2. Moreover, this closed 
tetra-ubiquitin represents the minimal signal 
for degradation3. This ability to form high-
order structures is possibly not unique for 
K48-linked ubiquitin. The crystal packing of 
K11-linked di-ubiquitin shows the stacking of 
two ring-shaped tetramers, forming a barrel-
shaped octamer4. This ubiquitin organization 
will have a profound effect on the hydrolysis by 
DUBs. Therefore future studies are required to 
determine the minimal length of all ubiquitin 
chain-types needed to invoke their biological 
function or a high-order structure. Only then 
we will obtain the full picture of the differential 
effects of ubiquitin linkages on the hydrolysis 
by DUBs.
Overall, the biological relevance of the enzyme 
properties will depend much on the protein 
complex they are part of5. DUBs are promiscuous 
enzymes by nature. They often have limited 
substrate specificity and deubiquitinate many 
proteins in the cell. Therefore, the activity of the 
DUBs is regulated by interacting proteins. So, we 
need to understand more of the larger protein 
complexes to fully understand the function of 
the preferences for ubiquitin topoisomers and 
the large variations in enzyme properties.
Activity modulation
Another way to regulate the activity of DUBs is 
by modulating its activity. The characterization 
of the enzymatic properties of the USPs, 
revealed that the activity of several USPs can 
Both ubiquitination and deubiquitination play important roles in many cellular processes, and they 
often have a causal role in diseases. Over the last decade our knowledge on DUBs has increased 
significantly, however many questions regarding their biochemical behavior and structural features 
remain unanswered. Since DUBs are increasingly acknowledged as possible drug targets, it is 
imperative that we understand how they work. This will not only give better insights in the biology 
of the enzymes that will be inhibited, but will also aid in the drug development itself. To this end, 
we present in this thesis new biochemical, structural and mechanistic insights concerning the 
modulation of the activity of the largest DUB family; the USPs.
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be modulated. In light of the promiscuous 
behavior of the USPs, it is not surprising that 
domains and interacting proteins can influence 
the activity. After all, this allows the adjustment 
of the activity to match the requirements within 
a larger protein complex. This modulation of the 
activity can happen at several levels, by small 
variations in the catalytic domain, by internal 
domains or by interacting proteins. 
Some USPs have structural plasticity or small 
insertions in the catalytic domains that possibly 
influence their activity. For example, the 
two ubiquitin-binding surface loops in USP4 
(chapter three) and USP146 block the active site, 
but relocate after ubiquitin binding. Another 
example is the catalytic domain of USP87. Due 
to an inserted α-helix at the backside of the 
finger region it is in a closed conformation. This 
suggests a perturbed ubiquitin binding, which 
nicely correlates in the weak KM value observed 
in the kinetic analysis.
In USP4, USP7 and USP16 the activity 
is modulated by internal domains. The 
mechanisms of USP4 (UBL inserted in the 
catalytic domain) and USP7 (HUBL domain) are 
discussed in chapters three and four. To date, 
the activation mechanism of USP16 by the 
ZnF-UBP domain is unclear. This domain is also 
present in USP5 where it is involved in ubiquitin 
binding and is responsible for activating USP5 
by increasing the affinity for poly-ubiquitin8. But 
since the domain in USP16 increases kcat rather 
than KM, the activation mechanism in USP16 is 
probably different. 
The activity of DUBs can also be modulated by 
interacting proteins. In this thesis we discuss 
the activation of USP7 by GMPS (chapter four). 
We also characterized the UAF1 activation 
of USP1, USP12 and USP46. Both these 
modulators increase the kcat of their associated 
USP. However GMPS and UAF1 probably use a 
different activation mechanism. GMPS hyper-
activates USP7, which on its own already is 
active. On the other hand, USP1, USP12 and 
USP46 show only very limited activity without 
UAF1. Modulators have also been found in other 
DUB families. For example in drosophila the UCH 
DUB Calypso (BAP1 is the closest homologue in 
humans) needs to interact to the Asx protein to 
be active9. Also, the Ubp8 (yeast homologue of 
USP22) is only active when it is embedded in 
the SAGA complex10,11. Unfortunately, we do not 
yet understand all the mechanisms underlying 
the activation. 
It is clear that (often small) details do seem to 
add up to large difference in the overall activity 
of the USPs. Crystal structures will reveal 
many of these details and will be valuable for 
(structure-based) drug design. Therefore, what 
is missing are (more) structures of catalytic 
domains with large insertions, full-length multi-
domain enzymes or even complex structures 
to fully explain the function and activity of the 
DUBs.
Ubiquitin-like domains in Ubiquitin-Specific 
Proteases
The presence of ubiquitin-like domains within 
the context of ubiquitin-specific proteases is 
surprising, and their incorporation in at least 17 
USPs makes them abundant as well. This thesis 
shows that UBL domains have diverse functions 
in USPs. Judging by their low sequence identity 
with each other and with ubiquitin, they have 
been incorporated in the USPs early in the 
evolution (Figure 1). Still, in USP4 the UBL 
domain sufficiently mimics ubiquitin to allow 
competition for ubiquitin binding. 
When looking at the sequence similarity of 
the USP family members, one can identify two 
distinct clusters of UBL integrations. The first 
contains almost all the USPs with insertions in 
the catalytic domain. The second group has a 
relatively large sequence divergence compared 
to the first, and contains the USPs with 
N-terminal and C-terminal UBL domains. The 
N-terminal and C-terminal UBL containing USPs 
in turn cluster in two subgroups, with USP47 in 
between, which contains UBL at both sides of 
the catalytic domain.
The UBL domains are capable to modulate the 
activity of the USPs. Chapter three describes the 
mechanistic characterization of the competition 
for binding between a UBL and ubiquitin to the 
catalytic domain in USP4. This competition is 
intriguing, since the UBL in solution is such a 
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good ubiquitin mimic that the binding behavior 
to the catalytic domain is very similar. In fact, 
both binding constants to the catalytic domain 
are identical. This poses a problem that is not 
fully understood yet. The local concentration 
of the UBL is very high (after all it is in the 
same chain) and is always (much) higher than 
the concentration of ubiquitin. Therefore, 
one would suspect that only in a very limited 
number of conditions, the ubiquitin would be 
able to successfully compete for binding to the 
catalytic domain. However, this does not seem 
to be the case, since the enzyme with the UBL 
still shows robust activity. Apparently the ability 
of the UBL to bind to the catalytic domain is 
impaired when it is within the same chain as the 
catalytic domain. It is unclear what causes this 
impaired binding. Possibly, the ability of the UBL 
to bind to the catalytic domain changes during 
the reaction cycle. Alternatively, there could 
be structural elements in the rest of the insert 
modulate the binding of the UBL. What these 
conditions and features are is still unknown. 
In some cases, the UBLs have evolved beyond 
ubiquitin mimics and have taken up different 
functions. Chapter four describes how USP7 
has UBL domains that can function as protein-
protein interaction domains with interesting 
functional consequences. In contrast to the 
two UBLs in USP4, there are five consecutive 
UBLs in the HUBL domain, making it a unique 
domain amongst USPs. Based on our SAXS 
experiments, the HUBL domain can be divided 
into two different regions, HUBL-123 and 
HUBL-45, connected through a flexible linker. 
Both HUBL subdomains are protein-protein 
interaction sites, capable of binding to different 
proteins. We show that HUBL-123 is dispensable 
for USP7 activity, but rather it serves as a 
binding platform and interacts with GMPS. 
This interaction allosterically activates USP7. 
From the literature we know that HUBL-123 also 
binds to the E3 ligases ICP0 and HDM2. ICP0 
and HDM2 seem to have no activating role, but 
interact to prevent their auto-ubiquitination12,13. 
In contrast to HUBL-123, HUBL-45 is the active 
unit within the HUBL domain and is sufficient for 
the activation of USP7. It makes a (weak) intra-
molecular interaction with the catalytic domain 
of USP7. This interaction remodels a switching 
loop, which in turn re-aligns the catalytic 
residues to form an active enzyme. This “switch” 
results in the increase of ubiquitin affinity and 
catalytic turnover. The binding of GMPS to 
HUBL-123 promotes the binding of HUBL-45 to 
the catalytic domain. This shifts the equilibrium 
between “active” and “inactive” conformations 
towards the active state, and therefore results 
in more active molecules. The fact that GMPS 
can enhance the interaction between HUBL-
45 and the catalytic domain, suggests that 
this interaction is dynamic. Therefore GMPS 
probably acts as a molecular lock, preventing 
the flexibility within the HUBL domain. The 
crystal structure of the complex of USP7 and 
GMPS complex would explain the molecular 
details of this interaction and activation.
Figure 1. Dendogram showing the phylogenetic relationship of part of the USPs. This revealed two likely evolutionary UBL 
integration points (stars). Diagram adapted from Nijman et al. Cell (2005). 
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However, HUBL-45 also serves as a binding 
platform and interacts with two different USP7 
substrates: p53 and FOXO4. It is unknown 
whether these interactions affect USP7 activity. 
A large proteomics effort has identified a list of 
additional interactors of USP7, for which most 
neither interaction site nor function are known5. 
Since the HUBL domain is flexible, potentially 
different proteins can interact with different 
conformations of the HUBL domain. GMPS 
binds to a conformation that promotes activity, 
but it could be possible that one of those 
interactors binds to a conformation that does 
not allow HUBL activation. This protein would 
be able to negatively regulate USP7 activity. 
Future research is needed to see whether the 
uncharacterized interactors have implications 
for the USP7 function, and whether the dynamic 
switching between different conformations 
of the HUBL domain induces different binding 
profiles of interacting proteins. 
So, in contrast to the inhibition by a UBL in 
USP4, there is an activation of USP7. Moreover, 
the UBL domain in USP14 is needed for the 
recruitment to the proteasome14. Therefore, to 
date three UBL domains in the USP family have 
been functionally characterized and all have 
a different function. The phylogenetics show 
that the three USPs are relatively distant family 
members (Figure 1). Probably the inserted UBL 
domains in USP11 and USP15 apply a similar 
auto-inhibiting as we have seen in USP4. 
However, the large sequence divergence of 
the UBL domains allows for large variations in 
function. So for now, it is difficult to extrapolate 
our results and predict the functions of the 
other UBL domains. Also, to date it remains 
unclear why the USPs have evolved to use 
ubiquitin-like β-grasp for their function. 
Regulation of the modulation
The intriguing consequence of activity 
modulation is that it creates possibilities for 
regulation. In chapter three we describe that 
USP4 can be relieved of its auto-inhibition 
by the sequestering of the UBL by at least 
two other USPs. Since this UBL seems to be a 
good ubiquitin mimic, it is therefore possible 
that more USPs can bind and have functional 
consequences. It is also possible that this UBL 
can bind to ubiquitin-binding domains, which 
would mean that many more proteins are able 
to regulate USP4 activity.
USP7 plays a pivotal role in directly regulating 
many important cellular processes. Therefore, 
the regulation of the HUBL activation could 
provide a fast response to external stimuli. 
As seen in chapter four, the HUBL domain 
activation is also essential for the activity of USP7 
in cells. From literature we know that the GMPS 
interaction activates USP7 towards p53 and is 
essential for H2B deubiquitination in vivo15-17. 
However, in vivo not all USP7 is bound to GMPS 
and vice versa, which suggests that there are 
distinct conditions in which USP7 needs to be 
modulated by GMPS. In other words, the USP7 
activity modulation is regulated. This is possibly 
regulated by post-translational modifications 
on USP7 itself18. 
It is tempting and exciting to speculate that 
the dynamic regulation of USP7 activity by 
its internal HUBL domain also exists in cells. 
Hopefully in the near future, we will be able 
to study this switching of states insides cells. 
This will enable the analysis of USP7 regulation 
under diverse cellular conditions and with the 
many known USP7 interacting proteins. This 
might identify the situations where targeting 
USP7 with drugs is most beneficial.
Overall, this thesis presents new insights in 
the activity characteristics of the USP family. 
DUBs are involved in several diseases19-24, and 
have been acknowledged as promising drug 
targets25. The unique features of the USPs in 
both enzyme kinetics and activity mechanisms 
that we present in this thesis, create new 
possibilities in designing specific drugs. 
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Summary
In concert with DNA, proteins form the hart of all 
cellular processes. They are therefore essential 
for the cell to perform its task. To ensure optimal 
control of these processes, tight regulating of 
these proteins is required. To achieve this, the 
cell controls the levels of protein synthesis, 
degradation or modification. Posttranslational 
modifications are both a powerful and rapid 
way to dramatically change the fate of the 
protein, its function or subcellular localization. 
Especially in signaling cascades, they provide 
a fast and accurate way to ensure control over 
protein function, sometimes in very complex 
networks. 
Several chemical modifications exist in cells, 
ranging from small chemical groups, like 
phosphorylation, methylation or acetylation, to 
even small proteins. The most famous protein 
modification is the covalent attachment of the 
small protein ubiquitin to lysine residues of 
the target protein. This essential, common and 
widespread modification is involved in virtually 
all cellular processes. Like other modifications, 
ubiquitination is a dynamic process. The 
ubiquitin moieties can be removed from target 
proteins by Deubiquitinating enzymes (DUBs). 
They provide negative feedback, and therefore 
are an important and integral part of the 
ubiquitin conjugation system.
The work described in this thesis provides 
mechanistic insight in de-ubiquitination by 
describing biochemical and structural aspects 
of the largest DUB family, the Ubiquitin Specific 
proteases (USPs). USP family members share a 
homologous catalytic domain, which would 
suggest they share biochemical properties. 
However, protein sequence analysis and crystal 
structures identified several distinct variations 
that affect their properties. Since we lack the 
tools to predict the effect of these variations 
on the activity, we performed a large-scale 
kinetic analysis of twelve USP family members, 
as described in chapter two. The very large 
differences in both in the catalytic turnover and 
ubiquitin binding that we observed, result in a 
unique kinetic behaviour of each USP. On top of 
this great diversity in kinetic properties, an extra 
layer of regulation exists by means of activity 
modulation. This way a domain or interacting 
protein can change the activity characteristics. 
We characterized the activation or inhibition of 
the catalytic domain of three USPs by internal 
domains. In addition, four USPs can bind to a 
non-DUB protein which results in an increase of 
the catalytic turnover. 
One of the major questions of the DUBs in 
general, concerns their differential activity 
towards the different poly-ubiquitin linkages. So 
far, most studies have focussed on the canonical 
K48- and K63-linked poly-ubiquitin. Although 
we do not fully understand the functions and 
biological roles of the other five linkages, they 
serve equally important functions in the cell. 
Therefore, we also describe for the first time the 
activity of all our twelve USPs towards all seven 
lysine-linked di-ubiquitin topoisoforms. We 
found that the small, but surprising differences 
are most likely due to a steric hindrance of one 
of the ubiquitin moieties. Future research is 
required to determine the biological relevance 
of these differences. 
Some USPs contain surprising additional 
domains. One of the most striking is the 
Ubiquitin-like (UBL) domain. Fold recognition 
algorithms show that at least 17 USPs contain 
such a UBL domain in their context. Chapter 
three describes the function of a UBL inserted 
in the catalytic domain of USP4. We determined 
the crystal structure of the USP4 catalytic 
domain without the UBL. This UBL was able to 
compete for ubiquitin binding to this catalytic 
domain, and was therefore able to inhibit its 
activity. Additionally, other USPs can bind to 
this UBL insert, which in turn relieves USP4 from 
its auto-inhibition.
However, not all UBL domains behave as 
competitive inhibitors. In USP7, also known as 
Hausp, UBL domains just outside its catalytic 
domain are essential for the activity. USP7 is one 
of the most famous and best studied DUBs, since 
it directly regulates many important proteins 
in oncogenic pathways, like p53, MDM2 and 
PTEN. This makes it an interesting drug target 
that is actively pursued by both academia and 
the pharmaceutical industry. Chapter four 
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describes the activation mechanism of USP7 by 
this Hausp UBL (HUBL) domain. We solved the 
crystal structure of HUBL domain, which showed 
us that it contains five consecutive UBL domains 
with two novel di-UBL units (2-1-2). The last two 
UBLs (HUBL-45) were sufficient to achieve full 
activity and ubiquitin binding. This di-UBL unit 
interacted directly with the catalytic domain, 
which caused the remodeling of the active site 
to an active conformation. Therefore, binding 
of HUBL-45 resulted in the switching from an 
‘inactive’ to an ‘active’ state. This switching is 
dynamic, because the metabolic enzyme GMP 
sythetase (GMPS) can bind to HUBL-123, which 
promotes the ‘active’ state by increasing the 
affinity of HUBL-45 to the catalytic domain. 
Therefore the HUBL activation is allosterically 
regulated by GMPS binding, resulting in more 
active enzymes. 
Overall, USPs play important role in many 
cellular processes, and often have a causal role 
in diseases. They have been acknowledged 
as promising drug targets. However, to aid 
the (structure-based) drug design, it is also 
important to understand the biochemical 
and biophysical properties and activity 
mechanisms. Together this will give us a 
complete picture of how the enzymes work. 
Therefore we performed a general biochemical 
characterization, which provided new insights 
in the linkage specificity and variability within 
the USP family. In this thesis we also show that 
the activity of individual USPs can be modulated 
by both intra- and intermolecular domains or 
proteins, and we elucidated the modulation 
mechansism of USP4 and USP7. The fact that 
USPs have unique characteristics and activity 
mechansisms, presents opportunities in the 
development of new and specific drugs. 
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Samenvatting
Samen met DNA, vormen eiwitten het hart van 
alle cellulaire processen. Zonder eiwitten zou 
een cel zijn taken niet kunnen uitvoeren. Echter 
om te zorgen dat de eiwitten hun taken goed 
uitvoeren, moet de cel wel strikte controle over 
ze houden. Dit kan op verschillende manieren. 
De cel kan bijvoorbeeld reguleren hoeveel 
er van een bepaald eiwit aanwezig is. Maar 
hij kan ook besluiten een eiwit te inactiveren 
door het te laten afbreken. In dit proefschrift 
hebben we het vooral over de mogelijkheid om 
chemische veranderingen aan te brengen aan 
bestaande eiwitten. De chemische verandering 
van een eiwit zorgt ervoor dat het nieuwe 
eigenschappen krijgt. Hierdoor kan de activiteit 
van een eiwit veranderd worden, maar ook 
bijvoorbeeld de functie of locatie in de cel. 
Er zijn verschillende soorten chemische 
modificaties mogelijk. Zo kan een eiwit 
gemodificeerd worden door kleine chemische 
groepen, zoals fosfor, methyl-groepen of 
acetaat. Maar er worden ook kleine eiwitten 
gebruikt en de meest bekende is met een 
eiwit genaamd ubiquitine. Door middel van 
een cascade van drie enzymen (E1, E2 en E3) 
kan heel specifiek een covalente koppeling 
gemaakt worden tussen het substraateiwit 
en de ubiquitine. Dit ubiquitine conjugatie 
systeem is essentieel en wordt veel gebruikt en 
is betrokken in bijna alle processen in een cel. 
Echter, de ubiquitine kan ook weer verwijderd 
worden van het substraateiwit waardoor het 
weer in de oude toestand terugkeert. Dit wordt 
gedaan door Deubiquitinerende Enzymen 
(DUBs in het Engels). Deze enzymen spelen 
dus ook een belangrijke rol in de dynamische 
regulatie van eiwitten. Het is dus ook geen 
verassing dat meerdere DUBs betrokken zijn 
in verschillende ziektes. Mede daarom worden 
DUBs ook gezien als interessante enzymen voor 
de ontwikkeling van medicijnen. Onze kennis 
over de DUBs is groeiende, maar er zijn nog veel 
open vragen. En om het medicijnonderzoek te 
vergemakkelijken is het belangrijk dat we beter 
begrijpen hoe deze enzymen werken. 
In dit proefschrift beschrijven we een 
karakterisatie van de grootste familie van 
deubiquitinerende enzymen: de Ubiquitine 
Specifieke Proteasen (USPs). Alle USPs 
hebben een homoloog katalytisch domein, 
wat suggereert dat ook de biochemische 
eigenschappen vergelijkbaar zijn. Echter, 
de eiwitsequentie en de drie dimensionale 
eiwitstructuren brachten specifieke verschillen 
aan het licht die invloed kunnen hebben op de 
biochemische eigenschappen. Bovendien is er 
veel variatie in de domeinen die de USPs hebben 
naast hun katalytisch domein. Aangezien we 
niet kunnen voorspellen hoe die verschillen 
zich precies laten vertalen, hebben we op grote 
schaal een analyse gedaan naar de kinetische 
eigenschappen van twaalf USPs. Het resultaat 
hiervan staat beschreven in hoofdstuk twee. 
Dit laat zeer grote verschillen zien in zowel 
de reactie snelheid als de ubiquitine binding. 
Dit betekent dat elke USP unieke kinetische 
eigenschappen heeft ontwikkeld. 
Ubiquitine kan in verschillende vormen in de 
cel voorkomen. Het kan namelijk ook ketens 
vormen door gekoppeld te worden aan andere 
ubiquitine moleculen. Deze ketens worden 
gevormd door gebruik te maken van de zeven 
lysine aminozuren van ubiquitine. Welke 
lysine wordt gebruikt bepaald bovendien 
wat de functie van de keten is. Verschillende 
soorten ketens hebben namelijk een andere 
uitwerking op het substraateiwit. DUBs kunnen 
deze keten afbreken door de verbindingen 
tussen de ubiquitines te hydrolyseren. Maar 
een belangrijke vraag is of ze misschien een 
voorkeur het voor een bepaald type keten. 
Tot nu toe werd er voornamelijk gekeken 
naar twee van de zeven mogelijke ubiquitine 
ketens (gekoppeld via lysine 48 en 63). Onze 
kennis van de andere vijf soorten ketens is nog 
relatief beperkt, maar het is wel duidelijk dat ze 
belangrijke functies hebben in de cel.
Om te zien of onze twaalf USPs een voorkeur 
hebben voor een bepaald type ubiquitine keten, 
hebben wij voor de eerste keer systematisch 
gekeken naar alle zeven verschillende (lysine) 
koppelingen. We vonden inderdaad variaties 
en we kunnen die waarschijnlijk verklaren 
doordat bij sommige ubiquitine koppelingen 
de onderlinge oriëntatie van twee ubiquitines 
de binding aan het katalytisch domein 
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verstoort. Wat de biologische relevantie van 
deze verschillen is, moet nog verder onderzocht 
worden. 
Buiten het katalytisch domein hebben USPs 
extra domeinen. Een van de meeste verassende 
domeinen is het Ubiquitine Achtige domein 
(UBL in het Engels). Eiwit vouwing herkenning 
algoritmes voorspellen op basis van eiwit 
sequentie dat minstens 17 USPs een UBL 
domein in hun context hebben. In hoofdstuk 
twee zagen we al dat de UBL domeinen van 
USP4 en USP7 de activiteit van hun USP kunnen 
beïnvloeden. In hoofdstuk drie beschrijven 
we de functie van een UBL domein dat midden 
in het katalytische domein van USP4 zit. We 
hebben de structuur van het katalytisch domein 
zonder het UBL domein opgelost. We vonden 
dat de activiteit van USP4 werd verlaagd door 
het UBL domein, omdat het concurreert met 
ubiquitine voor het binden aan het katalytische 
domein. Bovendien kunnen ook andere USPs 
aan het UBL domein van USP4 binden. Hierdoor 
wordt het UBL domein dan weggevangen, 
waardoor de zelfremmende functie van de UBL 
wordt tegengaan. 
Niet alle UBL domeinen hebben een remmende 
werking. In USP7, ook wel bekend onder de 
naam Hausp, wordt de activiteit verassend 
genoeg juist verhoogd door de UBL domeinen 
die net buiten het katalytische domein liggen. 
De activiteit van USP7 is zelfs bijna helemaal 
afhankelijk van deze UBL domeinen. USP7 
reguleert de functie van de eiwitten p53, 
HDM2 en PTEN. Omdat dit eiwitten zijn die 
een belangrijke rol spelen in het ontstaan van 
kanker, is USP7 een van de meest bestudeerde 
DUBs. Daarom is het een interessant eiwit 
voor medicijnonderzoek en zijn zowel de 
farmaceutische industrie als academische 
onderzoeksgroepen actief op zoek naar 
een specifieke remmer. In hoofdstuk vier 
beschrijven we het mechanisme waarmee 
het Hausp UBL (HUBL) domein de activiteit 
van USP7 verhoogd. We hebben de structuur 
van het HUBL domein opgelost, en deze 
bleek te bestaan uit vijf opeenvolgende UBL 
domeinen met twee nog nooit vertoonde di-
UBL eenheden (2-1-2). De laatste twee UBL 
domeinen (HUBL-45) bleken voldoende om 
het activerende effect van het HUBL domein 
tot stand te brengen. Dit di-UBL eenheid bleek 
direct te binden aan het katalytische domein, 
en deze interactie bepaalt of het eiwit zich in 
een ‘actieve’ of een ‘inactieve’ toestand bevindt. 
Deze omschakeling tussen de twee toestanden 
is dynamisch. Immers, het binden van het 
metabolisch enzym GMP synthetase (GMPS) 
aan HUBL-123, promoot de actieve toestand 
door de bindingsterkte tussen HUBL-45 en het 
katalytische domein te verhogen. Het binden 
van GMPS aan USP7 resulteert daarom in een 
toename van de hoeveelheid actieve enzym 
moleculen. 
Kortom, DUBs zijn belangrijk zijn in tal 
van cellulaire processen, en zijn dus ook 
vaak betrokken bij de ontwikkeling van 
ziektes. DUBs zijn daarom interessant voor 
de medicijnontwikkeling. Om daarmee 
te helpen is het belangrijk dat we de 
biochemische en biofysische eigenschappen 
en werkingsmechanismen begrijpen. Dit 
proefschrift laat zien dat er grote variatie 
bestaat in de USP familie en dat er een voorkeur 
bestaat voor bepaalde types ubiquitine ketens. 
We laten ook zien dat de activiteit van sommige 
USPs gemoduleerd wordt door zowel de 
intramoleculaire domeinen of interacterende 
eiwitten. Dit laat zien dat ondanks dat de USPs 
een homoloog katalytische domein hebben, 
zij toch persoonlijke werkingsmechanismen 
hanteren. Het feit dat de USPs unieke 
eigenschappen en mechanismen hebben, 
biedt mogelijkheden tot de ontwikkeling van 
nieuwe en specifieke medicijnen.
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List of abbreviations
Å  Ångstrom (1 Ångstrom = 0.1 nm)
APC  Anaphase promoting complex
ATM  Ataxia telangiectasia mutated
ATR  Ataxia telangiectasia and Rad3-related
CD  Catalytic domain
Da  Dalton
DNA  Deoxyribonucleic acid
DUB   Deubiquitinating enzyme
E1  Ubiquitin-activating enzyme
E2  Ubiquitin-conjugating enzyme
E3  Ubiquitin ligase
EBNA-1  Epstein Barr Virus Nuclear Antigen –1
FL  Full-length
FOXO   Forkhead box protein O
FP  Fluorescence Polarization
GFP  Green fluorescence protein
GMPS   GMP-synthetase
GST  Glutathione S-transferase
H2B   Histone 2B
HDM2  Human Double Minute 2
HUBL  Hausp Ubiquitin-like
hDaxx   Death domain-associated protein 6
HDM2   Human orthologue of Murine Double Minute 2 (MDM2)
ICP0   Infected Cell Protein 0
ITC  Isothermal Titration Calorimetry
K48  Lysine on position 48
kcat  Catalytic turnover
Kd  Dissociation constant
Ki  dissociation constant for inhibitor binding
KM  Michaelis-Menten constant
MJD  Machodo-Josephin Disease protease
OTU  Ovarian Tumour protease
p53   Tumour antigen p53
PML   Promyelocytic leukaemia protein
PRC  Polycomb repressive complex
PTEN   Phosphatase and tensin homolog
RMSD  Root Mean Square Deviation
SAXS  Small Angle X-ray Scattering
SPR  Surface Plasmon Resonance
TRAF   Tumour necrosis factor receptor associated factor
UAF1  USP1 associated factor 1
UCH  Ubiquitin C-terminal Hydrolase
Ub  Ubiquitin
UBA  Ubiquitin-associated
UBD  Ubiquitin binding domain
UBL   Ubiquitin-like
UIM  Ubiquitin interacting motif
USP  Ubiquitin Specific Protease
Znf UBP  Zinc-finger ubiquitin specific protease
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Dankwoord
A long journey trough rough terrain. Trying to reach the top of the mountain that is visible from the start, 
yet seemingly out of reach. The road winding downhill, it seems, more often than uphill. Shortcuts can’t 
be taken for lack of the right climbing gear. And there is no roadmap. Faced with such a challenge, it has 
been comforting to know there were always people ready to give directions when I needed them. Even if 
sometimes unwillingly pointing me the wrong way. This is how  I made it to the top: independently, but 
not alone.
Het was een heel avontuur. Onderweg ben ik verbaasd, soms teleurgesteld, maar heb ik vooral ook 
gelachen en gejuicht. Een van de mooiste  dingen in de wetenschap is het ontmoeten van mensen 
die echt geven om wat ze doen. Daarom wilde ik graag een aantal van de mensen bedanken die 
onderweg een grote rol hebben gespeeld in het tot stand brengen van dit boekje. 
Laten we uiteraard beginnen met Titia. Mijn sollicitatie staat me nog vers in mijn geheugen. Ik was 
erg onder de indruk en misschien zelfs wel geïntimideerd. Ik had duidelijk een gebrek aan kennis 
en ervaring. Dank je wel dat je me deze kans hebt gegeven en voor het geduld dat je hebt gehad 
om me mijn lessen te laten leren. De vele levendige discussies en individuele werkbesprekingen 
hebben eraan bijgedragen dat ik enorm veel van je heb geleerd en ik hoop dat ik je dat enigszins 
terug heb kunnen betalen. 
Mark, ik kan me nog goed herinneren dat we naar je project zaten te kijken tijdens mijn sollicitatie. 
Als we toch eens wisten wat er nog allemaal op ons pad zou komen. Ik zie ons ook nog zo zitten op 
het terras op Texel. Ik was net de week ervoor begonnen en we hadden allebei grootse plannen! Ik 
vond het erg leuk om het laatste stuk intensief met je samen te werken. Ik denk dat we elkaar heel 
mooi aanvulden en dat blijkt ook uit de enorme hoeveelheid werk die we verzet hebben. Vandaag 
gaat de kroon op het werk, en gaan we samen (en als elkaars paranimfen) die bul ophalen! Dank je 
wel voor al je hulp en het gezamenlijke USP avontuur. Veel succes in New York.
Tassos, first thing that comes to my mind is your seemingly endless knowledge of crystallography. 
But equally impressive is your attitude and approach towards life and science. The interplay with Titia 
was very interesting to watch ;-). During our synchrotron trips you were an excellent teacher, and I 
was always welcome for discussions on SAXS, enzyme kinetics and even career advice. Hopefully at 
some point we will understand the Russian-English manuals. Thanks for all your help! 
Pim, altijd sta je klaar om te helpen. Zonder jou zou dit lab een heel stuk minder soepel lopen. Herrie, 
sorry dat we je elke dag kwamen lastig vallen tijdens je lunch. Tati, thanks for all your help, you are a 
star! Always ready to help and always you do just a little bit extra. When my mutagenesis fails again, 
I’ll know where to find you!
Annette, we moesten gescheiden worden van H2 om eindelijk samen te werken en publiceren. 
Dank je wel en veel succes in je carrière.
De vele discussies op de gang, in het lab, tijdens lunch of gewoon tijdens de werkbesprekingen 
hebben veel bijgedragen aan mijn projecten, maar ook zeker aan de lol. Rick, altijd kritisch en 
moeilijk te overtuigen, maar juist daarom al heel snel een zeer gewaardeerde collega. Judith, 
eindelijk begint het voor jou te werken! Hopelijk het wordt een mooi verhaal en een mooi (en snel) 
einde. Prakash, you are still my favourite grumpy post-doc. All the best in Lille! Sasha, thanks for your 
help when the Biacore when it misbehaved again. Francesca, you were a lovely office and bench 
mate. Of course you can steal my buffers. Fingers crossed for your paper! Flora, het gaat je lukken 
met het grote complex! Also I would like to thank all the other (former) B8 members for all your help, 
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advice and fun over the last years. Succes gewenst voor allemaal!
Natuurlijk ook een bedankje voor de Ovaa-clan. Huib, Farid, Paul, Remco, Reggy en Anitha, we wisten 
elkaar steeds beter te vinden en uiteindelijk hadden we samen een mooie symbiose met meerdere 
papers. Ik weet zeker dat jullie nog vele mooie chemical tools gaan maken. Succes en dank jullie wel!
En dan hebben we natuurlijk ook Marlieke nog. Ik zal de vele autoritten naar trainingen, lessen, 
lectures, wedstrijden en demonstraties niet snel vergeten. Je lijkt zo stil maar je kan heel veel praten! 
Veel over dansen, maar we lossen net zo gemakkelijk alle wetenschappelijke problemen op tijdens 
een autoritje. Ondanks onze gezamenlijke publicatie (!), hebben we allebei onze danscarrière 
redelijk stil gehouden op het NKI. Bijna niemand weet hoe hard we samen gewerkt hebben, maar 
daar ging het ook niet om. We kregen helaas zelden loon naar werken, maar ik ben heel trots op 
wat we bereikt hebben. We hebben samen wel heel veel mee gemaakt, veel geleerd en iets moois 
opgebouwd. Dank je wel voor je energieke en enthousiaste aanwezigheid. Ik wens je al het beste 
met het afronden van de promotie! 
Pap, Mam en Marloes, waarschijnlijk is het nooit helemaal duidelijk geworden wat ik nou precies 
deed daar in Amsterdam. Ondanks dat, was er onophoudelijke steun en interesse voor mijn 
gegoochel met eiwitjes. Mam, ondanks al je eigen tegenslag bleef je onuitputtelijk geïnteresseerd 
in wat ik doe. Pap, ik weet dat je heel trots bent, dank je wel dat je mijn paranimf wilde zijn. Die steun 
in mijn rug van jullie heb ik altijd al gevoeld, ik ben blij dat je straks naast me staat.
Casper en Romy, jullie zijn het mooiste relativeringmiddel dat je je kunt voorstellen. Casper, vaak als 
ik je naar bed breng, zeg je dat ik niet mag gaan werken. Ik ben bang dat ik af en toe gelogen heb. 
Romy, je begroeting als ik thuis kom is heerlijk. Hopelijk kan ik een goed voorbeeld voor jullie zijn.
Suzan, ik vroeg om zilver, ik kreeg goud.
Het gaat jullie allen goed,
Alex
